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A hexanucleotide repeat expansion in the C9orf72 gene is the most common cause of familial 
amyotrophic lateral sclerosis and frontotemporal dementia. Genetic testing for this pathogenic 
mutation is challenging due to its GC rich, repetitive nature. I developed PCR based assays to 
detect the presence of the pathogenic variant, which were used in screening an archival cohort 
of Scottish ALS patients, and have also been implemented within a diagnostic setting. These 
PCR assays allow amplification of larger repeat expansions than have previously been 
reported, and can determine whether a C9orf72 expansion of greater than 100 repeats is present 
or not. It is not well understood how the repeat expansion leads to disease, but several potential 
mechanisms have been hypothesised, including reduced expression, RNA toxicity and protein 
toxicity via dipeptide repeat proteins produced through repeat associated non-AUG 
translation. Motor neurons are an understandably well studied target in amyotrophic lateral 
sclerosis, however the role of glia, particularly oligodendrocytes, in the pathogenesis of the 
disease has recently been highlighted from studies on rodent models and post mortem tissue. 
To investigate the effect of the C9orf72 repeat expansion on oligodendrocytes, we have 
applied a differentiation protocol to hiPSCs with the expansion and controls, including an 
isogenic control which has been generated in the lab. There was no difference in the production 
of neuronal and glial cell types between these cell lines. I went on to look for evidence of the 
main proposed pathological mechanisms of C9orf72 repeat expansions: loss of function or 
gain of function through either RNA or protein toxicity. hiPSC derived oligodendrocytes from 
both carrier and control showed low expression of C9orf72 mRNA, and there was no 
difference due to the presence of a repeat expansion. Carrier hiPSC derived oligodendrocytes 
displayed sense RNA foci, which did not appear to have an effect on cellular morphology. The 
detection of dipeptide repeat proteins proved challenging, and the results were inconclusive as 
to their presence in hiPSC derived oligodendrocytes. I went on to show there was no evidence 
of mislocalisation of TDP-43 in C9orf72 carrier oligodendrocytes. Finally, the study showed 
similar levels of cell death in basal conditions in carrier and control cells, and no clear 
difference in the response to endoplasmic reticulum stress. Further research will be required 








Motor neuron disease (MND) is a devastating disease where motor nerves in the brain and 
spinal cord stop working and eventually die. This means that messages from the brain can no 
longer reach the muscles, leading to weakness and wasting. The most common form of MND 
is called amyotrophic lateral sclerosis (ALS). In some cases of the disease, it is passed on 
through families. The most common reason for this is that there is a fault in a gene called 
C9orf72. This faulty gene has extra material in it, and this can be quite difficult to detect. I 
have developed genetic tests for detecting this gene fault that are quicker and more reliable 
than were available before. 
The genetic tests which I have developed allow us to work out whether or not ALS is likely to 
be caused by a fault in the C9orf72 gene, which is important to help patient’s families know if 
they might also be at risk of the disease. In the Scottish patients which were tested, about 1 in 
10 cases of ALS which has been recorded in the last 20 years have been found to have this 
gene change.  
Lots of research into the disease has focussed on the motor nerves, however recently it has 
become clear that some of the cells which support the nerves may not be working properly 
either. These cells, which are called oligodendrocytes, usually insulate the nerves. They also 
help to transfer energy to nerves. In people with motor neuron disease, these cells may not be 
as good at supporting the nerves as they should be.  
It is difficult to investigate oligodendrocytes in patients as they are inaccessible. To get around 
this problem, we can take skin cells from a patient who has a genetic fault in C9orf72, and 
then generate stem cells. Stem cells are cells which are able to form any type of cell in the 
body. I took these stem cells, which still have the same genetic fault, and by feeding them 
specific chemicals over several months, encouraged them to form oligodendrocytes. By 
comparing these oligodendrocytes to ones which were made in the same way from healthy 
people, I tried to find any differences that might be due to the genetic fault. I found that both 
groups of cells formed oligodendrocytes in the same way. 
There are a few ways that the C9orf72 gene fault could cause MND. It might be that there is 
less of the gene product made, or it might be that the product that is made is different from the 
normal product in a way that is detrimental to the cells. I wanted to see if any of these could 
be affecting oligodendrocytes. I found that there was the same amount of the gene product in 
oligodendrocytes even when the gene fault was there. The extra DNA present in the C9orf72 
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gene fault leads to ‘RNA foci’ being made, which might stick to important proteins in the cell 
and stop them working. The oligodendrocytes that were made from patients with the gene fault 
had this sticky RNA. Finally, the gene fault might cause abnormal proteins to build up in the 
cells. I looked at a number of different proteins which can lead to disease in this way, but they 
were either not seen in the oligodendrocytes or proved too difficult to detect. Finally, I looked 
to see if the levels of cell death were higher in the oligodendrocytes with the gene fault and 
found that they were similar to those without it. Further research is needed to see if 
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Chapter 1. General Introduction 
1.1 MND and FTD 
The first description of disorders with motor symptoms resembling motor neuron disease 
(MND) and with cognitive and behavioural symptoms resembling frontotemporal dementia 
(FTD) were noted in the late 19th century (Ferrari et al., 2011). In the 150 years since they were 
first reported, there has been increasing evidence that there is a clinical overlap between these 
two devastating neurodegenerative disorders, for which there is currently no effective 
treatment (Ferrari et al., 2011).  
1.1.1 Clinical features of ALS  
Amyotrophic lateral sclerosis (ALS) is the most common form of MND. It is an adult-onset 
neurodegenerative condition which affects the upper and lower motor neurons. In the majority 
of cases, it is a rapidly progressive disease which causes muscle weakness, then paralysis, and 
within three to five years, death through respiratory failure (Zoccolella et al., 2008). However, 
the phenotype is variable and a fifth of patients survive for longer than 5 years (McDermott 
and Shaw, 2008). The incidence of ALS is gender and age related, and affects 2.6 per 100 000 
females and 3.9 per 100 000 males per year in the UK, with a peak incidence between 75-79 
years (Alonso et al., 2009). The lifetime prevalence is around 1 in 350 for males and 1 in 472 
for females in the UK (Alonso et al., 2009; Johnston et al., 2006). The underlying pathological 
mechanisms have been proposed to include neuroinflammation, glial activation, neuronal 
trafficking deficits, excitotoxicity, mitochondrial dysfunction and oxidative stress (Pasinelli 
and Brown, 2006). An alteration in protein homeostasis is also thought to play a role in 
pathogenesis, and in this respect targeting endoplasmic reticulum (ER) stress has emerged as 
a potential therapeutic target in ALS (Matus et al., 2013). There are currently no effective drug 
treatments available for ALS, aside from the glutamate release inhibitor Riluzole, which only 
has a slight impact on survival (Miller et al., 2012). The disease tends to begin in one area and 
then spreads through the motor system (Ravits, 2014).                                                                                                                           
Within the Scottish population, there are approximately 160 patients diagnosed with ALS each 
year, and at any one time, there are approximately 400 people living with the condition (Pal, 
personal communication).  
1.1.2. Clinical features of FTD 
FTD covers a heterogeneous range of neurodegenerative disorders which cause cognitive and 
behavioural impairments, as a result of frontotemporal lobar degeneration (FTLD) (Neary et 
al., 1998). FTD is one of the commonest causes of early onset dementia, affecting 3.5 per 100 
18 
 
000 people aged 45-64, per year, in a detailed study in Cambridgeshire (Mercy et al., 2008). 
The majority of FTD cases have onset in the fifth or sixth decade of life, and present with 
characteristic progressive behavioural changes, executive dysfunction and language 
difficulties, without major memory deficits (Perry and Miller, 2013). The disorder is broadly 
classified into the clinical variants of behavioural variant FTD and primary progressive aphasia 
(PPA). Early symptoms of behavioural variant FTD are changes in personality, disinhibition 
and apathy which can result in tactless and socially inappropriate behaviour and 
impulsiveness. There may also be loss of interest in people and activities, as well as a loss of 
empathy and responsiveness to the needs of others. Stereotyped behaviours, such as repetitive 
movements and compulsive ritualistic behaviours may also manifest. Patients tend to be 
unaware of their own condition and it is usually reported by a family member of caregiver. 
Patients with PPA show a progressive loss of language skills, which is shown by deficits in 
object naming, syntax, or understanding of words. Word-finding difficulties characterise 
semantic-variant PPA while non-fluent variant PPA leads to agrammatism and speech apraxia 
(Bang et al., 2015).  
1.1.3 Links between ALS and FTD 
Both genetic and neuropathological findings suggest that ALS and FTD are conditions which 
are at opposite ends of a disease spectrum, and many patients are found to suffer combined 
symptoms (Morris et al., 2012). Approximately 15% of ALS patients have concurrent FTD 
(Elamin et al., 2011; Lomen-Hoerth et al., 2002), and up to 50% have some evidence of 
cognitive or behavioural defects (Lomen-Hoerth et al., 2003). Conversely, up to 40% of 
patients with FTD have motor impairments, with approximately 12.5% developing motor 
neuron disease (Burrell et al., 2011; Lomen-Hoerth et al., 2002). Distinct populations of 
neurons are susceptible in ALS and FTD, and these clinical phenotypes correlate with the 
pattern of neuronal loss. Upper and lower motor neurons are affected in ALS while frontal and 
anterior or medial temporal neurons are lost in FTD (Neumann et al., 2006).  
Neuropathologically, ALS and FTD are classified based on the major protein aggregates which 
are detected. In ~60% of FTD and ~90% of ALS cases, phosphorylated 43kDa transactive 
response (TAR)-DNA binding protein (pTDP-43) inclusions are found in neurons and glia of 
the areas with most severe neurodegeneration (Mackenzie et al., 2007; Neumann et al., 2006).   
1.1.4 Cellular autonomy versus non-cellular autonomy in 
neurodegeneration 
Historically, research on neurodegenerative conditions such as ALS and FTD has focused on 
the principal cells, neurons, whose loss results in disease. The prevailing view was of cell 
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autonomous effects, where the neurons themselves were defective (Lobsiger and Cleveland, 
2007). However, with increased understanding of the function of non-neuronal neighbouring 
cells, glial, it is becoming apparent that there is damage to multiple cell types, which converges 
to result in neuronal loss and a clinical phenotype. The main glial cell types in the central 
nervous system are astrocytes, microglia, and oligodendrocytes, and these cells are now 
thought to be implicated in the development and progression of ALS (Boillée et al., 2006; Di 
Giorgio et al., 2007; Philips et al., 2013). These interactions between different cell types are 
known as non-cell autonomous effects, and include cross-talk between neurons and glia, and 
between different types of glial cells (Meyer and Kaspar, 2016). It is therefore of interest to 
study various cell types in the context of ALS, both to investigate any cell autonomous effects, 
and then ultimately to elucidate how the cells interact to result in disease.  
1.2 Genetics of ALS and FTD 
It is estimated that around 5% of ALS patients have an affected first degree relative, which 
suggests that there is a genetic component to the disease risk (Byrne et al., 2011b). The 
discovery of pathogenic variants in superoxide dismutase 1 (SOD1) (Rosen et al., 1993), 
TARDBP (Kabashi et al., 2008; Sreedharan et al., 2008) and the noncoding (G4C2)n 
hexanucleotide repeat expansion (HRE) in chromosome 9 open reading frame 72 (C9orf72) 
(DeJesus-Hernandez et al., 2011; Renton et al., 2011), have been major advances towards 
understanding pathogenic mechanisms in ALS.  
There are now over 25 genes that have been implicated in the disease, which is usually 
inherited in a dominant manner. However, the identification of pathogenic variants in sporadic 
cases of ALS has blurred the distinction between familial and sporadic disease (Boylan, 2015; 
Renton et al., 2014). Cases are generally classified as familial when there is a first-degree 
relative with ALS. They are ‘probably’ familial if a second degree relative has ALS, and 
possibly also if a first or second degree relative has been diagnosed with FTD (Byrne et al., 
2011a). Cases with an underlying genetic cause could be classified erroneously as sporadic 
due to reduced penetrance, small family size, inaccurate diagnoses in family members, 
incomplete family history or death from other causes, prior to disease onset in genetically at 
risk family members (Byrne et al., 2011a). Currently, a genetic cause can be identified in 60-
70% of familial ALS cases and ~10% of apparently sporadic cases as shown in Figure 1 




Figure 1.1 Proportion of familial and sporadic ALS cases attributed to mutations 
in different genes 
68% of familial ALS cases of European ancestry, and 11% of sporadic cases, have 
pathogenic variants in one of the known genes listed above. Reproduced with 
permission (Renton et al., 2014). 
 
Developments in high-throughput DNA sequencing of patients with ALS has increased the 
number of genes known to be associated with ALS, and although most of these genes are rare 
causes of the disease, investigating the functional characteristics of these and more common 
ALS genes, has elucidated some of the molecular pathways involved in ALS pathogenesis 
(Boylan, 2015). Pathogenic variants in the functionally related RNA-binding proteins encoded 
by TARDBP and Fused in sarcoma/Translocated in sarcoma (FUS) genes, have suggested that 
RNA-processing defects are implicated in ALS pathogenesis (Kwiatkowski et al., 2009; Vance 
et al., 2009). 
Around 40% of patients who are diagnosed with FTD have a family history of dementia (Rosso 
et al., 2003), with 10% of cases showing a clear autosomal dominant inheritance pattern 
(Rohrer et al., 2009). Pathogenic variants in microtubule associated protein tau (MAPT) 
(Hutton et al., 1998) and progranulin (PGRN) have been identified in FTD patients (Baker et 
al., 2006), and together with C9orf72 expansions, account for 60% of inherited cases (Le Ber, 
2013). Most of the other genes which are implicated in FTD overlap with those that are 
associated with ALS, including C9orf72 HRE, TARDBP, and valosin containing protein 
(VCP). This observation that genetic variants in the same genes can cause either ALS or FTD 
is further evidence that these disorders are part of a disease continuum (Ling et al., 2013). 
Cases of combined ALS-FTD are familial in ~30% of cases (Goldman et al., 2005). The 
C9orf72 HRE is the commonest genetic cause of combined ALS-FTD, with rare cases also 
being caused by pathogenic variants in VCP, sequestosome-1 (SQSTM1), optineurin (OPTN) 
and ubiquilin-2 (UBQLN2) (Al-Chalabi and Hardiman, 2013; Hardy and Rogaeva, 2014). 
Furthermore, loss of function mutations in TANK-binding kinase 1 (TBK1) have also been 
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implicated in ALS and FTD, reinforcing a link between autophagy and ALS pathology 
(Freischmidt et al., 2015; Pottier et al., 2015).  
It is clear that ALS and FTLD are genetically heterogeneous, and it may be the case that 
pathogenic variants in different genes cause the disease via diverse mechanisms (Valori et al., 
2014). There have also been reports of oligogenic inheritance in ALS and FTD but the 
consequences of this to the clinical phenotype are not known (Lashley et al., 2014; van 
Blitterswijk et al., 2012).  
The identification of pTDP-43 inclusions in affected neurons of ALS (Neumann et al., 2006) 
and the later identification of pathogenic variants in TDP-43, revealed a link between the 
genetics and pathology of the condition (Kabashi et al., 2008; Sreedharan et al., 2008). Other 
proteins also found to contain pathogenic mutations in ALS have since been identified in 
cellular inclusions, including SOD1, FUS and UBQLN2 (Deng et al., 2011; Deng et al., 2010; 
Shibata et al., 1996) reinforcing this link. It is important to note that these aggregates, 
particularly pTDP-43, are common to both familial and sporadic cases, which also have similar 
clinical features (Al-Chalabi et al., 2012). In FTD cases, there are often similar intracellular 
protein accumulations associated with the disorder and these can be categorized into molecular 
subtypes (Mackenzie et al., 2009). The most common neuronal inclusions in FTD cases are 
formed of ubiquitin, which is associated with pTDP-43 (Mackenzie et al., 2006; Neumann et 
al., 2006). In other cases, there are accumulations of hyperphosphorylated tau protein in 
neurons and glia, or FUS (Mackenzie et al., 2009; Munoz et al., 2009; Neumann et al., 2009). 
1.3 C9orf72 HRE  
A hexanucleotide (G4C2)n repeat expansion in a non-coding region of C9orf72 has been 
identified as a significant cause of FTD, ALS and ALS-FTD (DeJesus-Hernandez et al., 2011; 
Renton et al., 2011).  
1.3.1 Molecular Genetics 
The C9orf72 HRE was identified by studies of the risk locus at 9p21.2, which had previously 
been identified through both linkage studies in affected families and genome wide association 
studies for ALS and FTD (Laaksovirta et al., 2010; Luty et al., 2008; Morita et al., 2006; 
Shatunov et al., 2010; Valdmanis et al., 2007; Van Deerlin et al., 2010; van Es et al., 2009; 
Vance et al., 2006). 
The C9orf72 gene has 11 exons, with two alternatively spliced non-coding exons 1a and 1b. 
There are three major mRNA transcripts that encode two protein isoforms of 481 and 222 
amino acids. The repeat expansion is in the upstream regulatory region in variant 1 
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(NM_018325.4) and in intron 1 of transcript variants 2 and 3 (NM_145005.6 and 
NM_001256054.2). 
The G4C2 repeat number is normally between 2 and 25 in controls (median of 2 repeats) but is 
frequently expanded to greater than 1000 in disease cases (DeJesus-Hernandez et al., 2011; 
Renton et al., 2011).  
The C9orf72 protein is found in both the nucleus and cytoplasm, and is thought to be similar 
in structure to the differentially expressed in normal and neoplasia (DENN) proteins, which 
have a guanine (GDP and GTP) nucleotide exchange factor (GEF) domain, and are thought to 
play a role in membrane trafficking and autophagy (Farg et al., 2014; Levine et al., 2013; Tang, 
2016). There is evidence from both immunoprecipitation experiments and in vitro binding 
assays that C9orf72 binds with Rab1a, and the data suggests that C9orf72 acts as a Rab1a 
effector, and plays a role in the initiation of autophagy (Webster et al., 2016). It is also thought 
to play a role in promoting the clearance of protein aggregates via p62 (Ciura et al., 2016; 
Sellier et al., 2016) Autophagy is a cellular process whereby cytosolic components are 
transported to the lysosome for degradation. This process is critical in neurodegenerative 
diseases which are associated with diminished clearance of toxic protein or RNA inclusions 
(Jain and Ganesh, 2016).  
1.3.2 C9orf72 HRE related phenotypes 
The HRE in the C9orf72 gene is the commonest genetic variant found in Caucasian ALS cases. 
It accounts for ~6% of sporadic ALS and FTD cases, and 40% and 25% of familial ALS and 
FTD cases, respectively (Majounie et al., 2012). In addition, the HRE in C9orf72 is associated 
with a clinically varied presentation and prognosis (Devenney et al., 2015). As well as ALS 
and FTD, there are a variety of clinical syndromes which have been associated with the HRE, 
including Huntington-like disease, Alzheimer’s disease (AD) (Beck et al., 2013), ataxia 
(Lindquist et al., 2013) and some psychiatric diseases (Bieniek et al., 2014). It is unclear 
whether the expansion directly causes this wide spectrum of disease, or whether it indirectly 
affects susceptibility to neurodegeneration (Burrell et al., 2016).  
1.3.3 C9orf72 HRE genotype-phenotype correlations 
The pathogenic size range of the expansion has not been well defined, and was originally 
hypothesised to be around 30 repeats (Renton et al., 2011), which is based partly on the size 
detected in controls, and partly on limitations in polymerase chain reaction (PCR) based 
detection, as the GC-rich nature and size of the repeat hampers PCR (Dobson-Stone et al., 
2013). The largest UK study to date using Southern blotting showed that the 68 C9orf72 
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expansions detected in their extensive series (2974 cases with FTLD, ALS, AD, sporadic 
Creutzfeldt-Jakob disease, Huntington Disease-like syndrome) were approximately 800-4400 
repeats in length (Beck et al., 2013). Further large scale studies will be needed to further 
delineate the pathogenic size range. There is one report in the literature of a patient who 
developed FTLD in his late fifties, who had ~65 repeats, but no family studies were carried 
out so it is not possible to conclusively say that the expansion was the cause of the disease in 
this case (Dobson-Stone et al., 2013). Short (45-78 repeats) expansions were detected in 5.6% 
of 72 C9orf72 HRE positive index cases in another study, with co-segregation with disease 
observed in two families (Gijselinck et al., 2016). Conversely, there is also one report of a 
stable 70 repeat allele in an unaffected 89-year-old individual expanding in four of his 
offspring, but further studies are required to determine whether anticipation is commonly 
associated with this repeat expansion (Xi et al., 2015a). Analysis of families from the CEPH 
cohort suggests an overall intergenerational change rate of 0.29%, with all detected changes 
occurring in normal alleles which were greater than 10 repeats (Beck et al., 2013). There have 
been reports in three families of a decrease in age of onset between parents and offspring of 
between 16-25 years, suggesting that anticipation may be occurring, although the underlying 
molecular genetic basis of this is still unclear (Gijselinck et al., 2016). 
The detection of C9orf72 expansions in 11/7579 (0.15%) of 54-year old healthy controls, 
suggests that the mutation has incomplete penetrance since this frequency is higher than would 
be expected given the prevalence of ALS/FTD (Beck et al., 2013). Other studies have 
suggested that penetrance appears to be age-related, with approximately 50% penetrance at 
the age of 58 years and almost full penetrance by 80 years (Majounie et al., 2012). In an 
extensive UK study, large expansions were detected at a frequency of 1 in 600 in the control 
population tested (cohort of unaffected 54 year olds) (Beck et al., 2013). Recent evidence 
suggests that the average age of onset for ALS and FTD in C9orf72 cases is 57.9 and 63.6 
years. As this is higher than the age of the control population used in the study by Beck et al., 
it seems likely that the frequency of unaffected mutation carriers has been overestimated as 
they may go on to develop either ALS or FTD.  
It is currently unclear whether there is a correlation between repeat length and age of onset, 
disease severity or speed of progression, because relatively few cases have been tested using 
Southern blotting, and the studies which have been done have given conflicting results  (Fong 
et al., 2012). The Xpansize-72 study found no correlation between repeat length and age at 
onset or sample collection, except for FTD where there was an inverse correlation between 
age of onset and repeat length in frontal cortex (van Blitterswijk et al., 2013b). The largest 
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study in the United Kingdom to date has suggested there was no correlation between repeat 
size and clinical presentation, disease course or severity, but repeat size does correlate 
inversely with age of onset (Beck et al., 2013). This study has not shed light on the potential 
role of intermediate alleles (30-800 repeats) as none were detected (Beck et al., 2013). This 
was in contrast to another more recent study where 5.6% of C9orf72 HRE index cases were 
found to have short (45-78 repeats) expansions (Gijselinck et al., 2016). Currently therefore, 
using Southern blotting in a diagnostic setting to generate information on repeat size does not 
provide any extra clinically useful information for patients.  
DNA hypermethylation is a proposed disease modulator in C9orf72 HRE carriers. 
Hypermethylation of nearby cytosine-phosphate-guanine (CpG) islands and the C9orf72 
repeat expansion itself have been observed (Xi et al., 2014; Xi et al., 2015b; Xi et al., 2013), 
and repressive histone trimethylation has also been noted in the region, and has been found to 
be associated with shorter disease duration in ALS (Belzil et al., 2013). However, in contrast, 
a study on C9orf72 lymphoblasts and brain tissue suggested that hypermethylation was 
protective, as it resulted in reduced vulnerability to oxidative and autophagic stress (Liu et al., 
2014). Hypermethylation resulted in reduced RNA foci and dipeptide repeat protein (DPR) 
production, as well as the expected reduction in expression levels (Liu et al., 2014). 
Methylation levels are reportedly similar in ALS and FTD, however C9orf72 
hypermethylation was associated with shorter repeat sizes, increased age at death and longer 
disease duration for FTD (Russ et al., 2015). More large scale studies are required to ascertain 
whether there are any correlations between age of onset and methylation with repeat size 
(Gijselinck et al., 2016). 
1.3.2 Detection of the C9orf72 HRE 
Genetic testing in ALS and FTLD is important in contributing to a definitive diagnosis, can 
avoid prolonged and unnecessary investigations from being carried out and can allow a more 
accurate risk to the wider family to be determined. Pre-symptomatic patients with known ALS 
genetic variants may offer insight into early disease processes if appropriate research studies 
are performed, as has been demonstrated for Huntington’s Disease (Tabrizi et al., 2009). 
Genetic test results will likely be increasingly used to stratify patients in clinical trials, 
particularly for gene-targeted therapy (Boylan, 2015). Such trials have already been carried 
out, albeit on a small scale, for therapies targeting SOD1 mediated disease (Miller et al., 
2013b).  
Molecular genetic testing for the G4C2 repeat expansion is challenging due to its highly GC 
rich, repetitive nature and frequent large size. A summary of the main techniques that are 
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currently used is shown in Figure 1.2. It is challenging to amplify large expansions by 
conventional flanking PCR assay, and for this reason, repeat primed (RP-) PCR is commonly 
used, as for other repeat expansion disorders (Warner et al., 1996). This technique allows 
detection of the presence or absence of a repeat expansion, but does not allow sizing of the 
expansion. The 30 repeat cut-off is frequently used in the literature to denote the pathogenic 
size range for C9orf72 expansions, however this is likely to have arisen as a result of the 
limitations of RP-PCR in determining the expansion size. Southern blotting is often quoted as 
being the ‘gold standard’ method (Akimoto et al., 2014), however this is not without 
drawbacks. Aside from being a time-consuming and cumbersome technique, which requires a 
large amount of high quality DNA (minimum 1-3µg), interpretation of results can be 
complicated as the signal from heterogeneous sized repeat expansions are difficult to 
differentiate from background probe hybridisation (Buchman et al., 2013). This is particularly 
true when assessing expansions in DNA derived from whole blood samples, which show a 
smear rather than distinct bands (Hubers et al., 2014). Difficulties in assessing the exact size 
of the repeat lengths have been reported by others and this is thought to be due to extensive 
somatic heterogeneity (Beck et al., 2013; Nordin et al., 2015). It is also possible that due to 
the repetitive nature of the DNA fragments, that they adopt unusual structures which can result 
in abnormal migration during agarose gel electrophoresis, making inference of size and repeat 
number inaccurate (Mirkin, 2007). There are a number of Southern blotting protocols that have 
been developed, and each has differing advantages and disadvantages. One method is to 
enhance the signal by using a probe containing the (G4C2)n repeat rather than flanking 
sequence, however this may interfere with the detection of normal alleles (Beck et al., 2013; 
Hubers et al., 2014). It is desirable to ensure the size range of detection allows normal alleles 
to be visualised in addition to expansions, but this is difficult to achieve without loss of 




Figure 1.2 Summary of the main methods currently used in molecular genetic 
testing for C9orf72 expansion repeats. 
 
(a) Conventional PCR, where primers flanking the repeat are used to generate products 
which can then be accurately sized following capillary or agarose gel electrophoresis. (b) 
RP-PCR, where one flanking primer is used, alongside a primer specific for the repeat 
with a tail which has no homology to the human genome, and a primer for the tail. This 
produces products corresponding to each repeat unit, which can be detected following 
capillary electrophoresis, giving a ladder of fragments with a saw-tooth pattern. (c) 
Southern blotting, where DNA is digested with specific restriction enzymes which result in 
different sized fragments depending on the number of repeats present. These are 
separated by agarose gel electrophoresis before the products are transferred to a filter 
(blotting) and a probe to detect the expansion containing fragment is hybridised. After 
washing, the blot can be imaged or developed depending on whether chemiluminescent 
or radioactive techniques are used.  
1.3.4 Pathogenic mechanisms of the C9orf72 HRE 
The pathology of C9orf72 HRE cases shows pTDP-43 positive inclusions in anterior horn 
neurons, dentate gyrus and sometimes neocortex, but the more unusual feature is the presence 
of p62 positive, pTDP-43 negative inclusions in the pyramidal cells of the hippocampus and 
cerebellum (Al-Chalabi et al., 2012; Therrien et al., 2013). There are three proposed, non-
mutually exclusive hypotheses surrounding the potential pathogenic mechanisms of the 
C9orf72 hexanucleotide expansion (Figure 1.3):  
A. Loss of function (haploinsufficiency) 
B. Gain of function via RNA foci 





Figure 1.3 Schematic of main proposed pathological mechanisms for C9orf72 
HRE (Ling et al., 2013) 
A schematic of the C9orf72 gene, showing the intronic location of the (GGGGCC)n repeat 
expansion (yellow = UTRs; blue = exons). There are at least three non-mutually exclusive 
mechanisms by which a C9orf72 repeat expansion could mediate pathogenesis: (A) It 
could prevent or reduce transcription of the gene resulting in reduced expression of the 
protein (haploinsufficiency) (Gijselinck et al., 2012); (B) RNA foci containing repeat RNA 
could mediate toxicity via sequestration of RNA-binding proteins (DeJesus-Hernandez et 
al., 2011); (C) Dipeptide repeat proteins, generated via Repeat associated non-AUG 
(RAN) translation, may exert a toxic effect  (Mori et al., 2013c). Image reproduced with 
permission.  
There is a great deal of interest in determining whether one of these proposed pathogenic 
mechanisms is predominantly responsible for the resulting disease. It is hoped that 
understanding the disease mechanism may lead to targeted therapies from being developed 
(Gitler and Tsuiji, 2016). It may be that there is a complex interplay between each mechanism, 
and they are actually all responsible to some extent, for example RNA toxicity could make 
cells more susceptible to loss of C9orf72 (Sivadasan et al., 2016). How these proposed 
C9orf72 HRE specific mechanisms lead to the resulting TDP-43 mislocalisation and p62 
28 
 
inclusion formation, is still an area of investigation, with defective nucleocytoplasmic 
transport being a prime candidate (Boeynaems et al., 2016; Freibaum et al., 2015; Jovicic et 
al., 2015). 
1.3.4.1 Loss of function 
When the C9orf72 hexanucleotide repeat was first described, it was noted that the mutation 
affected C9orf72 expression in a transcript specific manner by quantitative reverse 
transcriptase (qRT)-PCR (DeJesus-Hernandez et al., 2011). The transcripts vary in that the 
repeat expansion is found either in the promoter (NM_018325.4) or in the first intron 
(NM_145005.6 and NM_001256054.2) which may explain this transcript specific expression 
pattern (van Blitterswijk et al., 2015). These findings have been replicated in numerous studies 
of post-mortem tissue (Fratta et al., 2013; Gijselinck et al., 2012) and hiPSC derived neuronal 
cells from patients (Almeida et al., 2013; Donnelly et al., 2013), although this finding has not 
been consistent (Sareen et al., 2013). Determining the effect of the C9orf72 expansion on 
protein expression levels initially proved challenging due to a lack of reliable commercial 
antibodies, and difficulties distinguishing the two protein isoforms, however studies have now 
shown that there is a reduction in protein levels of the longer C9orf72 isoform in expansion 
carriers (DeJesus-Hernandez et al., 2011; Waite et al., 2014; Xiao et al., 2015).  
The development of specific antibodies to the two different C9orf72 protein isoforms has 
shown reduced levels of the long isoform in frontal and temporal cortex, and a redistribution 
of the short isoform from the nuclear membrane to the plasma membrane in motor neurons of 
C9orf72 expansion cases (Xiao et al., 2015). This has also contributed to our understanding of 
the normal function of C9orf72 protein, which has been found to interact with Importin β1 and 
Ran-GTPase which form part of the nuclear pore complex, suggesting that C9orf72 is involved 
in nucleocytoplasmic transport (Xiao et al., 2015). Given that TDP-43 requires nuclear 
trafficking, it is possible that this provides a mechanistic link between C9orf72 loss of function 
and TDP-43 mislocalisation, which was found to correlate with loss of the short isoform of 
C9orf72, Importin β1 and Ran-GTPase from the nuclear membrane. Support for the role of 
loss of function in disease, comes from the observation that C9orf72 HREs have been found 
to impede nucleocytoplasmic transport (Freibaum et al., 2015; Zhang et al., 2015). 
There are several hypotheses which could explain how the HRE in C9orf72 could influence 
expression levels, including that the complex secondary structures (G-quadruplexes and R-
loops) which are formed by the repeat (Fratta et al., 2012; Reddy et al., 2013) result in abortive 
transcription (Haeusler et al., 2014). Hypermethylation of nearby CpG islands and the C9orf72 
repeat expansion itself is another proposed mechanism resulting in reduced expression in 
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expansion carriers (Xi et al., 2014; Xi et al., 2015b; Xi et al., 2013), and histone trimethylation, 
a repressive chromatin mark, has also been noted in the region (Belzil et al., 2013). One study 
showed that C9orf72 hypermethylation resulted in a faster disease progression, suggesting that 
hypermethylation was deleterious (Xi et al., 2013), however this has not been replicated and 
others have found that it may actually be a protective factor (Liu et al., 2014; Russ et al., 2015). 
A recent study found a correlation between methylation status and expansion length, with 
lower methylation levels being found in short expansion carriers (Gijselinck et al., 2016). 
Evidence from human genetics suggests that C9orf72 loss of expression is not likely to be the 
primary mechanism of pathogenesis, as a study on 389 ALS patients failed to detect any coding 
mutations in C9orf72 (Harms et al., 2013). A further study on 276 Chinese patients with ALS 
revealed one patient with a novel splice site variant, (c.601-2A>G) which was associated with 
reduced mRNA levels, but there was no segregation studies performed (Liu et al., 2016). In 
addition, a patient who was found to be homozygous for C9orf72 HRE, did not display a 
clinical phenotype outwith the normal range, which would not be expected if the disease was 
only mediated via loss of function (Fratta et al., 2013).  
Animal models have been generated to try and elucidate the impact of C9orf72 loss of 
function. In zebrafish, knockdown of the C9orf72 orthologue led to motor neuron axonopathy 
and motor deficits, and the phenotype was reversed by introducing human C9orf72 (Ciura et 
al., 2013). Similarly, homozyogous loss of the C9orf72 orthologue in C. elegans results in 
motility defects and stress susceptibility (Therrien et al., 2013). These models suggest that 
haploinsufficiency may contribute to C9orf72 pathogenesis, however in contrast these findings 
have not been consistent in mouse models (Koppers et al., 2015; Lagier-Tourenne et al., 2013). 
Reducing C9orf72 levels in mouse brain and spinal cord by injecting antisense 
oligonucleotides by stereotactic intracerebroventricular injection, did not result in behavioural 
or motor phenotypes, nor did it result in TDP-43 cytoplasmic mislocalisation (Lagier-
Tourenne et al., 2013). Similarly, the generation of a conditional C9orf72 knockout mouse 
using the Cre/loxP system, which inactivated C9orf72 in neurons and glia from E10.5, did not 
result in motor neuron loss, reduced motor function or TDP-43 accumulation (Koppers et al., 
2015). Interestingly, more recent studies which have generated homozygous mutant mice 
which constitutively lack C9orf72, have shown that this leads to splenomegaly, myeloid cell 
expansion, immune response deficits and impaired microglial function (Atanasio et al., 2016; 
O'Rourke et al., 2016). Thus, loss of function of C9orf72 in non-neuronal tissues could still 
influence the development of disease.  
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1.3.4.2 Gain of function via RNA foci 
The nuclear and/or cytoplasmic accumulation of repeat expansion containing RNA has been 
reported in several conditions caused by noncoding repeat expansions such as type 1 myotonic 
dystrophy and fragile X tremor and ataxia syndrome (Todd and Paulson, 2010). The presence 
of (G4C2)n sense RNA foci in the cells of patients with G4C2 repeat expansions in C9orf72 was 
reported when details of the mutation emerged (DeJesus-Hernandez et al., 2011). As seen in 
other noncoding repeat expansions (Todd and Paulson, 2010), (C4G2)n antisense RNA foci 
were also detected in neuronal and glial cells from post-mortem tissue of C9orf72 HRE carriers 
(Mizielinska et al., 2013). Antisense foci were present in fewer cells than sense foci, but the 
average number of foci per cell was higher (Mizielinska et al., 2013). Either sense or antisense 
foci alone, or both types, have been detected in individual cells (Mizielinska et al., 2013). 
Having a higher percentage of neurons containing foci in frontal cortex has been correlated to 
a lower age of disease onset, suggesting that RNA foci are implicated in disease pathology 
(Mizielinska et al., 2013).  
RNA foci have been reported in a wide variety of cell types including fibroblasts, hiPSCs, 
immortalized lymphoblasts, astrocytes and microglia from C9orf72 expansion patients 
(Almeida et al., 2013; Donnelly et al., 2013; Lagier-Tourenne et al., 2013). The presence of 
sense RNA foci has been quantified in post-mortem tissue, which suggested that a higher 
proportion of neuronal cells contained foci (21-37%, depending on brain region) than 
astrocytes (~5%), oligodendrocytes (~10%) or microglia (~13%) (Mizielinska et al., 2013). 
This observation is consistent with higher C9orf72 expression levels in neurons than glia in 
mice (Suzuki et al., 2013). Most RNA foci are observed in the nucleus, although they are also 
detected in the cytoplasm, consistent with an intermediary role in DPR production 
(Mizielinska et al., 2013). 
The mechanism by which RNA foci are proposed to cause disease relates mainly to the 
sequestration of essential RNA binding proteins (O'Rourke and Swanson, 2009), which could 
potentially affect the expression and downstream processing of hundreds of genes in a cell 
type dependent manner (Yokoyama et al., 2014). The identification of proteins which bind to 
C9orf72 RNA foci is important in determining their contribution to pathogenesis (Mizielinska 
et al., 2013). Initial studies investigating the binding partners of sense and antisense RNA foci 
did not reach consensus on the most important binding partners. Using an RNA pulldown 
assay based on sense RNA foci on whole cell lysates from human neuronal cell lines and 
cerebellum tissue, followed by mass spectrometry, 103 proteins which bound to (G4C2)5 were 
identified (Cooper-Knock et al., 2014). Several well-characterised targets were investigated 
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further to determine if there was co-localization in cerebellar granule neurons or motor 
neurons, which showed that there was some degree of overlap (19-30%) between sense RNA 
foci and heterogeneous ribonucleoprotein particle (hnRNP) A1, hnRNP H1/F, Aly/REF export 
factor (ALYREF) and serine and arginine rich splicing factor 2 (SRSF2) (Cooper-Knock et 
al., 2014). Several of the targets had been identified previously in association with sense RNA 
foci including hnRNP A1 (Sareen et al., 2013), hnRNP H1/F and SRSF2 (Lee et al., 2013). 
Further studies suggested that antisense RNA shared similar binding partners (Cooper-Knock 
et al., 2015; Haeusler et al., 2014). The multitude of proteins identified, and the low percentage 
of RNA foci displaying co-localization, suggests that a dynamic sequestration of multiple 
targets may be occurring, rather than an irreversible binding to a single factor (Cooper-Knock 
et al., 2014). Other proposed binding partners include RNA specific B2 adenosine deaminase 
(ADARB2) (Donnelly et al., 2013), nucleolin (Haeusler et al., 2014) and Pur-alpha (Xu et al., 
2013).  
Support for a role of RNA foci has come from studies which have used antisense 
oligonucleotides to reduce the abundance of sense RNA foci and reverse the toxicity in patient 
fibroblasts and hiPSC derived neurons (Donnelly et al., 2013; Lagier-Tourenne et al., 2013; 
Sareen et al., 2013). However, the link between RNA foci and DPRs is still poorly understood 
so it can be challenging to tease apart these two entities. The RNA pulldown described 
previously suggested that several mRNA export adaptors were associated with sense RNA 
foci, which could potentially be involved in the export of expanded C9orf72 mRNA into the 
cytoplasm where they could be translated (Cooper-Knock et al., 2014). RNA foci have also 
been observed in the cytoplasm in fibroblasts from C9orf72 HRE carriers (Donnelly et al., 
2013; Lagier-Tourenne et al., 2013; Sareen et al., 2013). Studies using hiPSC derived neurons 
carrying C9orf72 HREs, primary rodent neurons and Drosophila have shown that sense repeat 
RNA localizes in neurites where it associates with ribonucleoprotein transport granules and 
interferes with local translation, which is associated with neuritic branching defects 
(Schweizer Burguete et al., 2015). 
Conversely, several studies using transgenic Drosophila which express C9orf72 G4C2 repeat 
expansions have provided some evidence against RNA toxicity. Such flies show evidence of 
RNA foci and DPRs (Freibaum et al., 2015; Mizielinska et al., 2014; Tran et al., 2015). To 
then try and determine the contributions of RNA and DPRs, two fly lines were engineered 
with G4C2 repeats, one of which contained regular stop codons within it, which prevented the 
formation of DPRs (Mizielinska et al., 2014). Both fly lines expressed RNA foci, but only the 
pure repeat (without stop codons) led to toxicity and early death, suggesting that DPRs are 
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responsible for this effect (Mizielinska et al., 2014). Another group have generated an intronic 
G4C2 repeat containing Drosophila line, which does not display neurodegeneration (Tran et 
al., 2015). It is likely that this difference in phenotypes is due to the relative expression levels 
of the G4C2 repeats in each model, as the Mizielinska et al. flies express this as an mRNA with 
a 3’UTR, allowing export to the cytoplasm and efficient production of DPRs, which lead to 
neurodegeneration. Because the Tran et al. flies express the G4C2 repeat in the context of an 
intron, they show high levels of RNA foci in the nucleus, but low DPR levels, suggesting that 
the sense RNA in the nucleus is insufficient to lead to neuronal loss. Neither of these models 
investigate the contribution of antisense RNA, which should be investigated before RNA 
toxicity is excluded as a pathogenic mechanism in the fly model (Gitler and Tsuiji, 2016). 
1.3.4.3 Gain of function via C9RAN peptides 
The occurrence of repeat-associated non-ATG (RAN) translation (Zu et al., 2011) in C9orf72 
expansion cases results in the production of DPRs from both sense and antisense strands, in 
each possible reading frame (Ash et al., 2013; Gendron et al., 2013; Mori et al., 2013c; Zu et 
al., 2013). The DPR which are formed from the sense strand are polymers of glycine-alanine 
(GA), glycine-proline (GP) and glycine-arginine (GR), while glycine-proline (GP), alanine-
proline (AP) and proline-arginine (PR) are translated from the antisense strand, as shown in 
Fig 1.4 (Gendron et al., 2013). Although poly-GP is produced from both sense and antisense 
strands, the carboxyl terminal tails will differ (Zu et al., 2013).   
 
Figure 1.4 Potential dipeptide repeat proteins arising from RAN translation 
(Gendron et al., 2013). 
Schematic showing the potential DPRs which could arise from RAN translation of 
expanded G4C2 (sense) and C4G2 (antisense) repeats in C9orf72. Note that poly-GP 
dipeptides can be formed in both directions.  
 
All DPR proteins have been found in neuronal cytoplasmic inclusions in post-mortem C9orf72 
expansion cases (Ash et al., 2013; Gendron et al., 2013; Mori et al., 2013c; Zu et al., 2013), 
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where they appear to co-localise with p62, but not pTDP-43 inclusions (Mackenzie et al., 
2013; Mori et al., 2013a; Mori et al., 2013c). A small number of patients with a C9orf72 HRE, 
who died prematurely of causes unrelated to their presenting FTD, showed high levels of DPR 
in some pyramidal cells and interneurons in the cerebral cortex and hippocampus, but very 
little evidence of TDP-43 pathology which may suggest that DPR accumulation precedes 
TDP-43 mislocalisation (Baborie et al., 2015; Proudfoot et al., 2014). In a sample of 10 ALS 
cases, there was little evidence of DPR accumulation in the spinal cord or co-localisation with 
TDP-43, and DPR were rare in motor neurons (Gomez-Deza et al., 2015). Given that TDP-43 
inclusions are present in C9orf72-related ALS cases, it is difficult to establish where DPR 
accumulation fits into the neurodegenerative process (Gomez-Deza et al., 2015). The most 
recent studies have used an extensive array of antibodies against each of the DPR species, and 
investigated their presence in a variety of different brain regions, including frontal lobes and 
spinal cord which are most prone to neurodegeneration, and other regions which are of less 
clinical relevance to ALS and FTD (Mackenzie, 2016). These have confirmed the previous 
suggestions that there is a lack of correlation between the presence of DPR and 
neurodegeneration or clinical features (Davidson et al., 2016; Mackenzie et al., 2015).  
Much of the evidence suggesting that DPR are toxic have come from studies where DPRs have 
been expressed in cell lines or model organisms, therefore caution should be exercised when 
interpreting these results as the expression levels may differ significantly from those seen in 
patients with C9orf72 repeat expansions. The expression of poly-GA, poly-GP and poly-GR, 
independent of (G4C2)n RNA in cultured cells, resulted in toxicity in cultured neuronal cells 
and in cortical neurons in vivo (Yamakawa et al., 2015). Numerous studies have found that the 
most abundant DPR inclusion protein in patients is poly-GA (Mackenzie et al., 2015; Mori et 
al., 2013c; Zhang et al., 2014b). Poly-GA expression in primary neurons led to impaired 
proteasome activity, endoplasmic reticulum stress and neurotoxicity, all in the absence of RNA 
foci (Zhang et al., 2014b). Poly-GA has also been found to sequester Unc119, which is thought 
to play a role in neurodegeneration (May et al., 2014). Poly-GA appears to form an amyloid 
like structure, and has properties which suggest that cell-to-cell transmission may be possible 
(Chang et al., 2016). A mouse model which produces poly-GA in the CNS shows 
neurodegeneration and behavioural problems which are similar to those seen in ALS and FTD 
(Zhang et al., 2016). In this study, poly-GA  was found to form aggregates which can sequester 
HR23 and nuclear pore proteins, providing a link between poly-GA accumulation and 
deficiencies in the ubiquitin proteasome system (Yamakawa et al., 2015; Zhang et al., 2016). 
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Other studies have focussed on the arginine-rich DPRs poly-GR and poly-PR. Expression of 
these in Drosophila cause neurodegeneration, independent of RNA toxicity (Mizielinska et 
al., 2014). The arginine-rich DPRs were also found to bind nucleoli in cultured cells, impairing 
mRNA splicing and production of ribosomal RNA, leading to cell death (Kwon et al., 2014).  
1.3.4.4 TDP-43 and p62 pathology 
Loss of nuclear TDP-43 and cytoplasmic mislocalisation is characteristic of most types of 
ALS, including C9orf72 expansion cases (Neumann et al., 2006). Although the 
neuropathology of C9orf72 ALS cases are similar to non-C9orf72 cases in terms of loss of 
anterior horn and cranial nerve nuclei motor neurons, and microglial activation, there are also 
some differences. ALS associated with C9orf72 HREs also have large inclusions, with RNA 
foci and DPRs, which also contain ubiquitin and p62, rather than TDP-43 (Mackenzie et al., 
2014). These are particularly found in extra-motor regions including the hippocampus and 
cerebellum (Cooper-Knock et al., 2012). 
The link between C9orf72 specific pathologies and TDP-43 mislocalisation is intriguing. Post-
mortem studies have suggested that there is no difference in the proportion of sense RNA foci 
containing motor neurons with and without nuclear TDP-43 (Cooper-Knock et al., 2014). 
However, the occurrence of antisense RNA foci has been shown to be significantly associated 
with TDP-43 mislocalisation in motor neurons, as shown by co-labelling experiments 
(Cooper-Knock et al., 2015).  
Recently, there has been an intense interest around deficiencies in nucleocytoplasmic transport 
related to C9orf72 HREs (Boeynaems et al., 2016; Freibaum et al., 2015; Jovicic et al., 2015; 
Zhang et al., 2015). The trafficking of RNA and protein between the nucleus and cytoplasm is 
a highly regulated process (Burns and Wente, 2012). Disruption of normal nucleocytoplasmic 
transport could lead to the characteristic cytoplasmic accumulation of TDP-43 observed in 
ALS and FTD cases attributed to C9orf72 HREs (Gitler and Tsuiji, 2016). Although several 
studies have now implicated nucleocytoplasmic transport impairment in pathology, using a 
range of different methods and model systems, there is no consensus on whether the root cause 
of this defect is related to toxic RNA or DPRs (Gitler and Tsuiji, 2016).  
1.3.5 Disease modifiers 
As the majority of ALS cases (95%) are not familial in nature, it seems clear that there are 
significant environmental factors which influence the disease (Al-Chalabi and Hardiman, 
2013). Twin studies have been used to estimate the heritability of ALS and suggest that 
approximately 60% of the risk of ALS is genetic and the remaining 40% is due to 
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environmental influences (Al-Chalabi et al., 2010). Another study investigating concordance 
between parents and offspring has suggested a lower genetic risk of around 40% (Wingo et 
al., 2011). 
The environmental influences are largely unknown for ALS, partly due to the infinite nature 
of possible influences and the difficulty in extracting meaningful information of exposures 
from patients over their lifetimes (Al-Chalabi and Hardiman, 2013; Burrell et al., 2016). Many 
environmental factors have been suggested to be linked with ALS, including smoking, 
physical exercise, and exposure to metals or pesticides (Al-Chalabi and Hardiman, 2013).  
It may be the case that there are different environmental factors influencing disease in specific 
genetic backgrounds, and therefore studies should stratify for known genetic factors to enable 
detection of such interactions (Al-Chalabi and Hardiman, 2013).  
For C9orf72, there are no specific environmental influences that have thus far been reported 
to influence disease presentation or progression. There have been several studies which have 
investigated the influence of other genetic factors on disease such as variants in 
transmembrane protein 106B (TMEM106B), intermediate repeats in ataxin-2 (ATXN2) and 
the presence of mutations in other known ALS-associated genes (Gallagher et al., 2014; van 
Blitterswijk et al., 2013a; van Blitterswijk et al., 2014a; van Blitterswijk et al., 2014b). The 
TMEM106B genotype does not appear to influence ALS, with risk alleles only affecting FTD 
presentation (van Blitterswijk et al., 2014b). There is some evidence that intermediate repeats 
(>23 repeats) in ATXN2 influence the propensity to develop ALS as compared to FTD in 
C9orf72 HRE carriers (van Blitterswijk et al., 2014a), however this finding was not replicated 
in a larger study (Chiò et al., 2016). The influence of genomic instability around the HRE is 
another interesting area, with a 10 base pair deletion adjacent to the 3’ end of the repeat being 
associated with a lower prevalence of psychosis (Snowden et al., 2016). It is not clear whether 
this is a direct effect or due to cis-acting factors that are linked to this specific variant, and 
further studies are required to confirm this finding in other populations (Snowden et al., 2016).  
1.4 Studying ALS 
The progressive loss of motor neurons is a defining feature of ALS. Animal and cellular 
models have been used to study the roles of ALS related genes and pathogenic mutations; 
however there is still limited knowledge of the specific molecular mechanisms leading to 
neurodegeneration (Qiang et al., 2013). There has been a shift in the focus of research on 
intrinsic motor neuron defects, to non-cell-autonomous effects, as it has become clear that 
ALS is a disease of the motor system rather than just motor neurons (Taylor et al., 2016; Valori 
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et al., 2014). Studies in mice where mutant SOD1 is expressed exclusively in motor neurons 
have given support to this concept, as early onset of disease does not occur (Yamanaka et al., 
2008a). The reduction of mutant SOD1 in motor neurons, even before symptom onset, does 
not slow disease progression indicating non-cell-autonomous effects are at play (Boillée et al., 
2006). 
The main glial cells types in the CNS: astrocytes  (Lobsiger and Cleveland, 2007), microglia 
(Boillée and Cleveland, 2008) and more recently oligodendrocytes (Kang et al., 2013; Lee et 
al., 2012; Philips et al., 2013; Rohan et al., 2014) have been investigated in the context of ALS. 
This has mainly been done both through post-mortem studies and SOD1 mutant rodent studies 
where cell-type specific expression allowed the contribution of mutant glial cells to disease to 
be assessed (Lobsiger and Cleveland, 2007).  
Astrocytes are an abundant cell type in the CNS, and play a significant role in homeostasis. 
They are involved in the ion buffering, neurotransmitter recycling and metabolic support to 
neurons (Sofroniew and Vinters, 2010). In the context of ALS the most intensely studied glial 
influence has been mutant SOD1 astrocytes, which are thought to be toxic to motor neurons 
and drive disease progression (Ferraiuolo et al., 2011). The targeted reduction of mutant SOD1 
expression in astrocytes in mouse models either delayed disease onset or slowed disease 
progression (Wang et al., 2011; Yamanaka et al., 2008b). Astrocytes generated directly from 
fibroblasts with a C9orf72 HRE were found to be toxic to motor neurons in co-culture 
experiments (Meyer et al., 2014). 
Microglia are macrophages which reside in the CNS, acting as immune defenders and 
destroying any cellular debris (Kreutzberg, 1996). They secrete cytokines and upon activation 
following an injury or pathological insult to neuronal tissue, will rapidly transform from their 
resting ramified state to a migratory ameboid morphology. Once activated, microglia tend to 
be anti-inflammatory and provide neuroprotection in the early stages of ALS, but later a self-
propagating cycle of neuronal injury occurs as microglia release reactive oxygen species and 
pro-inflammatory cytokines in response to neurotoxic signals released from motor neurons 
(Appel et al., 2011). In a mouse model lacking murine C9orf72, abnormal microglia were 
observed, along with age-related neurodegeneration thus providing further evidence that 
microglial mediated inflammation plays a role in ALS (O'Rourke et al., 2016). 




1.4.1 Pathology studies and neuroimaging 
Histopathological studies on post-mortem material analyse disease down to the cellular level, 
investigating single neurons and synapses in the areas sampled (Turner and Verstraete, 2015). 
In the majority of cases, analysis focuses on the end-stage of disease, and due to the nature of 
the sampling, the process of death may confound results (Turner and Verstraete, 2015). One 
pathology study included three C9orf72 HRE carriers who died prematurely of non-FTD 
related disease, allowing some insight into earlier disease processes (Baborie et al., 2015). 
Histopathological studies allow investigations of cell loss (type, layer, quantification), the 
presence of specific protein inclusions and molecular characterization (Turner and Verstraete, 
2015).  
Neuroimaging, on the other hand, allows in vivo analysis on a whole-brain scale to be carried 
out, and typically reflects findings that have been revealed through post-mortem studies, whilst 
also allowing longitudinal studies in both pre-symptomatic and symptomatic individuals and 
analysis of network properties and efficiency (Turner and Verstraete, 2015).  Clinically, 
magnetic resonance imaging (MRI) is mainly used to exclude the presence of structural 
changes which could account for symptoms (Filippi et al., 2010). MRI is increasingly being 
used in biomarker discovery, for example corticospinal tract hyperintensity has been identified 
as a feature in ALS patients (Goodin et al., 1988). Future studies aim to find new biomarkers 
which may be useful in monitoring patients during clinical trials (Grolez et al., 2016).  Detailed 
imaging of living brains of C9orf72 HRE carriers, particularly if DPR could be detected, could 
help establish the links between DPRs and pathology, since the model systems and post-
mortem results appear disconnected (Gitler and Tsuiji, 2016). Such technology has allowed 
amyloid fibrils to be imaged in vivo using specific binding compounds and positron emission 
tomography, in Alzheimer disease (Mitsis et al., 2014). 
1.4.2 Animal models of disease 
There are several animal models for ALS and FTD, and the majority of studies have focused 
on rodent models of these diseases. As the first genetic cause of ALS identified, mutant SOD1 
based models which recapitulate several aspects of the disease, have been extensively studied 
to aid understanding of the underlying pathogenesis (McGoldrick et al., 2013). It has proved 
more challenging to develop rodent models for TDP-43 based disease, as they do not result in 
an ALS-like phenotype and results are highly variable depending on transgene expression 
levels (McGoldrick et al., 2013).  
The various models which have been generated to investigate the effects of loss of C9orf72 
function have been discussed in section 1.3.4.1. These studies have shown that different results 
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are obtained when investigating different animal models, making it hard to draw conclusions 
regarding the contribution of C9orf72 haploinsufficiency to the disease phenotype.  
For C9orf72, a murine model which expresses the 66 GGGGCC repeats throughout the central 
nervous system has been developed by adeno-associated virus mediated transgenesis, and 
shown to replicate both neuropathological and clinical aspects of human C9orf72 mediated 
ALS/FTD (Chew et al., 2015). Other strains of transgenic mouse which have been generated 
from a bacterial artificial chromosome which contains part of the human C9orf72 gene with 
an HRE of approximately 500 repeats, has shown the production of RNA foci and DPRs, but 
did not induce neurodegeneration (Peters et al., 2015). Similarly, another bacterial artificial 
chromosome (BAC) induced model with 100-1000 repeats had similar findings, while also 
reporting evidence of nucleolar stress (O'Rourke et al., 2016). The differences between these 
models are likely to be due to the expression levels of the repeat expansion, as the adeno-
associated virus model expresses this under the control of the chicken β-actin promoter, and 
is thus produced at a higher level than in the BAC models, which are more physiologically 
relevant to the human disease (O'Rourke et al., 2016). 
A major issue with transgenic animal models relates to the expression levels of the proposed 
pathological entities (McGoldrick et al., 2013). For example, poly-GR may well be toxic to 
cells if expressed at a high level, but unless it is actually expressed at a similar level in human 
cells, then this offers limited insight into the in vivo human pathogenic processes. A clear 
example where this has been demonstrated is in the poly-GA transgenic mouse model, which 
was found to have double the poly-GA levels found in a mouse model which expressed the 
(G4C2)66 repeat (Zhang et al., 2016).  Another important factor is that mouse models are inbred, 
which may affect the phenotype related to a pathogenic genetic variant compared to the more 
heterogeneous genetic backgrounds of humans (Saha and Jaenisch, 2009). 
Although much can be learnt from animal models, it is clear from other diseases that findings 
do not always translate between species (Benatar, 2007). An example of a drug which failed 
to translate between a murine model of ALS and human clinical trials was creatine, which 
extended survival and conserved motor neuron function in mice but had no apparent benefit 
to ALS patients (Shefner et al., 2004). Partly, the lack of translation may be due to the majority 
of studies being carried out on SOD1 disease models which may not reflect the underlying 
pathology of the majority of ALS cases, or because drugs have been tested presymptomatically 
on rodents but are then administered to patients in the late stages of disease (McGoldrick et 
al., 2013) The toxicity profiles of drugs also differ between animals, meaning that drug screens 
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on animal models may not always reveal results which are appropriate to humans (Singh and 
Gupta, 1985).  
1.4.3 hiPSC models of disease 
Studying neurodegenerative disease is challenging, as access to living tissue is impractical, 
and post-mortem tissue is unlikely to represent early disease processes. Animal models of 
neurodegenerative disease provide insight, but have limitations in recapitulating human 
disease, and findings may not translate to human systems (Bradl and Lassmann, 2009). The 
advent of technology to reprogram somatic cells to generate human induced pluripotent stem 
cell (hiPSC) lines using ectopic expression of transcription factors octamer-binding 
transcription factor 4 (OCT4), sex-determining region-Y-box-2 (SOX2), Kruppel-like factor 
4 (KLF4) and C-MYC (Takahashi et al., 2007), and the ability to direct their differentiation to 
specific cells of interest using morphogenic signals has offered a novel means to generate 
central nervous system cell types. hiPSC lines can be maintained and expanded in culture for 
many passages while retaining a capacity to generate all three embryonic germ layers like 
embryonic stem (ES) cells (Takahashi et al., 2007; Thomson et al., 1998). 
hiPSC technology is particularly exciting in the context of neurodegenerative diseases, as 
patient derived cells with pathogenic genetic variants can be studied. Early studies using hiPSC 
technology have provided a ‘proof of principle’ by recreating phenotypes that have previously 
been noted in animal models, or human pathology studies (Sandoe and Eggan, 2013). The 
generation of enriched populations of particular cell types allow for cell autonomous effects 
to be studied, and reductionist model co-culture systems can allow assessment of non-cell 
autonomous effects between specific cell types (Qiang et al., 2013). Such cells can also be 
used as a platform for drug screening where clear phenotypes are observed or may be used in 
cell-replacement therapies in the future (reviewed in Cundiff and Anderson, 2011).  
1.4.3.1 Cellular reprogramming 
There are a number of transcription factors, including OCT4, Nanog and Sox2, which are vital 
in ES cell maintenance, and give these cells their characteristic pluripotency and self-renewal 
properties. Expression of these transcription factors suppresses the expression of 
differentiation genes and promotes pluripotency gene expression (Loh et al., 2006). This led 
to speculation that forced expression of such genes in somatic cells could revert them to a 
pluripotent state, which was shown to be the case in mice by Takahashi and Yamanaka in 2006 
(Takahashi and Yamanaka, 2006). 
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There are various methods which can be used to reprogram somatic cells by inducing the 
expression of defined sets of transcription factors within the cells, and these include transgene-
based and transgene-free methods. Transgene-based methods involve the integration of genes 
encoding these transcription factors into the host genome, utilizing retroviral or lentiviral 
vectors (Brock et al., 2012). These methods are widely used but suffer from the risk of 
insertional mutagenesis, as the integration site is random and could inactivate a vital gene or 
otherwise disturb normal gene expression (Brock et al., 2012). Because of the limitations 
associated with a viral-mediated reprogramming methods, several other methods which are 
integration free, have now been developed. Non-integrating Sendai viruses and adenoviral 
vectors have been used to reprogram human somatic cells to hiPSCs (Fusaki et al., 2009; Zhou 
and Freed, 2009), whilst episomal approaches are becoming increasingly popular as they are 
cost-effective, transgene-free and viral-free (Yu et al., 2009). In the mouse, small molecules 
have been used in place of exogenous transcription factors (Hou et al., 2013), however this 
approach has not yet proved successful for generating hiPSCs. 
Reprogramming is an inefficient process, and stochastic events during clonal selection can 
influence the transcriptional and epigenetic states of the cells (Lund et al., 2012b). Because 
many cell types can be formed during the reprogramming process, including transformed cells 
or intermediates (Chan et al., 2009; Mikkelsen et al., 2008), it is important that newly 
generated cell lines are checked for pluripotency, through both showing the expression of 
transcription factors such as Nanog and OCT4 and the ability to generate all three germ layers 
(Ellis et al., 2009). It is also important to check that resulting hiPSCs are free from 
chromosomal abnormalities, and as cells in culture for extended time periods may acquire 
abnormal karyotypes, this should be done regularly during their maintenance (Taapken et al., 
2011). 
1.4.3.2 Studying ALS using hiPSC based models 
Using hiPSC derived cells is an attractive in vitro method to study cellular mechanisms 
underlying ALS as it allows human cells to be studies which are either from sporadic cases or 
familial cases which contain physiologically relevant expression of a mutated gene (Richard 
and Maragakis, 2015).  Most of the early studies using this technique have focused on 
investigating motor neurons in culture, while later work has now extended to non-neuronal 
cells and the impact that these may be having on disease pathogenesis (Richard and Maragakis, 
2015). 
Human iPSC-derived neurons have been generated from patients with C9orf72 HREs by 
several groups, who have shown that they display RNA foci, which is one of the key 
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pathological features associated with the repeat expansion (Almeida et al., 2013; Devlin et al., 
2015; Donnelly et al., 2013; Sareen et al., 2013). Further characterisation of these hiPSC-
derived neurons has suggested that (GGGGCC)n RNA foci could be sequestering several RNA 
binding proteins (such as ADARB2, hnRNPA1, hnRNPA1B2, Pur-α, FUS and TDP-43), and 
thus potentially disrupting their normal function (Donnelly et al., 2013; Sareen et al., 2013). 
These studies have been largely inconclusive, however, and the role of RNA foci in 
pathogenesis remains unclear.  The presence of DPRs, particularly poly(GP), have been shown 
in hiPSC-derived neurons (Almeida et al., 2013; Donnelly et al., 2013).  
RNA-sequencing of hiPSC derived neurons has suggested that C9orf72 HREs are associated 
with misregulation of genes involved in cell adhesion, synaptic transmission and neural 
differentiation (Donnelly et al., 2013; Sareen et al., 2013). C9orf72 HRE hiPSC-derived 
neurons show enhanced vulnerability to glutamate-mediated cytotoxicity  (Donnelly et al., 
2013) and the autophagy inhibitor chloroquine (Almeida et al., 2013).  
C9orf72 HRE hiPSC-derived neurons also offer a means of screening potential therapeutics. 
Studies have shown that antisense oligonucleotides that specifically target the GGGGCC 
containing transcripts can reduce RNA foci and revert transcriptional changes and 
vulnerability to glutamate toxicity (Donnelly et al., 2013; Sareen et al., 2013). The use of 
hiPSCs in drug screening should offer more physiologically relevant results, in terms of both 
drug efficacy and toxicity, from drug screening compared to using animal models (Rubin, 
2008).  
Reprogramming skin fibroblasts from patients with a heterozygous SOD1 A4V variant to 
produce hiPSCs, and converting these to motor neurons revealed that these cells were more 
prone to apoptosis, had a smaller soma, and a reduced number of neuronal processes, which 
were also shorter, when compared to an isogenic control line in which the A4V variant had 
been corrected using zinc finger nuclease (ZFN)-mediated gene targeting (Kiskinis et al., 
2014). Similar studies have been performed on hiPSC-derived neurons with pathogenic 
variants in TARDBP, which indicated that these cells showed an increase in TDP-43 protein 
in the insoluble fractions (Bilican et al., 2012; Egawa et al., 2012).  
Most studies of ALS using hiPSC derived cellular models have focused on generating neuronal 
cells to investigate the influence of genetic variants on specific clinically relevant neuronal 
subtypes, however more recent studies have been carried out to investigate glial influences in 
neurodegenerative disease using this type of approach. Such cells can be used to investigate 
the roles of cell autonomous and non-cell autonomous factors for these variants in motor 
neuron dysfunction. Particular interest has been shown to the role of astrocytes in ALS derived 
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from hiPSCs carrying the pathogenic M337V variant have been co-cultured with control motor 
neurons and shown not to have a non-cell autonomous cytotoxic effect on these cells (Serio et 
al., 2013). This contrasts with studies using co-cultures with post-mortem derived astrocytes 
from sporadic cases and SOD1 mutation carriers, which led to 45-70% reduced survival in 
motor neurons compared to controls (Haidet-Phillips et al., 2011).  
1.4.3.3 Limitations of disease studies on hiPSC based cells 
Like ES cell lines, which have been found to have variable differentiation efficiencies 
(Osafune et al., 2008), there have been similar concerns of differences between hiPSC lines 
(Hu et al., 2010). Not only are there differences in the differentiation capabilities of cell lines, 
but it is becoming increasingly clear that there are phenotypic differences between cell lines 
even with the same pathogenic mutation. For example there are differences reported in the 
electrophysiological properties of hiPSC-derived neurons with C9orf72 HREs (Devlin et al., 
2015; Sareen et al., 2013). Also, despite the same antibodies being used for detecting DPRs, 
these have not been consistently detected in all studies (Sareen et al., 2013). 
One way in which the variability between hiPSC lines can be accounted for is to use large 
cohorts of both patient and control lines, such as was carried out by the Huntington’s Disease 
hiPSC consortium who assessed 14 hiPSC lines (Consortium, 2012). This is a highly rigorous 
approach, particularly where there are multiple research groups who are performing 
phenotypic assessments, although it is still unclear how many lines may need to be studied to 
elucidate subtle phenotypes (Sandoe and Eggan, 2013), which may be even more difficult to 
detect when studying a genetic variant, such as the C9orf72 HRE, which is so clinically 
variable. Clearly, although this approach is scientifically a sound approach, there are 
significant practical and cost implications which may limit the number of cell lines which can 
be assessed (Sandoe and Eggan, 2013). 
It is thought that one of the major causes of variation between different hiPSC lines is the 
genetic background of the donor, which was shown in a study of the transcriptional profiles of 
25 hiPSC lines which were derived from three donors and aimed to determine the relative 
variation caused by tissue source versus donor genetic background to the transcriptional 
profiles of the derived hiPSCs (Rouhani et al., 2014). One approach which has been used to 
limit this effect is to use family members of affected individuals as a source of control cell 
lines (Ebert et al., 2009), however such a strategy must take into account the genetic status of 
the individual and the likelihood of them being pre-symptomatic carriers, and is less 
appropriate for studies of sporadic disease (Sandoe and Eggan, 2013). More recently, the 
problems with genetic background have been overcome through the ability to generate 
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isogenic control lines where pathogenic variants are corrected using gene targeting technology 
such as ZFN, transcription activator-like effector nucleases (TALENs) or clustered regularly 
interspaced short palindromic repeat (CRISPR)/Cas9-mediated gene editing (Soldner et al., 
2011).  
A potential limitation of studies on hiPSC-derived neurons is that they represent cells which 
are at an earlier developmental stage compared to those that manifest disease in vivo (Lee and 
Huang, 2015). The dynamics of pathogenesis are likely to be hugely different between a 
patient and in vitro cells differentiated from hiPSCs, particularly for neurodegenerative 
diseases which are associated with aging (Saha and Jaenisch, 2009). Various strategies have 
been utilised to artificially ‘age’ hiPSC derived cells, including the application of oxidative 
stress (Nguyen et al., 2011), expression of progerin (Miller et al., 2013a) and excessive 
glutamate induced stimulation (Koch et al., 2011). Recently, one study which looked at the 
gene expression profiles of a variety of cell types including hiPSCs, hiPSC-derived neurons 
and post-mortem tissues has suggested that hiPSC-derived neurons lose their aging signatures, 
which is in contrast with neurons generated via direct reprogramming from fibroblasts 
(iNeurons), which retain them (Mertens et al., 2015).  
Some other limitations of hiPSC models are that the cells undergo significant epigenetic 
changes during reprogramming, and the prolonged culture times and cell selection in vitro 
might introduce variation within the system (Lee and Huang, 2015). During reprogramming, 
there is a reduction in cytosine methylation throughout the genome (Leitch et al., 2013). It is 
thought that there is some degree of epigenetic memory whereby the DNA methylation 
patterns in hiPSCs are related to those seen in their cell type of origin, which may affect their 
differentiation capacity (Kim et al., 2010). Also, abnormalities in X-chromosome inactivation 
may occur and could have an impact on cellular phenotypes (Mekhoubad et al., 2012). This 
makes it challenging to study diseases with significant epigenetic components using hiPSCs 
(Saha and Jaenisch, 2009). Given the observation that C9orf72 HREs are associated with 
repressive epigenetic marks (Belzil et al., 2013), which could contribute to haploinsufficiency 
by reducing mRNA expression levels (Gendron et al., 2014), it is important to consider the 
effect of reprogramming on this locus. Recently, a study has shown that following 
reprogramming there was a reduction in DNA methylation at the C9orf72 promoter of hiPSCs 
compared to the hypermethylated state detected in an immortalized lymphocyte cell line from 
which they were derived (Esanov et al., 2016). A time-course study then revealed that as 
hiPSCs were differentiated to neural precursor cells, the levels of cytosine methylation at the 
C9orf72 promoter increased with differentiation which suggests that methylation patterns are 
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established during early neurodevelopment (Esanov et al., 2016). This study was limited to 
one patient, and another small study has revealed that two hiPSC lines with C9orf72 HREs 
were hypermethylated compared to fibroblasts and ES cells (Cohen-Hadad et al., 2016). Thus 
further studies are required to determine what influences C9orf72 methylation status during 
reprogramming and differentiation of hiPSCs. 
Long term cell culture of pluripotent stem cells can lead to the accumulation of karyotypic 
abnormalities, particularly those which confer a growth advantage (Baker et al., 2007; Cowan 
et al., 2004; Draper et al., 2004), and the reprogramming process to generate hiPSCs is also 
associated with copy number variation (Hussein et al., 2011). There are a number of common 
abnormalities which have been found in large scale studies of hESCs and hiPSCs which 
involve partial or whole gains of chromosomes 12, 17, 20 or X (Baker et al., 2007; Spits et al., 
2008; Taapken et al., 2011). It is therefore important that hiPSCs are checked for the presence 
of karyotypic abnormalities regularly, as these could alter the developmental properties and 
malignant potential of the cells (Lund et al., 2012a). 
A final challenge in using hiPSC derived cells for disease modelling is that human diseases 
rarely affect a single cell type, and are usually mediated via complex interactions between 
different cell types which are difficult to recreate in vitro. Nevertheless, studies on ALS have 
shown that hiPSC derived cells can be used to help elucidate glial influences on neurons, for 
example, by setting up co-culture systems (Almad et al., 2016; Ferraiuolo et al., 2016; Serio 
et al., 2013). Furthermore, recent developments in three-dimensional culture systems, 
particularly in creating cerebral organoids from hiPSCs hold potential in creating enhanced 
three-dimensional model systems in which to study neurodegenerative disease, as has been 
shown for Alzheimer’s Disease (Zhang et al., 2014a). For such late-onset diseases, in vivo 
approaches whereby chimeras are created from the grafting or transplantation of hiPSC 
derived cells into suitable model organisms, may be an informative approach for investigating 
disease processes (Saha and Jaenisch, 2009). 
1.4.3.4 Generating isogenic controls using CRISPR/Cas9-mediated gene 
editing 
The ability to generate isogenic cell lines is a significant breakthrough which overcomes the 
problems of background genetic variation between cell lines (Jaworska et al., 2016). Gene 
correction can be carried out using site-specific nucleases such as ZFNs, TALENs or 
CRISPR/Cas9 systems to generate double strand breaks in specific genomic locations, which 
are then repaired using non-homologous end joining, or homologous recombination where a 
repair template is included (Jaworska et al., 2016). This technology can be used to remove 
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disease associated repeat expansions from cells: for example, the CRISPR/Cas9 system has 
been used to remove the (CGG)n repeats from Fragile X syndrome hiPSCs as well as (CAG)n 
repeat expansions in Huntington Disease models (An et al., 2014; Park et al., 2015). 
CRISPR/Cas9 nucleases are generally preferred for use in hiPSCs compared to ZFNs and 
TALENs as they are easier to design and relatively low cost (Singh et al., 2015). CRISPR 
regions are transcribed to form pre-CRISR RNA (pre-crRNA) which are then processed to 
generate a target-specific crRNA. The locus also gives rise to trans-activating crRNA which 
aids in the processing of the pre-crRNA (Deltcheva et al., 2011). These RNA species form a 
complex with CRISPR-associated protein 9 (Cas9), and together they act as a DNA 
endonuclease (Gasiunas et al., 2012). This can cleave a 23 bp target DNA sequence which 
includes a 20 bp guide RNA within the crRNA, which can be modified to target regions of 
interest (Hsu et al., 2013; Jiang et al., 2013). Because the targeting relies on guide RNA in the 
CRISPR/Cas9 system, protein engineering is not required, and the specificity can be 
determined simply by cloning the appropriate DNA sequence into a vector which encodes 
crRNA (Kim and Kim, 2014). 
1.5 Oligodendrocytes in ALS and FTD 
1.5.1 Oligodendrocyte function 
Oligodendrocytes are a type of glial cell which were first known for their role in generating 
myelin sheaths on CNS axons, which increase electrical resistance and decrease capacitance 
allowing fast action potential conduction (Simons and Nave, 2016). Oligodendrocytes extend 
many processes, which contacts and wraps around neuronal axons, and subsequently condense 
to form myelin (Bunge et al., 1962; Bunge, 1968). Myelin is required for establishing nodes 
of Ranvier, which allow fast saltatory conduction through neurons of small diameter (Bunge, 
1968). More recently it has become clear that oligodendrocytes also have a key role in 
providing trophic support to neurons (Nave, 2010), mainly through the transfer of lactate via 
monocarboxylate transporter 1 (MCT1)  (Funfschilling et al., 2012; Lee et al., 2012).  
Disorders of myelin include multiple sclerosis (MS), Pelizaeus-Merzbacher disease (PMD) 
and Vanishing White Matter Disease (VWMD). All of these are devastating neurological 
conditions which highlight the importance of myelin (Clayton and Popko, 2016). In all of these 
disorders of CNS myelination, ER stress is thought to play a role, highlighting the 
susceptibility of oligodendrocytes to this type of stress (Clayton and Popko, 2016). This is 
presumably because myelin is rich in lipids and contain large amounts of proteins, the 
production of which places a strain on the cellular secretory systems (D'Antonio et al., 2009; 
Lin and Popko, 2009).  
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1.5.2 Oligodendrocytes in ALS/FTD 
Recent studies have suggested that oligodendrocyte pathology may contribute to disease in 
ALS. In ALS, the presence of p62 and pTDP-43 intracytoplasmic inclusions has been detected 
in the oligodendrocytes of patients (Mackenzie et al., 2011; Neumann et al., 2006; Seilhean et 
al., 2009). As well as the presence of these inclusions, myelin abnormalities, demyelination 
and oligodendrocyte degeneration have all been observed in ventral spinal cord gray matter of 
ALS patients (Kang et al., 2013). The presence of pTDP-43 inclusions in oligodendrocytes 
has been confirmed by double-labelling immunofluorescence with antibodies for TDP-43 and 
the oligodendrocyte marker anti-tubulin polymerisation promoting protein (p25α) 
(Brettschneider et al., 2014; Fatima et al., 2015; Song et al., 2007). Neuroimaging on a small 
number of ALS cases suggested that there is no significant difference in the overall cerebral 
myelin content compared to controls, but revealed reduced myelin in the frontal lobes which 
correlated with reduced cognitive scores in these patients with ALS (Kolind et al., 2013).  
Another study comparing histology and post-mortem MRI has tried to elucidate the MRI 
metrics which correlate to myelin content and the myelin sheath deterioration which is seen in 
end-stage disease, and this could allow investigations into earlier myelin changes in future 
MRI studies on patients (Meadowcroft et al., 2015). 
Alterations in myelin composition in a rat SOD1G93A ALS model have been reported, even in 
pre-symptomatic stages of the disease, although whether it was a secondary effect to axonal 
dysfunction was not established (Niebroj-Dobosz et al., 2007).  Post-mortem spinal cord and 
motor cortex samples from ALS patients also showed reduced myelin, indicated by luxol blue 
staining, compared to unaffected controls (Kang et al., 2013). In the SOD1G93A mouse ALS 
model, morphological changes are seen in oligodendrocytes before symptom onset and 
increase with disease course, before the cells die (Philips et al., 2013). The overall number of 
oligodendrocytes appears constant despite their increased death, so there appears to be 
compensatory increases in oligodendrocyte precursor cell proliferation and differentiation 
(Kang et al., 2013; Philips et al., 2013). However, the resulting cells are dysfunctional in terms 
of myelination and trophic support which is displayed by reduced myelin basic protein (MBP) 
and monocarboxylate transporter (MCT1) expression respectively (Kang et al., 2013; Philips 
et al., 2013). The loss of MCT1 from oligodendrocytes has been found to contribute to 
neurodegeneration (Lee et al., 2012). Ablation of motor neurons by ricin injection was not 
sufficient to cause the oligodendrocyte changes observed in the SOD1G93A mouse, and 
selectively removing mutant SOD1 expression in oligodendrocytes delayed disease onset 
suggesting that oligodendrocytes may play a role early in disease (Kang et al., 2013).   
47 
 
A recent study using ribosome tagging in SOD1 G37R and SOD1 G85R mutant mice to selectively 
analyse gene expression in motor neurons, astrocytes and oligodendrocytes has suggested that 
at disease onset, there are fewer genes which are dysregulated in oligodendrocytes than motor 
neurons, and that the changes are of lower magnitude (Sun et al., 2015). This study did not 
detect a decrease in MCT1 mRNA at either disease onset or early symptomatic stages of the 
disease, but did find a decrease in production of the main myelin proteins including MBP (Sun 
et al., 2015). This argued against early changes in oligodendrocytes being drivers of disease 
development, instead suggesting that changes were secondary to alterations in motor neurons 
and the surrounding environment, although this study did not investigate mRNA expression 
in oligodendrocyte precursor cells (Sun et al., 2015). 
Most studies on oligodendrocytes in ALS to date have focused on SOD1 models of the disease, 
as well as post-mortem tissue from sporadic patients. Mechanisms of cell autonomous and cell 
non-autonomous effects may differ in sporadic disease, and disease associated with pathogenic 
variants in other genes. This has been highlighted in a recent publication which compares 
hiPSC derived oligodendrocytes from both sporadic ALS patients and those with pathogenic 
mutations in a variety of ALS-associated genes  (Ferraiuolo et al., 2016). There has not been 
extensive investigation of oligodendrocyte dysfunction in FTD, with one small study 
suggesting that p62 inclusions were present in oligodendrocytes in an ALS/FTD patient but 
not in five FTD patients tested (Arai et al., 2003). 
The involvement of ER stress in ALS pathogenesis has been shown in post-mortem studies, 
animal models and in vitro cellular studies (Matus et al., 2013). ER stress activates the 
unfolded protein response (UPR) which is a signal transduction pathway which enhances the 
protein folding capacity and quality controls within the ER to regain homeostasis (Walter and 
Ron, 2011). ER stress may be the result of the accumulation of misfolded or unfolded proteins, 
problems with lipid synthesis or a reduction in calcium stores (Walter and Ron, 2011). Given 
the previously mentioned susceptibility of oligodendrocytes to ER stress in myelination 
disorders (section 1.5.1), this is an area which is worthy of investigation in oligodendrocytes 
with ALS related mutations.  
1.5.3 In vivo development of oligodendrocytes 
Oligodendrocyte development in vivo has been well characterised in animal models, 
particularly rodents, and is clearly defined by morphological features and expression of 
specific markers over time (Pfeiffer et al., 1993). The brain and spinal cord are thought to 
contain different subclasses of early OPCs, which arise from different origins and are 
characterized by the expression of different transcription factors and cell-specific markers. In 
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human fetal forebrain, distinct OPCs form from the ganglionic eminence and the cortical 
subventricular zone (Jakovcevski and Zecevic, 2005a; Rakic and Zecevic, 2003). It is unclear 
whether the resulting oligodendrocytes from these different sources have variation in their 
roles, myelination capacity or function within the context of disease. In mice, oligodendrocytes 
from the spinal cord have been found to form longer myelin sheaths than those derived from 
the cortex, independent of neuronal influences (Bechler et al., 2015). As well as any intrinsic 
differences between oligodendrocytes from different regions, there are also differences in the 
cellular microenvironments that these cells find themselves in which may influence their 
myelination and remyelination capacities and predisposition to demyelination (Ornelas et al., 
2016). 
Spinal cord derived oligodendrocytes, which are of interest in ALS, develop from the ventral 
ventricular zone of the neural tube (Kang et al., 2013). Their early specification is closely 
related to the transcriptional control of rostral-caudal and dorsal-ventral patterning of the 
neural tube by the morphogenic gradients of Sonic Hedgehog (Shh) and bone morphogenic 
protein (BMP) (Emery and Lu, 2015; Richardson et al., 2000). The developing neural tube is 
patterned along the rostral-caudal axis, primarily mediated by a gradient of retinoic acid (RA) 
(Figure 1.5). High levels of RA are produced by the caudal paraxial mesoderm and form a 
boundary between spinal cord and hindbrain. After spinal cord formation, RA is released from 
the somites, refining positioning along the rostral-caudal axis (Davis-Dusenbery et al., 2014).   
 
Figure 1.5 Caudalization of the neural tube by retinoic acid  
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Figure 1.5 Caudalization of the neural tube by retinoic acid  
The inner cell mass (ICM) forms the three germ layers (ectoderm, mesoderm and 
endoderm) during gastrulation. The dorsal portion of ectoderm is specified to 
neuroectoderm early in development, by inhibition of active and BMP signalling and 
activation of Wnt and FGF signalling. The neural tube is then formed, and patterned 
along the rostral-caudal axis (anterior-posterior) by a RA gradient. The initial boundary 
between spinal cord and hindbrain versus forebrain and hindbrain is set by high RA 
levels. Upon spinal cord formation, the release of RA from somites refined the position 
along the rostral-caudal axis. The opposing factors, Fgf8 and DGF11 specify more 
caudal cell types. The spinal cord is also then patterned along the dorsal-ventral axis. 
Reproduced with permission. (Davis-Dusenbery et al., 2014). 
Following caudalization, the anterior-posterior patterning is then determined by a gradient of 
Shh. Shh is secreted from the notochord and floor plate where a higher concentration leads to 
ventral patterning of the neural tube (Figure 1.6), while BMP and Wnt signalling from the roof 
plate lead to dorsal neural tube formation, and inhibit generation of the oligodendrocyte 
lineage (He and Lu, 2013). These morphogens result in the formation of 6 distinct progenitor 
domains along the dorsal-ventral axis: floor plate, p3, pMN, p2, p1 and p0. These domains all 
form specific cell types that express different homeodomain and basic helix-loop-helix 
transcription factors, which then act as downstream activators of Shh, and interact to generate 
the boundary between adjacent domains (Briscoe et al., 2000). OPCs mainly arise from the 
ventral pMN domain, following the production of motor neurons from a pool of precursors 
which are characterised by expression of Oligodendrocyte lineage transcription factor 2 
(Olig2), as shown in Figure 1.6 (Jacob and Briscoe, 2003; Richardson et al., 2000). Using a 
mouse model with an Shh-green fluorescent protein (GFP) fusion, it has been shown that the 
Shh expression exponentially decays along the dorsal-ventral axis, with maximal expression 
at p3, dropping at pMN, and is undetectable at p2 (Chamberlain et al., 2008), thus ventral cells 
are exposed to higher Shh concentration and for a longer time period than dorsal cells.  
 
Figure 1.6 Signaling regulation of OPC specification and development  
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Figure 1.6 Signaling regulation of OPC specification and development  
Ventral Shh from the notochord promotes OPC production in the pMN domain of the 
developing neural tube by promoting Olig2 expression, and competes against dorsal BMP 
signalling. Adapted, (Jacob and Briscoe, 2003). Reproduced with permission, copyright 
of Cold Spring Harbor Laboratory Press (Emery and Lu, 2015). 
 
Olig2 is a transcription factor which promotes motor neuron fate initially through binding to 
neurogenin-1 and neurogenin-2 (Zhou et al., 2001), and then after undergoing 
dephosphorylation at Ser147, switches to promote oligodendrocyte fate via preferential 
binding to different partner transcription factors (Li et al., 2011). OPCs arise from cells which 
co-express Olig2 and Nkx2.2, and the latter is thought to inhibit expression of neurogenins, 
providing for the neurogenic-gliogenic switch which is required for OPC production (Li et al., 
2011; Ribes and Briscoe, 2009). Olig2 is thought to be essential for early ventral OPC 
generation which produces 85-90% of the final oligodendrocyte population and is a consistent 
marker for the oligodendrocyte lineage, (Bradl and Lassmann, 2010; Emery and Lu, 2015; 
Fogarty et al., 2005; Vallstedt et al., 2005). The remaining 10% of OPCs arise more dorsally, 
later in rodent development, and these do not initially express Olig2 (Cai et al., 2005; Vallstedt 
et al., 2005), suggesting that there is compensation by other factors such as Olig1, and that 
Olig2 is not essential for specifying the oligodendrocyte lineage (Zhou and Anderson, 2002). 
Mice which are homozygously deleted for Olig2 fail to develop motor neurons or 
oligodendrocytes within their spinal cords, and die at birth (Takebayashi et al., 2002).  
Various transcription factors are expressed in OPCs as they migrate from where they are 
generated to throughout the central nervous system. Olig2 expression continues, and appears 
to promote expression of Sox10 and Nkx2.2 (Liu et al., 2007; Zhou et al., 2001). Sox9 and 
Sox10 promote the expression of PDGFR-α (Finzsch et al., 2008), which promotes survival 
and proliferation of OPCs via the binding of its ligand platelet-derived growth factor (PDGF) 
(Barres et al., 1993; Calver et al., 1998). 
For differentiation of oligodendrocytes to occur, OPCs must exit the cell cycle and this process 
must be highly regulated to control the timing of myelination and to ensure there is a pool of 
OPCs remaining (Emery and Lu, 2015). The Notch, BMP and Wnt signalling pathways inhibit 
OPC production and differentiation during development, and there are prodifferentiation 
factors which act to antagonize these inhibitory effects allowing differentiation to occur 
(Emery and Lu, 2015). These include Olig2 in combination with Brg1 (Yu et al., 2013), and 
the downstream target zinc finger homeobox transcription factor Zfhx1b which antagonizes 
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signals via BMP, Notch and Wnt signalling pathways allowing differentiation to occur (Weng 
et al., 2012).  
OPCs can be characterised by the expression of platelet-derived growth factor receptor α 
(PDGFR-α) (Pringle et al., 1992) and have either bipolar morphology, or a few short branches 
(Jakovcevski and Zecevic, 2005b) as shown in Figure 1.7. In humans, OPCs are first detected 
at 10 gestational weeks (gw) (Jakovcevski et al., 2009). These cells then continue proliferating 
from 10-15 gw, before migrating dorsally from the cortical ventricular zone and subventricular 
zone (Jakovcevski et al., 2009). Development progresses from late OPCs to immature 
oligodendrocytes, characterised by expression of the O4 sulfatide (Jakovcevski and Zecevic, 
2005b; Schachner et al., 1981) to pre-myelinating oligodendrocytes, with mature myelin basic 
protein (MBP) expressing, highly branched cells first appearing at 18gw and then increasing 
in number with time (Jakovcevski et al., 2009), as shown in Figure 1.7. Postnatally, 
oligodendrocytes are found throughout the central nervous system, and are most abundant in 
white matter tracts (Rowitch, 2004). Following terminal differentiation, postmitotic 
oligodendrocytes undergo morphology changes, extending elaborate processes which then 
contact axons. Subsequently, most of these processes are withdrawn and the axons are 
ensheathed and nodes of Ranvier form (Emery and Lu, 2015). Myelination begins in the final 




Figure 1.7 Oligodendrocyte differentiation and maturation: markers and 
morphology 
At least three stages of oligodendrocyte maturation can be defined: oligodendrocyte 
progenitor cells, immature oligodendrocytes and mature oligodendrocytes. Stages are 
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identifiable by increasingly complex morphology with time, and the expression pattern of 
different transcription factors and cell surface markers. Oligodendrocyte precursor cells 
can also be defined by their ability to proliferate and migrate. CNPase, 2′,3′-cyclic 
nucleotide 3′-phosphodiesterase; GalC, galactocerebroside C; MAG, myelin associated 
glycoprotein; MOG, myelin oligodendrocyte glycoprotein. Markers in bold are used in this 
study. Adapted (Barateiro and Fernandes, 2014).  
 
1.5.4 Generating hiPSC derived oligodendrocytes  
The ability to generate differentiated cells from patient derived hiPSCs allows the study of cell 
autonomous factors in disease. For neurodegenerative diseases such as amyotrophic lateral 
sclerosis, hiPSC technology is particularly useful as brain and neuronal tissue from patients 
are inaccessible during early and intermediate stages of disease. To generate oligodendrocytes 
from hiPSCs, knowledge of their in vivo development can be used to attempt to recapitulate 
this in vitro. 
Protocols to derive OPCs and oligodendrocytes were first developed for murine systems, and 
these have been used to guide development of human based protocols, taking into account key 
differences in the signalling pathways involved in NPC patterning between mouse and human 
(Li et al., 2009). There are several published protocols for deriving OPCs and oligodendrocytes 
from human ES cells, all of which are time-consuming and take months rather than weeks as 
is the case in mouse (Hu et al., 2009a; Izrael et al., 2007; Kang et al., 2007; Nistor et al., 2005; 
Stacpoole et al., 2013). Initial attempts to apply protocols optimised on ES cells to hiPSCs 
were very low yielding with less than 0.01% of cells being O4 positive (Ogawa et al., 2011), 
and few cells displaying MBP (Pouya et al., 2011). Most early studies focused on generating 
OPCs from hiPSCs for transplantation studies (Wang et al., 2013), whereas for studying 
disease phenotypes, the study of more differentiated cells would also be desirable. The 
majority of oligodendrocyte protocols published prior to the beginning of this study had only 
been optimised on hESC lines, and their applicability to hiPSCs was controversial (Alsanie et 
al., 2013).  
To show that hESC and hiPSC derived oligodendrocytes are functional, an assessment of their 
myelination capacity is required. Other groups have shown that transplantation of hiPSC 
derived OPCs can myelinate and rescue early lethality in the congenitally hypomethylated 
shiverer mouse model (Douvaras et al., 2014; Wang et al., 2013). Other less costly and time 
consuming methods to assess myelination have been developed in the form of in vitro 
myelinating co-culture systems, including dissociated CNS cultures and ex vivo slice cultures 
(Jarjour et al., 2012). Although mouse ESC derived oligodendrocytes have been shown to 
myelinate using such techniques, such techniques have not yet been widely applied to human 
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iPSC derived oligodendrocytes (Kerman et al., 2015). There has been a report of hiPSC 
derived oligodendrocytes myelinating rat dorsal root ganglion neurons in an in vitro system 
(Thiruvalluvan et al., 2016). Recently, an in vitro human co-culture system between wild type 
Hb9-GFP+ motor neurons and hiPSC derived oligodendrocytes has been described (Ferraiuolo 
et al., 2016), and although this system did not permit myelination, this represents a step 
towards the goal of generating human systems to understand human disease. 
Finally, although studying hiPSC oligodendrocytes in vitro may allow us to identify cell 
autonomous effects within these cells, ultimately to understand how oligodendrocytes 
contribute to pathogenesis in diseases such as ALS requires investigation of their effect on 
neurons. Transplantation studies of hiPSC derived oligodendrocytes in vivo could allow their 
effects to be assessed at a cellular and organism level (Douvaras et al., 2014). Other approaches 
to understand oligodendrocyte-neuron interactions are in vitro techniques: the application of 
oligodendrocyte conditioned media to motor neurons to assess the effect of any soluble factors 
released from oligodendrocytes, or setting up co-culture experiments with neurons to assess 
cell contact mediated effects. Such experiments have recently been carried out for a hiPSC 
derived oligodendrocytes with a variety of ALS causing mutations, and have shown that they 
contribute to motor neuron death in vitro via both soluble factors, and cell-contact mediated 
effects (Ferraiuolo et al., 2016).  
1.6 Scope of study 
A major aim of this study was to investigate the effect of the C9orf72 HRE on 
oligodendrocytes, as it is currently unknown to what extent oligodendrocytes contribute to 
disease in cases of ALS caused by mutations in C9orf72. In order to investigate this, I have 
applied a differentiation protocol to generate oligodendrocytes from hiPSCs derived from 
controls and patients with C9orf72 HREs. To reduce genetic variability between the lines, we 
generated an isogenic control by taking one hiPSC line which carried a C9orf72 HRE and 
specifically deleting the repeat expansion using CRISPR/Cas9- mediated gene editing.  
To investigate the influence of C9orf72 HRE on hiPSC derived oligodendrocytes, the 
differentiation potential of the cell lines was first compared to investigate whether the mutation 
led to differences in the generation of oligodendrocytes and other cell types.  
I then went on to assess whether there was evidence for any of the main proposed pathological 
mechanisms involved in C9orf72 expansion cases, by measuring C9orf72 mRNA expression, 
RNA foci formation and investigating whether DPR were present. I also examined whether 
there was any TDP-43 mislocalisation or p62 inclusions. I also investigated whether there were 
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any differences in oligodendrocyte cell morphology in the presence of C9orf72 HRE, 
including whether RNA foci influenced this. Finally, I investigated whether there was an 
increased vulnerability to ER stress in C9orf72 HRE containing hiPSC derived 
oligodendrocytes.  
As part of this thesis, I developed PCR based strategies for detection of the C9orf72 HRE, 
which proved challenging and became a substantial undertaking. I used these assays not only 
for validating the presence of the expansion in the cell lines and in screening for HRE corrected 
isogenic cell lines, but also to screen a historical cohort of 450 Scottish ALS patients. I have 
also introduced this test into the National Health Service diagnostic service, where it is directly 




















Chapter 2. Materials and Methods 
 
2.1 Cell culture reagents 
2.1.1 Media and supplements 
Essential 8™ Complete: Essential 8™ Basal Medium (Life Technologies, A1516901) 
Essential 8™ Supplement (Life Technologies, A1517101) 1:50 
 
Chemically Defined Medium (CDM): 1:1 Iscove's Modified Dulbecco's Medium (Life  
Technologies, 21980-32): F-12 (Life Technologies, 31765-027) 
Bovine Serum Albumin (Europa Bioproducts, EQBAC62) 5% 
Chemically Defined Lipid (Life Technologies, 11905-031) 1:100 
Monothioglycerol (Sigma, M6145) 1:25   
Insulin (Roche 1376497) 7mg/ml 
Transferrin (Roche 652202) 15mg/ml 
Penicillin-Streptomycin (Life Technologies, 15070-63) 
 
Phase I:  CDM 
   N-acetyl cysteine (Sigma, A8199) 1mM 
   SB431542 (R&D Systems, 1614/1) 10µM 
   LDN193189 (Stratech, S2618) 100nM  
 
Phase II:  CDM 
   N-acetyl cysteine (Sigma, A8199) 1mM 
   Fibroblast growth factor 2 (FGF2) (Peprotech, 450-33) 5ng/ml 
   Heparin (Sigma, H3149) 5 ng/ml 
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RA (Sigma, R2625) 0.1 µM 
 
Phase III:   Adv DMEM/F12 (Life Technologies, 12634-010) 
   Antibiotic-antimycotic (Gibco, 15240-062) 1:100   
   B-27® (Life Technologies, 17504-044) 1:100 
   N-2 (Life Technologies, 17502-048) 1:200 
   Glutamax™ (Life Technologies, 35050-038) 1:200 
   FGF2 (Peprotech, 450-33) 5ng/ml 
   Heparin (Sigma, H3149) 5ng/ml 
   Purmorphamine (Merck Millipore, 540220) 1µM 
RA (Sigma, R2625) 1µM 
 
Phase III-FGF  As Phase III minus FGF2 and heparin 
 
Oligo Base:  Adv DMEM/F12 (Life Technologies, 12634-010) 
   Antibiotic-antimycotic (Gibco, 15240-062) 1:100   
   B-27® (Life Technologies, 17504-044) 1:100 
   N2 (Life Technologies, 17502-048) 1:100 
   Glutamax™ (Life Technologies, 35050-038) 1:100 
Heparin (Sigma, H3149) 5µg/ml 
 
Oligo Pro:  Oligo base 
   Insulin-like growth factor (IGF-1) (Peprotech, 100-11) 10ng/ml 
   FGF2 (Peprotech, 450-33) 20ng/ml 
   Purmorphamine (Merck Millipore, 540220) 1µM 
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   PDGF-AA (Peprotech, 100-13A) 20ng/ml 
   Smoothened agonist (SAG) (Merck Millipore, 566660) 1µM 
Triiodo-L-Thryonine (T3) (Sigma, T6397) 60ng/ml 
 
Oligo Diff:  Oligo base 
Insulin-transferrin-sodium selenite (ITS) (Life Technologies, 41400-
045) 1:100 
T3 (Sigma, T6397) 60ng/ml 
   IGF-1 (Peprotech, 100-11) 10ng/ml 
2.1.2 Cytokines Growth Factors and Inhibitors 
N-acetyl cysteine (Sigma, A8199), 500mM in DPBS 
SB431542 (R&D Systems, 1614/1) 10mM in DMSO 
LDN193189 (Sigma, S2618) 100µM in DMSO 
FGF2 (Peprotech, 450-33) 20µg/ml in 0.1% BSA in DPBS 
RA (Sigma, R2625) 1mM in ethanol 
Purmorphamine (Merck Millipore, 540220) 1mM in DMSO 
Heparin (Sigma, H3149) 5mg/ml in Advanced DMEMF12 
IGF-1 (Peprotech, 100-11) 20µg/ml in 0.1% BSA in DPBS 
PDGF-AA (Peprotech, 100-13A) 20µg/ml in 0.1% BSA in DPBS 
SAG (Merck Millipore, 566660) 1mM in H2O for embryo transfer 
T3 (Sigma, T6397) 20µg/ml in Advanced DMEM/F12 
 
2.1.3 Other Tissue Culture Reagents 
GFR BD Matrigel™ basement membrane matrix (SLS, 354230) 1:2 
Matrigel™ was thawed at 4°C for 1-2 hours and diluted in cold Advanced DMEM/F12 
using chilled stripettes and tips. Stored at -20°C. 
58 
 
Laminin (Sigma, L2020-1MG) 1:100 
Laminin (1mg/ml) was thawed at 4°C briefly before resuspending 1:100 in cold 
Advanced DMEM/F12. Stored at -20°C.  
Fibronectin (Sigma, F2006-2MG)  
1mg/ml in PBS pH 7.4 
hiPSC freezing mix: Complete Essential 8™ Media + DMSO (1:10) 
Poly-L-ornithine (Sigma, P3655) 100µg/ml in H2O 
Trypsin (Life Technologies, 25200-056) 
Dispase (Life Technologies, 17105-041) 
Collagenase Type IV (Life Technologies, 17104-014) 
Accutase (Sigma, A6964) 
Papain Dissociation System (Worthington Biochemical Corporation, LK003150) 
DNase (Worthington Biochemical Corporation, LS002060)  
Tryptan blue (Sigma, T8154) 
Water for embryo transfer (Sigma, A8199) 
Phosphate buffered saline (PBS) pH 7.4 (Ca-, Mg-) (Life Technologies, 10010-015) 
Dulbecco’s phosphate buffered saline (DPBS) (Ca-, Mg-) (Life Technologies, 14190-094) 
2.1.4 Cell lines 
Written informed consent was obtained from each of the participants who donated fibroblasts 
for this study.  
Control 1 = 33D9 – derived from a healthy 56 year old male. Reprogrammed by retrovirus.  
Control 2 = 34D6 – derived from a healthy 40 year old female. Reprogrammed by retrovirus. 
The derivation, characterisation and validation of these control cell lines has previously been 
described (Bilican et al., 2012; Devlin et al., 2015). 
Carrier 1 = DN19V4 – derived from a 58 year old male ALS patient with a C9orf72 HRE. 
Reprogrammed by retrovirus.  
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Carrier 2 = Becker S6 – derived from a 39 year old female ALS patient with a C9orf72 HRE. 
Reprogrammed by Sendai virus. The derivation, characterisation and validation of this cell 
line has previously been described (Devlin et al, 2015). 
Cell lines were already established when this project commenced. Thanks to Dr. Shyamanga 
Booroah, who reprogrammed Carrier 2, under the supervision of Dr. Ludovic Vallier at the 
Wellcome Trust-Medical Research Council Stem Cell Institute, Anne McLaren Laboratory for 
Regenerative Medicine, Department of Surgery, University of Cambridge, UK. The other cell 
lines were obtained from Prof. Chris Shaw at Kings College London. 
2.1.5 Plastics 
2ml aspirator pipettes (Fisher, 10332282) 
6 well Nunc plates (Fisher, TKT-190-110E) 
12 well Nunc plates (Fisher, 10098870) 
24 well Nunc plates (Fisher, TKT-190-010Y) 
4 well plates (Fisher, TKT-190-130V) 
FACS tubes (Falcon, 4009013) 
10µl filter tips (Thermo-scientific, AXC-4135) 
200µl filter tips (Thermo-scientific, AXC-4138) 
1000µl filter tips (Thermo-scientific, AXC-4140) 
500ml filter units (Fisher, 10229090) 
150ml receiver bottle (Scientific Laboratory Supplies, FIL8020) 
50ml steriflip (Millipore, SCGP00525) 
2.2 Cell culture 
2.2.1 Generating and validating iPSC lines 
hiPSCs were generated from fibroblasts of patients with ALS and healthy controls. Single 
clones from two ALS patients with C9orf72 HREs and two healthy controls without C9orf72 
HREs were used in this study. Reprogramming was performed by either retrovirus or Sendai 
virus. A summary of the cell lines used, including their patient of origin and reprogramming 
method, is shown in Table 2.1. Many thanks to Chris Shaw’s laboratory (King’s College, 
London) for reprogramming the cell lines and sharing them, and to Dr. Shyamanga Booroah 
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for reprogramming Carrier 2, under the supervision of Prof. Ludovic Vallier at the University 
of Cambridge.  
Cell line Age and sex Reprogramming method 
Control 1 56 years, male Retrovirus 
Control 2 40 years, female Retrovirus 
Carrier 1 58 years, male Retrovirus 
Carrier 2 39 years, female Sendai virus 
 Table 2.1 Cell line details 
The pluripotency of the hiPSC lines was confirmed by the expression of pluripotency markers 
NANOG, SOX2, TRA-1-60 and OCT3/4. The ability to form all three germ layers was also 
confirmed by immunocytochemistry, as shown in Figure 2.1a. The potential to develop 
neuroectoderm was demonstrated by expression of Nestin and Sex-determining region Y-box 
1 (SOX1); mesoderm by expression of Brachyury and Eomes; and endoderm by expression of 
forkhead box protein A2 (FoxA2) and GATA-4 as shown in Figure 2.1b. Thanks to Karen 
Burr for performing this work, which has already been published for Controls 1 and 2, and 
Carrier 2 (Devlin et al., 2015). 
 




Figure 2.1 Characterisation of hiPSC lines 
(a) Immunocytochemical staining of pluripotency markers NANOG, SOX2, OCT4 and 
TRA-1-60 in hiPSCs from controls 33D9 and 34D6 and C9orf72 hexanucleotide 
expansion patients. (b) Immunocytochemical staining showing the three germ layers 
differentiated from each of the control and patient-derived hiPSCs: SOX1 and 
NESTIN indicate neuroectoderm; BRACHYURY and EOMES indicate mesoderm; 
FOXA2 and GATA-4 indicate endoderm. Scale bar = 50µm. 
 
2.2.2 Tissue culture routine 
Aseptic technique was used throughout. All cells were incubated at 37°C, with 5% CO2 and 
normoxia.  
Mycoplasma testing was performed monthly. MycoRAZOR™ (Cambio, M040-100) was used 
to treat any infected hiPSC cultures. 
Karyotyping of hiPSC was performed regularly by G-banding, through TDL Genetics.  
Control 1 - abnormal at P49 (47, XYY) 
Control 2 - normal at P51 
Carrier 1 - normal at P21  
Carrier 2 - normal at P42, later become abnormal (Trisomy 12) 
2.2.3 hiPSC maintenance 
Matrigel™ dissolved in Advanced DMEM/F12 1:60 was used to coat all plates for hiPSCs.  
hiPSCs were stored in liquid nitrogen. Once cultures got beyond passage 60, they were 
replaced with stocks of earlier passage.  
Thawing hiPSCs: hiPSCs were removed from liquid nitrogen or -80°C freezer and quickly 
thawed in the water bath at 37°C. Cell were washed in 9ml E8 media and centrifuged at 2500 
rpm for 2.5 min. The supernatant was removed and the hiPSCs resuspended in 0.5-1ml E8 
medium, before being transferred to a fresh well with coating removed and containing 2ml E8 
medium. The plate was placed in the incubator and shaken gently to spread the colonies on the 
dish and then left overnight before being handled. 
hiPSC cultures were cleaned up using three different methods: pruning, haircut or selective 
passaging. Pruning was used to remove colonies which are not hiPSCs or which look 
62 
 
unhealthy. Haircutting was used if the colonies look good but are surrounded by single cells. 
Selective passaging is picking out good colonies from the culture and transferring them to a 
new plate.  
Pruning: Colonies to be removed were marked with the objective marker on the microscope, 
and then a 2ml tip was used to aspirate off the marked colonies quickly using the vacuum. 
Cells were then fed or passaged. 
Haircuts: Media was removed from the well requiring haircut, and 0.5 ml collagenase 
(2mg/ml) was added to the well and left for 2-5 min until single cells began to lift and come 
away from the edge of the colonies. The collagenase was then removed and 1ml DPBS added, 
which was then gently pipetted around the well to remove the single cells. Cells were then 
passaged. 
Selective passage: Coating was removed from a fresh 6-well plate, and 2ml of Complete E8 
medium added to each well. Healthy colonies were marked with the objective marker on the 
microscope, and then a 1ml pipette was used to remove the marked colonies which were then 
moved to the freshly prepared plate. The plate was shaken gently to spread the colonies on the 
dish and then left overnight before being handled.  
Passaging hiPSCs: hiPSCs were passaged when they reached around 90% confluence, or when 
the majority of the colonies were large. Coating was removed from a fresh 6-well plate, and 
2ml of Complete E8 medium added to each well. The media from the wells being passaged 
was removed and 0.75-1ml Dispase/Collagenase (1:1) mix was added to each well. The plates 
were placed into the 37°C incubator for 20-45 min. Once the colonies had lifted, 1ml DPBS 
was added to each well and used to flush the colonies from the well and transfer to a 15ml 
falcon tube. The colonies were then pipetted up and down to mechanically dissociate the cells. 
They were left to settle for 1-2 min before the supernatant was removed. The cells were washed 
in 2ml DPBS and then resuspended in E8 media (0.5ml per well), and distributed into a fresh 
plate. The plate was shaken gently to spread the colonies on the dish and then left overnight 
before being handled. 
hiPSCs were fed daily and passaged approximately once a week.  
Freezing hiPSCs: Protocol as per passaging, except that instead of resuspending the pellet in 
E8 media, hiPSC freezing mix was used. The cell suspension was then transferred to a cryovial 
before being transferred to the -80°C freezer, before being transferred to liquid nitrogen.  
63 
 
Pelleting hiPSCs: Protocol as per passaging, except that once the pellet has been washed in 
DPBS, the cell suspension was transferred to a 1.5ml tube and centrifuged at 3000 rpm for 3-
5min. The DPBS was then removed, before spinning again and removing any residual DPBS. 
The tubes were then placed in dry ice to snap freeze, before being stored in the freezer.  
hiPSC maintenance was carried out by Dr. Karen Burr, Nicola Miller, with assistance from 
Dr. Dario Magnani, Dr. Navneet Vasistha and Dr. Bhuvaneish Thangaraj Selvaraj, with all lab 
members contributing to weekend feeding. Verification of pluripotency of the lines was 
carried out by Dr. Karen Burr as described in earlier publications using these cell lines (Bilican 
et al., 2012; Devlin et al., 2015). 
2.2.3 Neuralisation and patterning 
2.2.3.1 Lifting hiPSCs to Phase I (Day 0) 
1ml of Dispase/Collagenase (1:1) was added to hiPSCs being passaged and cells were 
incubated for 20-45 min until cells had lifted. 1ml of DPBS (Life Technologies, 14190-094) 
was used to flush colonies from the well and transfer them to a 15ml falcon, where the cells 
were left to settle for 1-2min. The supernatant was removed and cells washed in DPBS for 1-
2 min. The supernatant was then removed and replaced with 10ml Phase I medium before 
being transferred to a 90mm dish and placed in the incubator on an orbital shaker.   
2.2.3.2 Phase I (Day 1-7) 
The first media change after the hiPSCs have been lifted was carried out either the same day 
if the media had turned cloudy, or the following day, and was always performed after allowing 
cells to settle in a 15ml falcon tube. Cell were then fed every 2-3 days, by replacing the media 
in the 90mm dish directly.  
2.2.3.3 Phase II (Day 7-14) 
After 7 days in Phase I medium, the spheres are transferred to a fresh 90mm dish containing 
10ml of Phase II medium. They are again placed on an orbital shaker in the incubator and have 
a full media change every 2-3 days.  
2.2.3.4 Plating down Phase II neurospheres (Day 14) 
6 well plates can be coated with Laminin (10µg/ml) and either left in the fridge (4°C) overnight 
or in the incubator (37°C) for four hours before use. Neurospheres and media are transferred 
from their 90mm dish to a 15ml falcon tube. After the spheres have settled for 1 min, the 
medium was aspirated off and resuspended in Phase II medium. After laminin has been 
removed from the fresh 6 well plates, the neurospheres are distributed evenly between the 
wells. The spheres were left to settle overnight and then after 2-3 days, once neural cells could 
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be identified, spheres were picked. Sometimes, spheres were kept plated down for up to 7 days 
in which case, they had a full media change every 2-3 days.  
2.2.3.5 Phase III (Day 16-23) 
Neural precursor cells were selected from the plated down Phase II spheres. In cases where 
the cultures were purely neuronal, Phase II media was removed along with any floating dead 
spheres and then replaced with 10ml Phase III media. A cell scraper was then used to detach 
the spheres from the well. The free floating spheres were then transferred to a fresh 90mm 
dish, and then placed on an orbital shaker in the incubator. 
In cases where the cultures were mixed (not purely neuronal), the neural rosettes were marked 
using an objective marker, and then a 200µl pipette was used to transfer them to a fresh 90mm 
plate prepared with 10ml Phase III medium. They were then placed on an orbital shaker in the 
incubator.  
After either selection method, the spheres were then given a full media change with 10ml 
Phase III media every 2-3 days.  
2.2.3.6 Phase III-FGF (Day 23-37) 
After 7 days of Phase III media, the medium is changed to Phase III-FGF. Cells had a full 
media change every 2-3 days for two weeks.  
These steps were performed by technical staff in the laboratory, including Dr. Karen Burr, 
Nicola Miller, and Rinku Rajan. A schematic showing the main stages is shown in Chapter 4.  
2.2.4 Differentiation of oligodendrocytes 
Oligoprogenitors and oligodendrocytes were generated from spinal conversion neurospheres. 
When the neurospheres had been fed Phase IIII – FGF for two weeks, the medium was 
switched to Oligo Pro. After a minimum of two weeks, with a full media change every 2-3 
days, these spheres can be dissociated and plated down for conversion to oligodendrocytes. 
Oligodendrocyte progenitor spheres can be maintained for up to two months, with chopping 
required when the spheres reach 5-10mm.  
2.2.4.1 Dissociation and plating down 
Oligooprogenitor spheres were dissociated using Papain dissociation system. The dissociation 
solutions were reconstituted according to the manufacturer’s instructions. Oligoprogenitor 
spheres (~0.5 ml) were transferred to a 15ml falcon tube and washed with 10ml DPBS. Once 
the spheres had settled at the bottom after 1-2 min, the supernatant was removed. 1ml 
Papain/DNase mix was added and the cells incubated at 37°C for 20-30min, with pipette 
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mixing of the media half every ten minutes. Once the spheres started to dissociate, they can be 
vigorously pipetted up and down until they are fully broken down. The cells were then 
centrifuged at 2.5rpm for 3.5 min, before the supernatant was removed. The pellet was then 
resuspended in 600µl of Inhibitor/DNase. A discontinuous density gradient was prepared by 
adding 1ml of reconstituted albumin-ovomucoid inhibitor solution to a fresh 15 ml tube. The 
cell suspension was then carefully layered on top and left for 1 min while any remaining 
spheres and debris settle at the bottom. A clear interface between the layers of the gradient 
was clearly visible, and the upper layer and the supernatant of the lower layer were slowly 
collected and transferred to a fresh 15 ml tube. Any spheres and debris should be left behind 
and discarded. The cell suspension was centrifuged at 2.5rpm for 2.5min and the supernatant 
was then discarded. The cell pellet is then resuspended in Oligo Pro medium. Cells were 
counted using Tryptan blue and a haemocytometer, before plating. 
Depending on the experimental needs, different formats of plates were used. All plates were 
first coated with poly-ornithine, which was then washed off three times with Water for Embryo 
transfer, and then coated with a mixture of Laminin/Matrigel™/Fibronectin (L/M/F) in 
Advanced DMEM/F12.  
For dry coating: Laminin 10µg/ml                 For wet coating:         Laminin 10µg/ml                  
  Matrigel™ 1:20       Matrigel™ 1:20 
  Fibronectin 20µg/ml       Fibronectin 10µg/ml 







Number of cells 




24 well + 
glass 
coverslip 
500µl Dry 40µl 40 000 40µl 
12 well 1ml Wet 600µl 500 000 1ml 
6 well 1ml Wet 1ml 1 500 000 2ml 
Table 2.2 Details of different plate formats 
This table shows the volume of poly-ornithine coating used, whether dry or wet coating 
was required, and the volume of L/M/F mixture. The final cell number and media 
required for plating down is also shown.  
For plating, in all cases, the L/M/F coating was first removed before an appropriate volume of 
cells were added to each well. For 24 well plates, cells were diluted in Oligo Pro media such 
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that there were 40 000 cells per 40µl. These plates were then carefully placed in the incubator 
for 2-3 hours before wells were flooded with 0.5ml Oligo Diff. For the other plate types, the 
cells were added to the plates and the Oligo Pro media subsequently adjusted to the volume 
shown in Table 2.2. The plates were rocked from side to side to spread the cells evenly across 
the plate surface before being placed in the incubator. After plate down, cells had a half-media 
change every 2-3 days with Oligo Diff.  
2.2.5.2 Chopping spheres 
Spheres were chopped when they reached between 5-10mm. DNase (25mg) was dissolved in 
5ml of Advanced DMEM/F12. The spheres requiring chopping were moved to the centre of 
the dish and the majority of media removed. Using a sterile blade, the spheres were chopped 
until there were no large lumps and all pieces were around the same size. 5ml Advanced 
DMEM/F12 was used to wash the chopped spheres and they were then transferred to a fresh 
15ml tube and pipetted up and down several times. The spheres were centrifuged at 400 rcf 
for 1 min before the supernatant was removed. 500µl of DNase was added and the spheres 
were incubated at 37°C with occasional shaking, for 10 min. 10ml Advanced DMEM/F12 was 
then added to the spheres to wash them. After allowing the spheres to settle for a few minutes, 
the supernatant was removed and replaced with 12ml Oligo Pro medium. The spheres and 
media were then transferred to a fresh 90mm plate and put back on an orbital shaker in the 
incubator.  
2.2.6 Magnetic-Activated Cell Sorting (MACS) 
For qRT-PCR and Western blotting, week-3 cell cultures were dissociated with Accutase, and 
separation of O4+ oligodendrocytes was achieved by MACS. 
2.2.6.1 MACS solutions and reagents 
MACS buffer:   Made up in PBS pH 7.4 (Ca-, Mg-) (Life Technologies) 
B-27® (Life Technologies, 17504-044) 1:50 
N-2 (Life Technologies, 17502-048) 1:100 
EDTA (Life Technologies, 15575-038) 0.8mM 
   MgCl2 (Sigma, M1028) 2mM 
   D+-Glucose solution (Sigma, G8769) 4.5% 
MACS® FcR blocking reagent, human (MACS, 130-059-901) 
anti-O4 MicroBeads (MACS, 130-096-670) 
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MACS® LS columns (MACS, 130-042-401) 
MACS® Smart Strainer 100µm (MACS, 130-098-463) 
2.2.6.2 MACS protocol 
Throughout the protocol, MACS buffer was kept on ice. Cells were lifted by replacing media 
with 1ml Accutase per well of a 6-well plate, and incubating at 37°C for ~5min until cells lift 
off. 1ml of Oligo Diff media was then added, and cells were collected into a 15ml falcon tube 
before being centrifuged at 2.5 rpm for 2.5 min. The supernatant was removed from the cell 
pellet, which was then resuspended in 12ml cold MACS buffer. The cell suspension was then 
passed through a 100µm MACS® Smart Strainer into a fresh 15ml falcon tube. The cells were 
centrifuged for 2.5 min at 2.5 rpm. The supernatant was then removed and the cell pellet 
resuspended in 70µl MACS buffer and 20µl MACS® FcR blocking reagent, before being 
incubated at 4°C for 10 min. 10µl of Anti-O4 microbeads were then added, and further 
incubated at 4°C for 15 min. An LS column was prepared within a magnetic stand, with a 15ml 
falcon tube for collection. The column was prepared by rinsing through 3ml MACS buffer. 
Once the cells had incubated with Anti-O4 Microbeads, 3ml MACS buffer was added and the 
cells centrifuged for 2.5 min at 2.5 rpm. The supernatant was removed and the cells 
resuspended in 500µl of MACS buffer before being applied to the MACS® LS column. The 
column was then washed 3 times with 3ml MACS buffer to remove the negative cell fraction. 
The column was then removed from the magnet, and a plunger used to elute the positive (O4) 
cell fraction into a fresh 15ml tube. 3ml MACS buffer was then added and the cells centrifuged 
for 2.5 min at 2.5 rpm. The supernatant was then removed and the cells resuspended in Oligo 
Diff media. Cells were counted using Tryptan blue, and were then either plated down (as 
described in Section 2.2.4) or pelleted for biochemical or molecular studies (as described for 
iPSCs in Section 2.2.2). 
2.2.7 Fluorescence-Activated Cell Sorting (FACS) 
2.2.7.1 FACS solutions and reagents 
Accutase (Sigma, A6964) 
FACS buffer: Made up in DPBS (Ca-, Mg-) (Life Technologies) 
           Bovine Serum Albumin (Europa Bioproducts, EQBAC62) 0.2% 
O4 antibody (R&D Systems, MAB1326) 
Alexa Fluor 647 Anti-mouse IgM (Life Technologies, A21238) 
CellEvent™ Caspase-3/7 Green Flow Cytometry Assay kit (Life Technologies, C10427) 
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2.2.7.2 FACS protocol 
Throughout the protocol, FACS buffer was kept on ice. Cells were lifted by replacing media 
with 1ml Accutase per well of a 6-well plate, and incubating at 37°C for ~5min until cells lift 
off. 1ml of Oligo Diff media was then added, and cells were collected into a 15ml falcon tube 
before being centrifuged at 2.5 rpm for 2.5 min. The supernatant was removed and the cell 
pellet resuspended in 100µl of FACS buffer. 1µl of O4 primary antibody (diluted 1:5 in FACS 
buffer) was added and incubated on ice for 30 min. 3ml FACS buffer was then added to wash 
the cells, followed by centrifugation at 1.5 rpm for 5 min. The pellet was then resuspended in 
200µl of Alexa Fluor 647 Anti-mouse IgM (diluted 1:2000 in FACS buffer) before incubating 
on ice, in the dark, for 30 min. 3ml FACS buffer was then added to wash the cells, followed 
by centrifugation at 1.5 rpm for 5 min. The pellet was then resuspended in 300µl CellEvent™ 
Caspase-3/7 (diluted 1:1000 in FACS buffer), and incubated at 37°C for 30 min. Secondary 
only and unstained controls were performed with each sample set.  
Flow cytometry was then performed on a FACSCalibur (Becton Dickinson, San Jose, CA). 
Cells were analysed by forward and side scatter for Alexa Fluor 488 fluorescence through a 
530 ± 30 nm band-pass and for Alex Fluor 647 through a 695 ± 40 nm band-pass. Unstained 
cells were used to set the background fluorescence; a false positive rate of 0.5% was accepted.  
Thanks to Dr. Karen Burr and Dr. Navneet Vasistha for optimising the FACS protocol and 
helping with running the samples on the FACSCalibur. 
2.2.7.3 Tunicamycin stress  
Tunicamycin (Sigma T7765) was dissolved in DMSO to a concentration of 1.2mM. This was 
then added to oligodendrocyte cultures in media to produce a final concentration of 0.5µM. 
Cells were subjected to tunicamycin stress for 48 hours prior to FACS analysis being 
performed. 
2.2.8 Gene editing of hiPSCs 
Cas9 and guide (g)RNA were cloned into an expression plasmid pSpCas9(BB)-2A-GFP 
(Px458) as described in a published protocol (Ran et al., 2013). CRISPR gRNA sequences 
were designed using the web tool http://crispr.mit.edu. The sequences of the gRNA’s were as 
follows: gRNA-1 AACTCAGGAGTCGCGCGCTAGGG and gRNA-2 
GGCCCGCCCCGACCACGCCCGG.  
Using Accutase, hiPSC were dissociated to produce a single cell suspension. Using the Amaxa 
4D nucleofector system (program CA137), 8x105 cells were then nucleofected with 2 µg of 
each Cas9-gRNA-1 and Cas9-gRNA-2 plasmids following the manufacturer’s instructions. 
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The transfected cells were then plated onto Matrigel coated plates and fed with Essential 8 
medium plus ROCK inhibitor (10 µM). Once cells were confluent, they were once again 
dissociated to single cells and re-plated at low density (2000 cells/ 10 cm dish) to permit clonal 
analysis. Individual colonies were picked and screened by PCR based methods for deletion of 
the expanded C9orf72 allele (Selvaraj, submitted).  
Assessment of off-target effects was carried out by Sanger sequencing of highly homologous 
regions of the genome.  
Location and sequence of highly 
homologous target 





















Table 2.3 Highly homologous sequences to gRNA targets and primers for 
Sanger sequencing (red sequence highlights difference in sequence between target 
and gRNA). 
 
The creation of the isogenic control was carried out by Dr. Bhuvaneish Thangaraj Selvaraj in 
combination with Bruce Whitelaw and Simon Lillico at the Roslin Institute (University of 
Edinburgh). PCR based screening methods were optimised based on the methods developed 
by myself and I also contributed by carrying out fluorescent capillary electrophoresis and 
analysing traces to select clones of interest. 
2.2.9 Electrophysiology  
Electrophysiology recordings were undertaken by Dr Matt Livesey and Dr Owain James. 
Whole-cell patch clamping was used to record macroscopic currents, which were typically 
low-pass filtered online at 2kHz, digitized to 10 kHz and recorded to computer using WinEDR 
V2 7.6 Electrophysiology Data Recorder. Rectification indices were calculated as described 





2.3.1 Solutions and reagents 
4% Paraformamyde (Sigma, 158127) in PBS 
Triton TM (Sigma X-100) 
Goat serum (DAKO, X0907) 
Hoescht (Invitrogen, H3569) 1:1500 
4-,6-diamidino-2-phenylindole (DAPI) (Sigma, D9542) 1:5000  
FluorSave™ (Calbiochem, 345789) 
PBS pH 7.4 (Ca-, Mg-) (Life Technologies, 10010-015) 
Primary antibodies: 
Antibody Type Company Catalogue 
number 
Dilution 
SOX1 Goat polyclonal R&D Systems AF3369 1:100 
Nestin Mouse monoclonal Millipore MAB5326 1:100 
Brachyury Goat polyclonal R&D Systems AF2085 1:100 
Eomes Rabbit polyclonal Abcam Ab23345 1:600 
FOXA2 Goat polyclonal R&D Systems AF2400 1:100 
GATA-4 Goat polyclonal Santa Cruz SC25310 1:100 
Olig2 Rabbit polyclonal Millipore 2519344 1:300 
PDGFRα Rabbit monoclonal Cell Signaling  52415 1:200 
O4 Mouse IgM R&D Systems MAB1326 1:600 
MBP Rat Abcam Ab7349 1:50 
GFAP Rabbit polyclonal DAKO 20334 1:500 
β-ΙΙΙ tubulin Mouse IgG2b Sigma T8660 1:1000 
TDP-43 Mouse IgG1 Abnova H00023435 1:200 
p62 Mouse IgG1 BD Biosciences 610832 1:200 
Table 2.4 Primary antibodies used, with dilutions used and details of origin. 
Secondary antibodies: 
Antibody Type Company Catalogue number Dilution 
Alexa Fluor 647  Goat anti-mouse 
IgM 
Life Technologies A21238 1:1000 
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Alexa Fluor 488 
(green) 
Goat anti-rat IgG Life Technologies A11006 1:1000 




Life Technologies A11008 1:1000 




Life Technologies A21242 1:1000 




Life Technologies A21428 1:1000 




Life Technologies A21121 1:1000 
Table 2.5 Secondary antibodies used, with dilutions used and details of origin. 
2.3.2 Live immunostaining and fixing 
Live immunostaining was performed with O4 antibody. O4 antibody was diluted 1:300 in 
Oligo Diff media. The media from the well was then removed, leaving behind ~150µl of media 
to prevent the cells drying out. 150µl of the diluted antibody was then added. The cells were 
then incubated at 37°C for 1 hour to allow antibody binding, before fixing.  
Fixing was performed by aspirating off media, and then adding ~0.5ml 4% PFA and incubating 
at room temperature for 10 min. Cells were then washed with PBS three times. Fixed cells 
were used immediately for RNA-FISH or kept for up to 7 days at 4°C prior to 
immunocytochemistry.  
2.3.3 Blocking and antibody incubation 
For all antibodies except for PDGFR-α, cells were permeabilised prior to blocking and 
antibody incubation. In the case of PDGFR-α, permeabilisation was not performed until after 
this primary antibody had been added, therefore for co-staining with other antibodies an extra 
primary antibody incubation was required. All steps were performed at room temperature. 
Cell membranes were permeabilised by applying 0.2% Triton X to the cells for 10 min. This 
was then removed and replaced by 3% goat serum as a blocking agent, for 1 hour. Primary 
antibodies, diluted in 3% goat serum were then applied and incubated for 1 hour. Cells were 
then washed three times, for 5 min each, with PBS. Secondary antibody, diluted in 3% goat 
serum, were then added to cells for 30 min. Cells were then washed three times, for 5 min 
each, with PBS. Hoescht or DAPI was then added for 5 min before washing three more times, 
for 5 min each, with PBS. Where coverslips were used, a drop of Fluorsave was placed on a 
microscope slide before mounting. Slides were left to dry overnight before being stored at 4°C. 
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2.3.4 Imaging of slides 
Imaging was performed using a Carl Zeiss Axio Observer microscope (Zeiss, Oberkochen, 
Germany), either x20 or x63 magnifications, and analyzed using Axiovision v4.8.1 (Zeiss) 
software.  Fields were selected based upon uniform DAPI staining and imaged in three/four 
fluorescent channels as required.  
2.3.5 Image analysis 
For quantitative immunocytochemistry, Image J64 (v1.47) was used to convert images to 
grayscale and the DAPI channel was used to create regions of interest. Cell quantification was 
perfomed manually with Image J64 (v1.47) software for an area of 162.4 µ2. Positive staining 
was indicated by signal which was clearly stronger than any background fluorescence in cell 
free areas. For all cell counting, at least three independent images per coverslip were taken, 
and a minimum of three independent cultures from three independent conversions were 
assessed.  
2.3.6 Sholl analysis 
Sholl analysis was performed using a plugin in ImageJ (Ferreira et al., 2014). Images were 
converted to 8-bit, and a threshold applied to remove background. A line was selected from 
the centre of the soma to the furthest point. The starting radius was set at 10µm as this was 
estimated to be the average cell body size after measuring a representative sample. The step 
size was set at 2.5µm. The software calculated the number of intersections the cell made at 
each radius around the cell body and this value was recorded in Microsoft Excel.  
2.4 Molecular biology 
2.4.1 DNA extraction 
2.4.1.1 Isolation of DNA from cultured cells 
Approximately 1 million cells were harvested using trypsin (for iPSCs) or Accutase (for 
oligodendrocytes). DNA was extracted using the Wizard SV Genomic DNA Purification 
System (Promega), according to the manufacturer’s instructions for cell culture DNA.  
2.4.1.2 Isolation of DNA from patient leukocytes 
Historic DNA samples relating to the Scottish Regenerative Neurology Tissue Bank were 
extracted from whole blood samples by phenol-chloroform or manual salting out. Recent 
samples were extracted by the Nucleon BACC3 genomic DNA kit (Tepnel Life Sciences). 
Samples for diagnostic testing were extracted from whole blood or saliva using the Chemagic 
DNA blood kit (Perkin Elmer), according to the manufacturer’s instructions. 
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2.4.2 PCR for C9orf72 genotyping 
2.4.2.1 C9orf72 genotyping reagents and solutions 
Multiplex PCR kit (Qiagen Ltd, 206143) 
DyNAzyme EXT DNA Polymerase (ThermoFisher Scientific, F505-L), 1U/µl 
DMSO (Sigma, D8418) 
Betaine (Sigma, B0300), 5M 
7-deaza-2'-dGTP (Roche, 10988537001), 10mM 
dNTPs (Scientific Lab Supplies, 28406551), 100mM each A,C,G,T 
HPE dNTP mix: 35µM dCTP and dGTP, 10 µM dATP and dTTP 
Primers stocks at 100µM (IDT): 
Primer  Sequence (5’-3’) 
F1 TAA CCA GAA GAA AAC AAG GAG GGA 
F2 FAM-CTG TAG CAA GCT CTG GAA CTC AGG AGT CG 
F3 FAM-AGC AAG CTC TGG AAC TCA GGA GTC G 
R1 GCC CCC GGG CCC GCC CCG ACC AC 
R2 FAM-GCA GGC ACC GCA ACC GCA GC 
R3 CCG CCT CCT CAC TCA CCC ACT 
R4 ATG CCG CCT CCT CAC TCA CCC ACT 
R6 CCT CAC TCA CCC ACT CGC CAC 
R8 CGG GCG CAG GCA CCG CAA CC 
Repeat R TAC GCA TCC CAG TTT GAG ACG CCC CGG CCC CGG CCC CGG CCC C 
Repeat F TAC GCA TCC CAG TTT GAG ACG GGG GCC GGG GCC GGG GCC GGG G 
Repeat F3 TAC GCA TCC CAG TTT GAG ACG GGC CGG GGC CGG GGC CGG 
Tail R TAC GCA TCC CAG TTT GAG ACG 
Table 2.6 C9orf72 genotyping primer sequences 
All primers were SNP checked. In chapter 3 there is a schematic which shows where these 
primers bind against the reference sequence. 
2.4.2.2 Original flanking PCR assay 
PCR mix: x1 (µl) 
Qiagen Multiplex Mastermix 12.5 
DMSO  1.75 
Betaine, 5M 3 
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F2 primer (FAM) + R1 primer, 5µM 5 
H2O 0.75 
DNA, 20ng/µl 2 
 25 
Cycling was performed using a GeneAmp® 9700 (Life Technologies) using the following 
conditions: 
94°C – 15 minutes  
94°C – 1 minute   
68°C – 1 minute      35 cycles 
72°C – 1 minute 
72°C – 10 minutes 
2.4.2.3 Nested RP-PCR 
The original flanking PCR (section 2.4.2.2) was performed, followed by product clean up with 
Agencourt Ampure XP (Beckman Coulter, A63881) and then nested PCR as follows: 
3’ RP PCR mix x1 (µl) 
Qiagen Multiplex Mastermix 10 
Q solution 4 
F2 primer (FAM), 5µM 1.5 
Repeat R primer, 5µM 0.75 
Tail R, 5µM 1.5 
H2O 1.5 
PCR product (1:500) 1 
 20 
Cycling was performed using a GeneAmp® 9700 (Life Technologies) using the following 
conditions: 
95°C – 15 minutes  
95°C – 1 minute   
*71°C – 1 minute      30 cycles 
72°C – 1 minute 
72°C – 10 minutes 




2.4.2.4 Original RP-PCR assays 
 
3’ RP PCR mix x1 (µl) 5’ RP PCR mix x1 (µl) 
Qiagen Multiplex Mastermix 12.5 Qiagen Multiplex Mastermix 12.5 
Betaine, 5M 3 Betaine, 5M 3 
DMSO 1.75 DMSO 1.75 
7-deaza-2'-dGTP 0.2 7-deaza-2'-dGTP 0.2 
R2 primer (FAM), 5µM 1.9 F2 primer (FAM), 5µM 1.9 
Repeat F primer, 5µM 0.9 Repeat R primer, 5µM 0.9 
Tail R, 5µM 2.9 Tail R 2.9 
H2O 0.85 H2O 0.85 
DNA,~200ng/µl 1 DNA (~200ng/µl) 1 
 25  25 
Cycling was performed using a GeneAmp® 9700 (Life Technologies) using the following 
conditions:  
 
95°C – 15 minutes  
95°C – 1 minute   
71°C – 1 minute      10 cycles 
72°C – 2 minutes 
95°C – 1 minute   
60°C – 1 minute      25 cycles 
72°C – 2 minutes 
72°C – 10 minutes 
 
 
2.4.2.5 HPE flanking PCR assay 
 x1 (µl) 
Optimized DyNAzyme EXT buffer, 10x 1.6 
Betaine, 5M 7.2 
HPE dNTP mix 0.3 
F3 primer (FAM)+ R6 primer, 5µM 5 
DyNAzyme EXT DNA Polymerase, 1U/µl 2.4 
H2O 2.5 




Cycling was performed using a Veriti® thermal cycler (Life Technologies) using the following 
conditions:  
94°C – 7 minutes 
95°C – 45 seconds  
98°C – 10 seconds   
61°C – 30 seconds        
78°C – 5 seconds*                                            
78°C – 2 seconds              x7                          35 cycles 
86°C – 2 seconds                                          
78°C – 2 seconds             x7 
90°C – 2 seconds 
78°C – 10 minutes 
*slow ramp (12% = 0.6°C/second) 
 
2.4.2.6 HPE RP-PCR assays 
3’ RP x1 (µl) 5’ RP x1 (µl) 
Optimized DyNAzyme EXT 
buffer, 10x 
1.6 Optimized DyNAzyme EXT 
buffer, 10x 
1.6 
Betaine, 5M 7.2 Betaine, 5M 7.2 
HPE dNTP mix 0.3 HPE dNTP mix 0.3 
R8 primer (FAM), 5µM 2 F2 primer (FAM), 5µM 2 
Repeat F3 primer, 5µM 1 Repeat R primer, 5µM 1 
Tail R, 5µM 3 Tail R 3 
DyNAzyme EXT DNA 
Polymerase, 1U/µl 
2.4 DyNAzyme EXT DNA 
Polymerase, 1U/µl 
2.4 
H2O 1.5 H2O 1.5 
DNA, ~200ng/ µl 1 DNA, ~200ng/ µl 1 
 20  20 
 
Cycling conditions were as described for the HPE flanking assay (section 2.4.2.4). 
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2.4.3 Capillary electrophoresis and analysis 
All RP-PCR products were ran neat whereas flanking PCR products were diluted 1:100 before 
loading. 2µl of sample was added to 9.5µl Hi-Di (Life Technologies, 4311320) and 0.5µl 
GenescanTM LIZ600 size standard (Life Technologies, 4366589) and denatured for 3 min at 
95°C prior to capillary electrophoresis using an ABI 3130xL Genetic Analyzer (Life 
Technologies). POP-7 polymer (Life Technologies, 4335615) was used, with a 50cm capillary 
array was used (Life Technologies, 4315930).  
For long injection protocol, the GeneScanTM LIZ1200 size standard (Life Technologies, 
4379950 was used.   
Data was analysed using GeneMarker® software v2.4.0 (Soft Genetics). 
2.4.4 Sanger sequencing 
2.4.4.1 Sanger sequencing reagents and solutions 
Agencourt Ampure XP (Beckman Coulter, A63881) 
BigDye® Terminator v3.1 Cycle Sequencing kit (Life Technologies, 4337455) 
BigDye® Terminator v1.1 and v3.1 Sequencing buffer (Life Technologies, 4336699) 5x 
Cleanseq® (Beckman Coulter, A29154) 
2.4.4.2 Sanger sequencing protocol 
For Sanger sequencing of the flanking PCR products, PCR was performed as described and 
then sequencing was carried out using R2 primer. For sequencing of the C9orf72 3’ region, 
repeat-primed PCR was performed as described above for HPE PCR 3’RP, with primer R6 
used in place of R8. In both cases, PCR products were purified using Agencourt Ampure XP, 
as per the manufacturer’s instructions, using a Biomek® NX robot (Beckman Coulter). 
Sequencing was then performed using BigDye® Terminator v3.1 (Life Technologies). 
Reactions were set up as shown below: 
 x1 (µl) 
BigDye v3.1 0.5 
BigDye Sequencing buffer, 5x 1.75 
R2 or R6 Primer, 3.2µM 1 
H2O 4.75 





Cycling were performed using a GeneAmp® 9700 thermal cycler (Life Technologies) using 
the following conditions:  
96°C – 75 seconds 
94°C – 15 seconds  
55°C – 10 seconds      30 cycles 
62°C – 4 minutes 
CleanSeQ was used, according to the manufacturer’s instructions to clean-up sequencing 
products prior to running on an ABI 3130xL Genetic Analyzer (Life Technologies). 
Sequencing was analysed using Mutation Surveyor v4.0.8 (Soft Genetics) or Sequence 
Scanner v1.0 (Applied Biosystems). 
2.4.5 Agarose gel electrophoresis 
BlueJuice™ loading buffer (ThermoFisher Scientific, 10816-015), 10x 
Tris-Borate EDTA (TBE) (Sigma, T3913), 0.5x 
UltraPure TM Agarose (ThermoFisher Scientific, 16500-500)  
GelRed (Cambridge Biosciences, BT41003), 10 000x 
100bp DNA ladder (Promega, G2101) 
1kb DNA extension ladder (Invitrogen, 10511012) 
Gels were prepared by melting agarose at the desired concentration (0.8-2%) in 0.5x TBE 
buffer using a microwave. Once the agarose had cooled, GelRed was added and the gel poured 
in a casting tray. Electrophoresis was preformed in BioRAD tanks at 100V in 0.5x TBE buffer. 
PCR products were visualised by UV transillumination and photographed using an 
AlphaDigiDoc system. When loading, samples were mixed with BlueJuice™ loading dye, and 
appropriate DNA ladders were run alongside the samples. 
2.4.6 RNA extraction 
Following MACS sorting, approximately 1 million cells were pelleted and either snap frozen 
in dry ice and stored at -80°C, or taken directly for RNA extraction. RNA was isolated with 
the RNeasy kit (Qiagen, 74104) following the manufacturer’s instructions, with 
homogenization performed by pipette mixing. RNA was eluted in 32µl RNase-free water. 
Genomic DNA was removed by treatment with Turbo DNA-free™ (Ambion, AM1907), 
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according to the manufacturer’s instructions. RNA concentration was estimated using 
spectrophotometry (NanoDrop 1000).  
2.4.7 cDNA synthesis 
cDNA was synthesized by using 1μg of total RNA with the DyNAmo cDNA Synthesis Kit 
(Life Technologies. F470-L), using random hexamers in a 20µl reaction. The manufacturer’s 
protocol was used. Briefly, 2µl of random hexamer primers were added to 1µg RNA (in a total 
volume of 7µl), with 10µl RT Buffer and 2µl RT enzyme (M-MuLV RNase H+ reverse 
transcriptase). These were placed in a thermal cycler to allow primer extension (25°C for 10 
min), cDNA synthesis (37°C for 30 min), followed by reaction termination (85°C for 5 min). 
A ‘minus RT’ control was included, where the RT enzyme was replaced with RNase-free 
water.  
2.4.8 qRT-PCR 
Real-time qPCR reactions were set up in triplicates with the DyNAmo ColorFlash SYBR 
Green qPCR Kit (ThermoFisher Scientific, F-416L) according to the manufacturer’s 
instructions. Primers were used at 200nM, and reactions run on an iCycler System (Bio-Rad). 
All results were normalized to β-actin and GAPDH using the delta delta Ct method, and were 
from 3 technical replicates of 5 independent biological samples. Primer sequences, annealing 
temperatures and reaction efficiencies are provided Table 2.6. Primers were designed using 
NCBI (website) with the exception of isoform specific C9orf72 primers (Fratta et al., 2013). 
Gene Primers (5’-3’) Ta (°C) Efficiency 
(%) 
r2 
MBP F: TGTACAAGGACTCACACCACC 60 109.5 0.997 
R: ACGGGGTTTTCATCTTGGGT 












F: GAGCAGGTGTGGGTTTAGGAGA 60 103.9 0.922 
R: TGGGCAAAGAGTCGACATCA 
B-actin F: GTTACAGGAAGTCCCTTGCCATCC 60 97.8 0.992 
R: CACCTCCCCTGTGTGGACTTGGG 




TDP-43 F: CGGCCTAGCGGGAAAAGTAAAAGA 65 94.4 0.915 
R: AGCACCGTCCCATCGTCTT  
Table 2.7 qRT-PCR primer details 
All PCR products were shown to be specific by a single band of the expected size after agarose 
gel electrophoresis and through post-PCR melt-curve analysis on the iCycler System (Bio-
Rad). 
2.4.9 RNA-FISH 
For experiments where RNA-fluorescence in situ hybridisation (RNA-FISH) was combined 
with immunocytochemistry for the O4 marker, O4 live staining was performed prior to fixation 
as described in section 2.3.2. 
2.4.9.1 RNA-FISH solutions and reagents 
All solutions and reagents must be RNase free. 
16% paraformaldehyde (Agar Scientific, AGR1026) 1:4 in PBS pH7.4 (Ca-, Mg-) 
Pre-hybridisation solution:  Made up in Water for embryo transfer (Sigma, A8199) 
    Formamide (Sigma F9037) 1:2 
    20x Saline sodium citrate (SSC) (Sigma, S8015) 1:10 
Hybridisation solution:   Made up in Water for embryo transfer (Sigma, A8199) 
    Formamide (Sigma F9037) 1:2 
    20x SSC (Sigma, S8015) 1:10 
    50% dextran sulphate (Millipore, S4030) 1:10 
    10mg/ml Yeast tRNA (Invitrogen, 15401-029) 1:10 
    10mg/ml salmon sperm DNA (Invitrogen, 15632-011) 1:10 
Alexa 546-conjugated (GGCCCC)4 oligonucleotide probe (IDT, custom made) 100ng/µl 
Alexa 546-conjugated (CAGG)6 oligonucleotide probe (IDT, custom made) 100ng/µl 
RNase A (Sigma R4642) 
2.4.9.2 RNA-FISH protocol 
Cells cultured on glass coverslips were fixed in sterile 4% paraformaldehyde for 15 min, before 
being washed 3 times with PBS. Membranes were permeabilized using 70% ethanol for 10 
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min (note this step was omitted if PDGFRα staining was performed). Cells were then incubated 
in pre-hybridisation solution for 10 min. During this time, the probe was denatured by heating 
to 95°C for 5 min and then snap freezing on ice. The probe was then diluted in hybridisation 
solution to a final concentration of 0.16ng/µl. The diluted probe was then added to the 
coverslips which were incubated in a humid chamber at 45°C for 2 hours. The coverslips were 
then washed in pre-hybridisation solution twice, for 30 min at 45°C, followed by a final 30 
min wash in 2x SSC at room temperature. If immunostaining was performed in addition, the 
protocol described in section 2.3 followed from the blocking stage. If immunostaining was not 
required, Hoescht or DAPI was then added for 5 min before washing three more times, for 5 
min each, with PBS. A drop of Fluorsave was placed on a microscope slide before mounting 
the coverslip. Slides were left to dry overnight before being stored at 4°C. 
For the RNase A experiments, after fixation, cells were incubated with 100 μg/ml RNase A 
(Sigma) for 1 h at 37°C. 
2.4.10 Western blotting  
2.4.10.1 Western Blotting solutions and reagents 
RIPA buffer:  Made up in Water for embryo transfer (Sigma, A8199) 
  Tris-hydrochloric acid pH 7.4 (Fisher, BP152-500) 50mM 
  Sodium chloride (Fisher S/3160160) 150mM 
  Triton X-100 (Sigma, T9284) 1% 
  Sodium deoxycholate (Sigma, D6750) 0.5% 
  Sodium dodecyl sulfate (Sigma, L3771) 0.1% 
  EDTA (Life Technologies, 15575-038) 2mM 
Urea buffer: Urea (Sigma, U4883) 9M 
  Sodium dodecyl sulfate (Sigma, L3771) 1% 
  Tris (Fisher, BP152-500) 25mM 
  EDTA (Life Technologies, 15575-038) 1mM 
PI: Complete Mini Protease Inhibitor tablets (Roche, 04 693 124 001) 
PhosSTOP: Phosphatase Inhibitor Cocktail tablets (Roche, 04 906 837 001) 
Pierce BCA Protein Assay kit (Thermo Scientific, 23227) 
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NuPAGE® Sample Reducing Agent (Life Technologies, NP0009) 
NuPAGE® LDS Sample buffer (Life Technologies, NP0007) 
4-20% Precise Protein gel (Thermo Scientific, 25224) 
SDS PAGE running buffer, BupHTM Tris-HEPES (Thermo Scientific, 28398) 
Protein ladder: Precision Plus Protein™ All Blue Standards (Bio-RAD, 161-0373) 
10x SDS PAGE Transfer buffer: Made up in deionised water 
     Tris (Fisher, BP152-500) 
     Glycine (Sigma, G8898) 
1x SDS PAGE Transfer solution:  Made up in deionised water  
10x SDS PAGE Transfer buffer (1:10) 
     Methanol (1:5) 
Odyssey® blocking buffer (LiCor, 927-40100) 
PBS-T: 0.1% Triton X-100 in PBS 
Coomassie blue stain (Thermo Scientific, 20278) 
Coomassie blue destaining solution: Acetic Acid (SLS, CHE1014) 7.5% 
     Methanol (Sigma, 322415) 5%   
2.4.10.2 Protein preparation   
Frozen cell pellets (MACS sorted O4+) were lysed on ice in 100µl RIPA buffer, which was 
supplemented with fresh protease inhibitors (PI, 1:25; PhosSTOP, 1:10). The lysate was 
homogenised by pipetting regularly during a 30 min incubation on ice. Cell lysates were then 
centrifuged at 13 000 rpm for 30 min at 4°C. The cleared lysate (soluble fraction) was 
transferred to a fresh tube. 
The cell pellet was washed with 200µl RIPA buffer to minimise carry-over of the soluble 
fraction and then centrifuged at 13 000 rpm for 15 min before the lysate was discarded. The 
pellet was then resuspended in 50µl urea buffer (which was supplemented with fresh protease 
inhibitors (PI, 1:25; PhosSTOP, 1:10) and incubated on ice for 10 min. Lysates were then 
sonicated at 40 000Hz for two pulses of 10 s, followed by 1 min. The lysates were then left at 
room temperature for 20 min before being centrifuged at 13 000 rpm for 30 min at 4°C. The 
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supernatant (detergent insoluble fraction) was transferred to a fresh tube. The protein 
concentration of the soluble fraction was determined using the Pierce BCA Protein Assay kit, 
following the manufacturer’s protocol. 
2.4.10.3 SDS-PAGE 
4-20% Precise Protein gels were used. The comb was removed, and the gel rinsed in deionised 
water before being placed in the tank, where the wells were flooded with SDS PAGE running 
buffer. For the soluble fraction, 20µl volume was loaded, including 10 µg of sample, 
NuPAGE® Sample Reducing Agent (1:4), and NuPAGE® LDS Sample buffer (1:10). For the 
insoluble fraction, 5µl of sample and NuPAGE® Sample Reducing Agent (1:4), and 
NuPAGE® LDS Sample buffer (1:10) was loaded. All samples were heated to 95°C before 
loading. Protein ladder was added to one well. Gels were run at 110V for 70 min.  
2.4.10.4 Transfer 
The membrane was activated by soaking in 100% methanol for a minimum of 30s. The gel 
was removed from its casing, washed in deionised water before being rinsed with 1x SDS 
PAGE transfer solution. The transfer assembly was set up in a BioRAD electrophoresis tank 
with the membrane between two foam sponges and a wet sheet of filter paper on either side. 
The transfer was carried out at 30V for 1 hour.  
2.4.10.5 Blocking, antibody incubation and washing  
The membrane was placed protein side up in a LiCor staining box and incubated for 1 hour in 
Odyssey® blocking buffer at room temperature on a shaker. Primary antibodies were diluted 
in Odyssey® blocking buffer and incubated overnight at 4°C. The membrane was then washed 
3 times for 10 min each, in PBS-T. Secondary antibody, diluted in Odyssey® blocking buffer, 
was then added and incubated for 1 hour at room temperature. The membrane was then washed 
3 times for 10 min each, in PBS-T before being transferred to PBS before being imaged.  








Antibody Type Company Catalogue 
number 
Dilution 
TARDBP primary Rabbit ProteinTech 10782-2-AP 1:2000 
P62 primary Mouse IgG1 BD Biosciences 610832 1:1000 
GAPDH primary Mouse IgG1 Calbiochem CB1001 1:15000 
Secondary (800) Mouse IgG1 Li-Cor 925-32210 1:15000 
Secondary (680) Rabbit Li-Cor 925-68071 1:15000 
Table 2.8 Western blotting antibodies 
2.4.10.6 Imaging of membrane 
Imaging of the membrane was performed using an Odyssey Fc imager (Li- CO R Biosciences, 
UK).  
2.4.10.7 Coomassie staining 
After the gel had run, it was removed from its casing and rinsed in deionised water. It was 
placed protein side up and covered with Coomassie blue stain and left overnight on a shaker 
at room temperature. Destaining was performed using Coomassie blue destaining solution, 
with two 30 min washes followed by a final 1 hour wash. 
2.4.11 Transfections/HEK cells 
2.4.11.1 Reagents and solutions 
Opti-MEM® I Reduced Serum Medium (Life Technologies, 31985062) 
Lipofectamine® 2000 (Life Technologies, 11668019) 
Plasmids for expression of DPR were obtained from Biogen Idec. 
2.4.11.2 Transfection protocol 
Human Embryonic Kidney (HEK) 293 cells were plated down in a 24 well plate, with 100 000 
cells per well. The following day, when 70-90% confluent, the cells were transfected with 
plasmids. Lipofectamine® 2000 was gently mixed, diluted at 20µl/ml in Opti-MEM medium, 
and incubated for 5 min at room temperature. Meanwhile, plasmids (0.5µg for each DPR + 
0.5µg GFP per well) were diluted in Opti-MEM medium. The Lipofectamine solution was 
then added to the diluted plasmid in a 1:1 ratio, gently mixed and incubated at room 
temperature for 20 min. 100µl of this complex was then added to each well containing cells 
and medium. Cells were incubated at 37°C in a CO2 incubator overnight, prior to checking for 
transgene expression and subsequence immunocytochemistry. 
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2.4.12 Statistical analysis 
All experiments were carried out on a minimum of three independent cultures. Within each 
experiment, three or more technical repeats were analysed. All data represented is from one 
hiPSC clone per individual with C9orf72 associated ALS.  
All quantitative immunocytochemistry was performed blind. All data is presented with error 
bars which represent the standard error of the mean (SEM). Comparisons between control and 
carrier lines was based on their individual data points. All data points were tested for normality 
using Anderson-Darling test, using Minitab17. Since most data was not normally distributed, 
non-parametric tests were used the Mann-Whitney test was mainly used. Statistical tests were 
run in GraphPad Prism5. P values <0.05 were considered statistically significant.  
2.5 Immunohistochemistry  
2.5.1 Solutions and reagents 
Xylene (VWR Chemicals, 28975.325) 
Ethanol (VWR Chemicals, 20821.330) 
10mM citric acid, pH 6:  Made up in distilled water  
    Citric acid (Fisher Scientific, C/6160/53) 
    pH to 6.0 with Sodium hydroxide  
3% hydrogen peroxide: Made up in distilled water 
    Hydrogen peroxide (Sigma, 349887) 
Blocking solution:  Made up in PBS 
    Horse serum (Vector laboratories, S-2000), 3% 
    Triton-X100, 0.2% 
PAP pen (Vector laboratories, H-4000) 
Vectastain® Universal Elite ABC kit (Vector Laboratories, PK-7200), containing: 
Normal Horse Serum 
    Biotinylated, Universal (Anti-Mouse IgG/Rabbit IgG) 
Antibody 
    Reagent A (Avidin DH) 
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    Reagent B (Biotinylated Horseradish Peroxidase H) 
TNS:    Made up in distilled water 
    Trizma® base (Sigma, T6066), 6g per litre 
    pH to 7.4 with Nitric Acid (Fisher Scientific, N/2300/PB17) 
DAB Peroxidase Substrate kit (Vector Laboratories, SK-4100), made up in TNS: 
    Buffer stock solution (1:50) 
    DAB stock solution (1:25) 
    Hydrogen Peroxide solution (1:50) 
    Nickel solution (1:50) 
Haematoxylin (Thermo Scientific, LAMB/170-D) 
Lithium carbonate (Sigma, L4283), saturated solution  
DpX mountant (Sigma, 44581) 
2.5.2 Immunohistochemistry protocol 
Paraffin sections (cut to 4µm) which were previously prepared in Colin Smith’s laboratory, 
were dewaxed in xylene and taken down to water through graded alcohols, by immersing in 
the following solutions for the times stated: 
• Xylene – 3 min 
• Xylene – 3 min 
• 100% Ethanol – 3 min 
• 95% Ethanol – 3 min 
• 70% Ethanol – 3 min 
• Water – 3 min 
 
Antigen retrieval was then performed by placing the slides in 10mM citric acid, pH 6 and 
heating in a pressure cooker to 125°C for 30 seconds. The slides were then washed in PBS 
twice for two minutes each time, before being incubated in 3% hydrogen peroxide. The slides 
were then washed in PBS, before being marked with a PAP pen.  
Blocking solution was then added to the slides, and incubated at room temperature for 1 hour 
in a humidified chamber. The primary antibody was prepared in 1% horse serum in 0.2% 
Triton-PBS. Excess blocking solution was removed and replaced with primary antibody 
solution, and incubated overnight at room temperature.  
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The slides were washed 3 times, for 10 min each in PBS. Secondary antibody (Biotinylated, 
universal; from Vectashield kit, diluted 1:200 in 1% horse serum in PBS) was then added and 
incubated for 2 hours. The slides were then washed 3 times, for 10 min each in PBS. 
Meanwhile, a mixture of Reagent A (1:200) and B (1:200) was prepared in PBS and left for 
20 minutes, before being applied to the slides for 1 hour.  
The slides were washed 3 times, for 10 min each in PBS, followed by two 10 min washes in 
TNS. DAB solution was freshly prepared and applied to the slides for approximately 3 min 
(test slide checked under microscope to determine optimal time, and all slides treated in this 
way). The slides were then washed in TNS for 10 min, before being transferred to distilled 
water. Counterstaining was performed by immersing slides in haemotoxylin for 1 min, 
followed by dipping in saturated lithium carbonate solution. The slides were then dehydrated 
into xylene by passing through the following solutions, for the stated times: 
• 70% ethanol – 30 seconds 
• 95% ethanol – 1 min 
• 100% ethanol – 2.5 min 
• Xylene – at least 1 min 
 
The slides were then fixed in DpX mountant.  
2.5.3 Antibodies 
The DPR antibodies were produced by Biogen Idec., and raised in rabbit.  
2.5.4 Imaging of slides 
Immunoreactivity was assessed at 20x objective, representative images were taken using a 









Chapter 3. Molecular genetic testing for the 
C9orf72 hexanucleotide repeat expansion 
3.1 Introduction 
Genetic testing for the C9orf72 HRE can help to define a diagnosis, and allows the risk to 
other family members to be assessed. Detection of the C9orf72 HRE is challenging because 
of its large size and GC rich, repetitive nature. The main techniques that are currently used 
were described in Figure 1.2. The amplification of large expansions (>1000 repeats) is 
generally unfeasible using a conventional flanking PCR, and therefore other techniques 
including RP-PCR and Southern blotting are required for the detection of these (Warner et al., 
1996). A summary of our current understanding of the repeat size ranges, and capacity to 
detect them is shown in Figure 3.1. 
 
Figure 3.1 Size ranges and detection methods for C9orf72 (G4C2)n repeats 
The coloured line indicates the range of possible (G4C2)n repeat sizes, where n= number 
of repeat units, and the colour shows the estimated likelihood of causing disease (green 
being least likely to red most likely). The majority of normal controls tested have less than 
25 repeats. Short expansions (25 to 80 repeats) have been reported to segregate with 
disease in several families, whilst other in other cases have suggested anticipation can 
occur (Gijselinck et al., 2016; Xi et al., 2015a). There is then a jump in reported expansion 
sizes, with cases typically having between 400 and 4400 repeats (Beck et al., 2013). 
Current PCR methods allow identification of normal alleles and RP-PCR can detected 
whether an expansion is 30-50 repeats. The RP-PCR method described here can indicate 
that an expansion is at least 100 repeats and the flanking assay can detect up to 900 
repeats in cell lines. Southern blotting can cover the entire range, but gives a weak signal 




A further challenge, which applies both to flanking PCR and Southern blotting, is the somatic 
heterogeneity which is seen in C9orf72 HREs, particularly from blood samples presumably as 
they become increasingly unstable (Hubers et al., 2014). This results in a diffuse signal, which 
can be difficult to differentiate from background noise, and also makes assessment of the size 
of the expansion extremely challenging (Buchman et al., 2013).  
3.1.1 PCR based methods 
Within both research and diagnostic settings, it is desirable to have high-throughput, rapid 
PCR based tests which are highly accurate and use small quantities of input DNA (20-100ng). 
PCR is a widely used technique, and with optimisation can be used to amplify most DNA 
templates. However, the amplification of GC-rich and long repetitive sequences remains 
challenging. DNA with (GGGGCC)n expansions can form stable secondary structures such as 
G-quadruplexes (Haeusler et al., 2014; Sket et al., 2015), which are thought to prevent DNA 
polymerase from extending the template during PCR. In terms of genetic testing for the 
presence of the C9orf72 HRE, a conventional flanking PCR can be used to accurately define 
the size of most normal alleles (up to around 30 repeats). RP-PCR can be used to determine 
whether there is an expansion present or not, although cannot reliably provide information on 
the size of large expansions. The difficulties surrounding PCR amplification of the C9orf72 
HRE have been highlighted by a blinded international study which showed a wide variability 
in results obtained by different research laboratories using PCR methods (Akimoto et al., 
2014). Furthermore, the presence of variable deletions and insertions at the 3’ end of the repeat 
expansion (van der Zee et al., 2013), can affect the reliability of PCR assays targeting this 
region (Rollinson et al., 2015). Broadly, there have been two approaches to overcoming this 
problem, firstly reagent development and secondly optimization of cycling conditions (Orpana 
et al., 2012). 
The addition of co-solvents is a common approach to improve PCR amplification, particularly 
for GC-rich sequences. These co-solvents include DMSO (Seto et al., 1995; Sun et al., 1993), 
betaine and glycerol (Henke et al., 1997). These are thought to work by disrupting base pairing, 
reducing secondary structure formation and reducing the melting temperature of the DNA 
(McDowell et al., 1998). Similarly the inclusion of modified nucleotides such as 7-deaza-2’-
deoxyguanosine triphosphate (7-deaza dGTP) can also enhance amplification (Dierick et al., 
1993; McConlogue et al., 1988). Combinations of these reagents often work best (Musso et 
al., 2006), and it can be hard to predict which will work for a given template. This must be 
determined empirically, and care must be taken as DMSO, for example, can inhibit DNA 
polymerase in high concentrations (Landre et al., 1995). Developments in DNA polymerase 
90 
 
blends have also improved amplification of long, GC-rich templates (Hećimović et al., 1997; 
Mukai and Nakagawa, 1996).  
Alterations in conventional PCR cycling methods have also been applied to difficult templates. 
Examples of these include ‘Two-step hot PCR’ (Schuchard et al., 1993), ‘Slowdown PCR’ 
(Frey et al., 2008)  and ‘Hotstart and Touchdown PCR’ (D'Aquila et al., 1991; Don et al., 
1991). Another method which has emerged is ‘Heat Pulse Extension (HPE) PCR’ which has 
been applied to long-range PCR for Fragile X syndrome and Myotonic Dystrophy Type I, both 
of which are caused by large GC-rich triplet repeat expansions (Orpana et al., 2013; Orpana et 
al., 2012). In this technique, multiple short heat pulses are introduced to the extension stage of 
the PCR cycle, which are thought to destabilize any secondary structures which would 
otherwise cause the Taq polymerase to stall, improving PCR amplification efficiency (Orpana 
et al., 2012). The two reported applications of this technique have used a conventional style 
‘flanking PCR’ to detect amplicons which are up to a maximum of 5 kb in size (Orpana et al., 
2013). The larger C9orf72 expansions detected by Southern blot may not be amenable to PCR 
amplification, but I was interested to determine if HPE PCR could increase the current upper 
limit of detection by PCR. Also, since RP-PCR can be used to detect even the largest 
expansions, I wanted to determine whether the HPE PCR conditions would be successful for 
this type of assay. 
3.1.2 Objectives 
This chapter describes the original design and optimisation of PCR assays for the C9orf72 
HRE, which were then redesigned after the discovery of genomic instability in the 3’ region 
of the repeat. The aim of this work was to improve the detection range of PCR based methods 
for the C9orf72 HRE, as at the beginning of the study the published methods were limited to 
detection of alleles up to around 30 repeats by either flanking or RP-PCR, and Southern 
blotting was required to determine if there were greater than this number of repeats (DeJesus-
Hernandez et al., 2011; Renton et al., 2011). Expanding the detection range of short expansions 
by PCR is an important step towards helping to define the lower pathogenic size range of 
C9orf72 HRE. Having reliable PCR based assays to detect the presence of a C9orf72 HRE 
was vital to the quality control of the later cell culture based work described in chapters 4 and 
5 of this thesis, as well as the generation of an isogenic control line.  
The PCR assays described were used to determine the prevalence of the C9orf72 HRE in over 
500 Scottish MND patients who had donated a DNA sample to the Scottish MND Register 
between 1989-2015. In addition, the methods were applied in a clinical diagnostic setting for 
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ALS and FTD patients within the South East Scotland Regional Genetics Service, with over 
160 patients being tested between January 2013-November 2016.  
3.2 Results 
I designed a number of primers flanking the C9orf72 HRE using a combination of Primer 3 
(NCBI) and manual design. The primers were checked using OLIGO primer analysis software 
(Molecular Biology Insights, Inc, USA) to check for the predicted formation of secondary 
structures such as hairpins, dimers and self-complementation. The sequences and positions of 
these primers are detailed in Figure 3.2.  
 
Figure 3.2 Primer locations for C9orf72 PCR 
Sequence flanking the C9orf72 hexanucleotide repeat expansion (highlighted in red) with 
the location of the common 10 bp deletion which can hamper PCR (underlined). From 
GRCh37.p9 primary assembly, chr9: 27574028-27574389. F = forward, R = reverse and 
Rpt = Repeat. The main primers which have been used are shown and a complete list of 




3.2.1 Original flanking PCR 
To design the optimal flanking PCR, I selected primers as close to the repeat expansion site as 
possible, to enable the best possible resolution and theoretical upper size limit of detection by 
capillary electrophoresis. Initially, I used primers F1+R2 and F3+R3 as these were well 
matched combinations in terms of their melting temperatures. I first attempted PCR with the 
conditions used in one of the first published RP-PCR assays (Renton et al., 2011), using the 
Roche Fast Start High Fidelity PCR system (Roche, 04 738 284 001). Despite numerous 
attempts, which included making alterations to magnesium concentration, running annealing 
temperature gradients and introducing a hot start to help denature the template, there was either 
no amplification, or a predominance of non-specific products of varying size when separated 
by agarose gel electrophoresis (example shown in Figure 3.3a). However, amplification was 
more successful for both primer sets using Qiagen Multiplex Mastermix and Q solution 
(Figure 3.3a), with the manufacturer’s recommended cycling conditions (annealing 
temperature (Ta) = 60°C, 35 cycles) including a 15-minute initial denaturation step to activate 
the Hot Start Taq polymerase. Although primers F1+R2 showed some presumed non-specific 
products of approximately 600bp in size, the smaller size of the specific fragment (70 bp) was 
more desirable than that obtained with primers F3+R3 (150 bp). To try and improve the 
specificity of the reaction, I ran a gradient PCR for annealing temperatures of 60-70°C on three 
samples. The resulting gel shows that increasing the annealing temperature decreases the non-
specific band intensity, and that an annealing temperature of 68°C permits a single band to be 




Figure 3.3 Flanking PCR optimisation of polymerase mix and gradient PCR to 
determine annealing temperature 
(a) Products from flanking PCR of three normal control samples (1-3), and a zero (-) using 
either Roche Fast Start polymerase or Qiagen multiplex mastermix, and primer sets 
F2+R1 or F3+R3. (b) Gradient PCR for three samples using Qiagen multiplex mastermix 
and primers F2+R1, to assess the specificity of the reaction. The upper non-specific band 
is seen to gradually decrease in intensity as annealing temperature increases, and is not 
present at 68°C. Size in base pairs (bp). 
 
When running a number of normal controls using these conditions, I identified several samples 
which were apparently heterozygous for repeat sizes, and in these cases it was apparent that 
there was severe preferential amplification of the smaller alleles (Figure 3.4a). To try and 
overcome this, I carried out further optimisation by comparing Q solution to what had been 
determined as the optimal co-solvents for the RP-PCR (7% DMSO and 0.6M Betaine). This 
showed that the presence of DMSO and betaine promoted improved amplification of the larger 
alleles, as reflected by their approximately 4-5 fold increased fluorescence compared to Q 




Figure 3.4 Assessment of co-solvents in flanking PCR 
(a) Capillary electrophoresis trace following PCR amplification of two DNA samples with 
heterozygous normal repeat sizes, with Qiagen Muliplex Mastermix and Q solution. (b) 
Capillary electrophoresis trace following PCR amplification of the same two DNA samples 
with heterozygous normal repeat sizes, with Qiagen Multiplex Mastermix and 7% DMSO 
and 0.6M betaine. All fragment analysis traces are from GeneMarker (Soft Genetics) and 
x axis corresponds to size (bp) and y axis to relative fluorescent units.  
 
To calibrate the flanking PCR sizes to repeat number, it would have been desirable to sequence 
the products from homozygous samples. However, the fragment of 70 bp which was 
commonest, was too short for Sanger sequencing, Therefore, I performed PCR on four samples 
which gave this fragment size on the flanking PCR (F2+R1), using primers F1+R4, and 
sequenced the products, which revealed they contained two GGGGCC repeats (Figure 3.5a). 
To check the specificity of the flanking primers F1+R2, I carried out a nested RP-PCR, using 
primers for the repeat sequence (F2+Repeat R+Tail R), on PCR products which were 
apparently heterozygous for normal repeat sizes. This revealed a saw-tooth pattern with peaks 
approximately every 6 bp, which suggested that the flanking PCR was specific to the C9orf72 
expansion (Figure 3.5b-c). This also provided another method by which to check the sizes 
against the number of repeats as the repeat containing primer had 3 repeats, and therefore the 
first peak (75 bp) of the saw-tooth pattern corresponds to 3 repeats and the others can be 
counted from this (Figure 3.5c). Therefore, for sample 1, the 70 and 117 bp peaks in the 
flanking PCR correspond with 2 and 10 repeats respectively, and for sample 2, the 100 and 





Figure 3.5 Calibration of original flanking assay 
(a) Sequencing result from a flanking PCR product, from a sample which gives a 
homozygous 70 bp allele, showing the presence of two GGGGCC repeats (in reverse 
strand). Unidirectional sequencing only was performed. Sequencing trace was obtained 
from Sequence Scanner (Applied Biosystems). Y axis represents relative fluorescent units 
(rfu) (b) Flanking PCR products from two heterozygous normal samples after Ampure 
clean-up to remove primers, and prior to nested RP-PCR. (c) Products from samples in 
b, after nested RP-PCR. Repeat sizes are noted above the peaks, and corresponding size 
in base pairs (bp) is noted below the peak. All fragment analysis traces are from 
GeneMarker (Soft Genetics) and x axis corresponds to size (bp) and y axis to rfu. 
A range of control DNA samples were tested using these conditions, and revealed expected 
patterns with the majority having an allele at approximately 70 bp, and some having an 
additional larger allele. This assay was used in diagnostic testing for 92 samples from 2013-
2015. The upper size limit of the assay was determined to be approximately 26 repeats and 
was not expected to amplify alleles that were greater than around 30 repeats. Some example 
traces with a range of normal alleles are shown in Figure 3.6, and it can be seen from these 
that preferential amplification of the smaller allele becomes an increasing problem when there 




Figure 3.6 Original flanking PCR examples 
Capillary electrophoresis traces from flanking PCR products of heterozygous normal 
samples with (a) 2 and 5 repeats, (b) 2 and 16 repeats, (c) 2 and 24 repeats and (d) 8 and 
26 repeats. These show the preferential amplification of larger alleles which becomes 
more pronounced when there is an allele greater than ~20 repeats. All fragment analysis 
traces are from GeneMarker (Soft Genetics) and x axis corresponds to size (bp) and y 
axis to relative fluorescent units. 
3.2.2 Redesigned flanking PCR 
Following the observation of common deletions and insertions at the 3’ end of the HRE 
(Rollinson et al., 2015; van der Zee et al., 2013), and which were under the site of one of the 
flanking PCR primers (R1), I decided to re-design these primers. At the same time, I decided 
to try altering the PCR mixture and cycling conditions based on an assay that had been 
developed for another GC-rich PCR template which used heat-pulse extension PCR (Orpana 
et al., 2012). Although this method reportedly relies heavily on unusual cycling conditions, 
the polymerase mix that is used, DyNAzyme EXT Taq (ThermoScientific), is suited to 
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difficult templates and long range PCR. The aim was to investigate whether these changes to 
PCR conditions could increase the size range which could be detected above 30 repeats. 
I applied these conditions for several primer sets (F2+R2, F2+R3, F2+R4), and also ran 
annealing temperature gradients for these, however there was either no amplification or non-
specific products were generated (data not shown). Because some of these primers were mis-
matched for their melting temperature and the fragments were shorter than recommended for 
HPE PCR, I designed new reverse primers and found that a combination of F3+R6 gave the 
expected allele sizes for a number of samples which were of known repeat size from previous 
testing. It became clear after running several samples that these reaction conditions were 
allowing amplification of larger alleles than the original PCR assay, and that preferential 
amplification was reduced.  
Having identified a cell line DNA sample which appeared to have an allele which was 576 bp 
(estimated 88 repeats), I ran an annealing temperature gradient using this sample (Figure 3.7). 
The highest level of fluorescence for the larger repeat allele (1350 rfu) was obtained at 58°C, 
with this product becoming gradually less abundant as the annealing temperature increased, 
until at 64°C and above there is very little or no amplification of even the 2 repeat allele. 
 
Figure 3.7 Gradient PCR for HPE flanking PCR 
Capillary electrophoresis traces from flanking PCR products showing an annealing 
temperature gradient for primers F3+R6 on a cell line DNA sample with 2 and 88 
(GGGGCC) repeats. (a) 58°C shows the highest yield of 88 repeat containing material (b) 
60°C (c) 62°C and (d) 64°C only permits weak amplification of the 2 repeat allele (e) 66°C 
and (f) 68°C does not allow amplification. All fragment analysis traces are from 




As the products were slightly larger for this PCR than the original one, Sanger sequencing was 
directly performed to check that the specificity of the product and to calibrate the fragment 
sizes to repeat numbers (example in Figure 3.8). A range of flanking PCR product sizes were 
sequenced (up to 20 repeats). I also ran 41 samples which had been genotyped using the 
original assay and confirmed that these gave concordant sizing results.  
 
Figure 3.8 Example of Sanger sequencing of HPE flanking PCR products to 
calibrate fragment size to number of repeats 
(a) Capillary electrophoresis trace of flanking PCR products from a patient who is 
homozygous, with one allele at 178 bp. Fragment analysis traces are from GeneMarker 
(Soft Genetics) and x axis corresponds to size (bp) and y axis to relative fluorescent units. 
(b) Sanger sequencing of the product reveals that it contains 8 GGGGCC repeats. 
Traces are from Mutation Surveyor (Soft Genetics) (upper panel is reference 










Because of the somewhat unconventional cycling conditions, I decided to test which aspects 
of this were necessary for amplification by comparing this for samples with the large normal 
alleles. Heat pulse extension was compared to constant temperature extension, and then the 
the two-step denaturation and the slow ramping were subsequently removed. A schematic of 
the cycling conditions which were compared is shown in Figure 3.9a. The first feature that I 
tested was whether the heat pulses to 86°C or 90°C during the extension phase altered the 
intensity of the products. The results of this comparison, as exemplified by the results for a 
sample with 8 and 26 repeats, showed that replacing the heat pulses with constant temperature 
extension at 78°C for 6 minutes made little difference to the amplification of larger allele (both 
show >9000 rfu) (Figure 3.9b,c). Considering the potential detrimental effects of pulsing on 
the PCR machine, and the observation that a constant temperature extension improved the RP-
PCR assays, I decided to use constant temperature extension for further optimisation. I then 
investigated whether the slow ramp (12% or 0.6°C/s) from annealing to extension temperature 
or two-step denaturation (94°C for 45s, then 98°C for 10 s) improved amplification. Replacing 
the two-step denaturation step with a single denaturation step (94°C for 55 s) resulted in a 
marginally reduced yield of the larger product (8800 rfu vs 9200 rfu) (Figure 3.9d), as did 
increasing the ramp rate to 100% (9100 rfu vs 9200 rfu) (Figure 3.9e). Finally, I compared the 
results of constant extension for 3 min versus 6 min (Figure 3.9f). For alleles up to 90 repeats 
in size, this appeared to make little difference, but there was a smear apparent in two positive 
cell line DNA samples that was more apparent with the longer extension time. Along with the 
results obtained for RP-PCR, the cycling conditions which were determined as optimal include 











Figure 3.9 Optimisation of cycling conditions for flanking PCR 
(a) Schematic of PCR cycling conditions which were compared. (b-e) Capillary 
electrophoresis traces showing an 8 and 26 repeat carrier with flanking PCR performed 
with (b) heat pulse extension, two-step denaturation and slow ramping, (c) constant 
temperature extension, two-step denaturation and slow ramping, (d) constant temperature 
extension, single-step denaturation and slow ramping and (e) constant temperature 
extension, high denaturation and normal ramping. (f) Agarose gel electrophoresis images 
showing PCR products after 3 or 6 minute constant temperature extension, two-step 
denaturation and slow ramping for (1) a cell line from an expansion carrier with 88 repeats 
present (2) a cell line from an expansion carrier with unknown repeat number (3) an 8 and 
26 repeat carrier (-) negative PCR control. All fragment analysis traces are from 
GeneMarker (Soft Genetics) and x axis corresponds to size (bp) and y axis to relative 
fluorescent units. 
These conditions allowed balanced amplification of normal alleles between 2 and 26 repeats 
in length (Figure 3.10a-c). Particularly because of the large smears of greater than 1000 bp 
that I had observed for several expanded samples after agarose gel electrophoresis, I wanted 
to determine what the upper range of the PCR assay was. I obtained two samples, from whole 
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blood with short expansions detected by Southern blot which were kindly sent by James Polke 
(Institute of Neurology, UCL, Queen Square, London). One of these samples had 
approximately 60 repeats, and was mosaic for a longer expansion (James Polke, personal 
communication), while the second sample had somatic mosaicism for 70-120 repeats 
estimated by Southern blotting (Fratta et al., 2015). Both of these samples had amplification 
of short expansions which were detectable following PCR with this assay, and these revealed 
a high level of mosaicism (Figure 3.10d-f). The highest peaks in the ‘60’ repeat sample 
corresponded with 71 repeats by the PCR method, while the ‘70-120’ repeat samples peaked 
at approximately 82 repeats. I observed that several patient samples which were positive for 
C9orf72 expansions on RP-PCR, revealed a large diffuse smear from 1 - >10 kb when the 












                      
Figure 3.10 Optimised flanking PCR results 
Flanking PCR products separated by capillary electrophoresis (a-e) from blood 
derived DNA with (a) 7 repeat and 13 repeat alleles (b) 2 and 20 repeat alleles (c) 8 
repeat and 26 repeat alleles (d) a sample estimated to have 5; 60 repeats, with 
somatic mosaicism for a large expansion by Southern blot and (e) a sample estimated 
to have 5; 70-120 repeats by Southern blot (Fratta et al., 2015). All traces are from 
GeneMarker (Soft Genetics) and x axis corresponds to size in base pairs (bp) and y 
axis to relative fluorescent units. The inner box shows the zoomed in trace where the 
x axis is consistent with that of the overall trace.  (f) Agarose gel electrophoresis of 
flanking PCR products from blood DNA with 100 bp and 1 kb extension DNA ladders. 
Lane: 1. Normal control (2;5 repeats). 2. Normal control (8;26 repeats). 3. Expansion 
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carrier (10;60 mosaic repeats). 4. Expansion carrier; (5;70-120 repeats). 5. Expansion 
carrier (8 repeats; expansion). 6. Normal control (2; 2 repeats). 7. Expansion carrier 
(8 repeats; expansion). 8. Expansion carrier (2 repeats; expansion). 9. Normal control 
(2; 5 repeats). 10. Expansion carrier (2 repeats; expansion). 11. Expansion carrier (2 
repeats; expansion). 12. No DNA control. 
The smears that I had observed on agarose gel electrophoresis following flanking PCR of 
expanded carriers were intriguing and I was interested in determining what the upper detection 
limit of the PCR was. As it had been observed that cell line DNA gave sharper bands and 
lower size than peripheral blood DNA using Southern blotting (Beck et al., 2013; van 
Blitterswijk et al., 2013b), I decided to test such samples by PCR. I obtained lymphoblast cell 
line (LCL) derived DNA from Coriell Cell Repositories, and tested these to try and establish 
the upper size range of amplification by PCR. After agarose gel electrophoresis, it was 
observed that several of the cell lines showed bands up to a size of 5.7kb, corresponding with 
approximately 900 repeats (Figure 3.11). Expanded material was detected in 4 out of 7 lines 
tested, which is presumably because the other lines contained expansions which were beyond 
the size limit of detection by this method, which is supported by previously published Southern 
blotting results for ND10966, ND11836 and ND14442 (Liu et al., 2014). Comparison of our 
PCR results with these suggest that the very largest expansions are not amplified.  
 
Figure 3.11 Flanking PCR for cell line DNA  
104 
 
Figure 3.11. Flanking PCR for cell line DNA  
Agarose gel electrophoresis of flanking PCR products with 100 bp and 1 kb extension 
DNA ladders. Lane 1-4 Blood derived DNA: 1. Normal control (2;5 repeats). 2. Normal 
control (8;26 repeats). 3. Expansion carrier (10;60 mosaic repeats). 4. Expansion carrier; 
(5;70-120 repeats). 5-11 Coriell Cell Repositories C9orf72 HRE positive LCL DNA: 5. 
ND09373 (10; Undetected expansion). 6. ND09438 (11; 570 repeats). 7. ND10966 (9; 
Undetected expansion). 8. ND10973 (9; Undetected expansion). 9. ND11836 (8; 860 
repeats). 10. ND12199 (6; 85 repeats). 11. ND14442 (2; 600,700,920 repeats). 12. No 
DNA control.  
3.2.3 Original RP-PCR 
Because the largest expansions cannot be detected by flanking PCR, another method such as 
RP-PCR is required to determine if there is an expanded allele preent. I initially tried using the 
Roche FastStart polymerase and conditions as described in one of the first described assays 
(Renton et al., 2011), but had no success. However, as with the original flanking PCR, using 
the Qiagen Multiplex Mastermix with standard cycling conditions (primer F2+Repeat R, 
Ta=71°C) was more successful. This generated a product, which was predominantly 75 bp, 
with some evidence of a saw tooth pattern, as would be expected from a sample with 
heterozygous repeat sizes (Figure 3.12a). To try and overcome the apparent preferential 
amplification and encourage a more prominent saw-tooth pattern, I then tested seven control 
samples with a range of co-solvents (7% DMSO, 0.6M betaine and a mixture of both) and 
compared the results (representative images, Figure 3.12b-d), which demonstrate a higher 
yield of product for the DMSO and betaine mixture. A positive control sample was kindly sent 
by James Polke (Institute of Neurology, UCL, Queen Square, London) and this was used to 
further optimise this assay (Figure 3.12e). I first established the optimal primer concentrations 
of flanking, repeat and Tail R (Figure 3.12f). I then altered the cycling conditions to promote 
the binding of the repeat primer by using a high anneal (Ta=71°C) for the first ten cycles, and 
then reducing to Ta=60°C for a further 25 cycles to allow Tail R to bind which increased the 
product yield further, and led to longer fragments being produced (Figure 3.12g). Finally, I 
added 7-deaza-dGTP to the PCR mix, to try and further disrupt secondary structure formation, 








Figure 3.12 Optimisation of original 5’ RP-PCR assay 
Capillary electrophoresis traces of 5’RP-PCR products from normal controls (a-d) and 
C9orf72 hexanucleotide expansion carriers (e-h) during optimisation of 5’RP-PCR. Using 
standard cycling conditions, Ta=71°C, different co-solvents were used to determine the 
optimal PCR mix for a sample with 2 and 10 repeats (a) 1x Q solution (b) 0.6M Betaine 
(c) 7% DMSO and (d) 7% DMSO plus 0.6M betaine. (e) This combination of DMSO and 
betaine allowed detection of the expanded repeat allele (zoomed in traces shown). (f) The 
PCR amplification was gradually improved by optimising primer concentrations and ratios 
between flanking primer, repeat primer and Tail R. (g) A two-step PCR protocol which 
involved lowering Ta to 60°C for the final 25 cycles to encourage priming by Tail R. (h) 
The addition of 7-deaza dGTP increased the signal strength and maximum product sizes 
obtained. All traces are from GeneMarker (Soft Genetics) and x axis corresponds to size 
(bp) and y axis to relative fluorescent units.  
In line with recommendations for other repeat expansion disorders, I also developed an RP-
PCR assay for the 3’ end of the repeat. The optimised conditions for the 5’ RP-PCR assay 
were then applied to PCR with primer R2, which appeared to have a similar amplification 
pattern, but tested whether there was a repeat from the 3’ direction (Figure 3.13).  The 
maximum size of fragments produced by the RP-PCR assays was around 350 bp, which 
corresponded to around 50 repeats. Thus, this assay could allow detection of an allele with an 
expansion of 30 repeats or more, which was the range suggested by the original paper to be 




Figure 3.13 Original 3’ RP-PCR examples 
Capillary electrophoresis traces of 3’RP-PCR products from (a) a C9orf72 HRE carrier (b) 
a normal heterozygous control with a maximum of 10 repeats. Repeats are counted from 
the first peak, which corresponds with the number of repeats in the primer (3). All traces 
are from GeneMarker (Soft Genetics) and x axis corresponds to size (bp) and y axis to 
relative fluorescent units. The inner box shows the zoomed in trace where the first peak 
corresponds with 30 repeats on the x axis.   
 
3.2.4 Re-designed RP-PCR 
3.2.4.1 5’RP-PCR 
Following the vast improvement that was obtained with the flanking PCR when applying the 
HPE PCR conditions, I went on to try these for the RP-PCR assays. Applying this PCR mix 
and cycling conditions for the 5’ RP-PCR assay, and using the previously optimised primer 
concentrations (for F2, Repeat R and Tail R), revealed a greatly improved amplification 
pattern. I ran a gradient PCR to establish the optimal annealing temperature for the primers, 
which was 62°C (data not shown). As for the flanking PCR, I investigated whether the heat 
pulses were necessary by comparing samples run with heat pulses or with a constant 
temperature extension of 6 minutes. This showed that there was a higher fluorescence at 30 
repeats (350 with pulses compared to 480 without), the maximum size of the products were 





Figure 3.14 5’RP-PCR assay with heat pulse extension compared to constant 
temperature extension 
Capillary electrophoresis traces of 5’RP-PCR with a C9orf72 expansion carrier with (a) 
heat pulse extension PCR (b) constant temperature extension. The inner box shows an 
image of the baseline in the affected range. All traces are from GeneMarker (Soft 
Genetics) and x axis corresponds to size (bp) and y axis to relative fluorescent units. The 
inner box shows the zoomed in trace where the first peak corresponds with 30 repeats on 
the x axis.   
Comparing samples tested by the original and newly optimised 5’ RP-PCR assay showed that 
the new conditions promoted superior amplification. The resulting PCR products from the 
newly optimised conditions gave a brighter trace (3000 versus 100 rfu at 30 repeats) after 
capillary electrophoresis, and consistently larger products when an expansion was present, 
with reduced preferential amplification of the normal allele as shown (Figure 3.15a,b). 
Previously, it was necessary to closely scrutinise the baseline of each trace to determine 
whether there was an expansion present, whereas the new assay gave a more striking pattern 
in expansion positive samples. To validate this assay, 14 previously identified expansion 
carriers and 16 normal controls were tested and gave the expected result in all cases. An 
example capillary electrophoresis trace of a normal control following the original assay 




Figure 3.15 Improved PCR amplification of expanded alleles using the re-
designed 5’ RP-PCR assay compared to the original assay 
(a) Capillary electrophoresis trace from the original 5’ RP-PCR assay of an expansion 
carrier (b) a trace from the HPE 5’ RP-PCR assay showing improved amplification. (c) 
Capillary electrophoresis trace from the original 5’ RP-PCR assay of a normal control (2/8 
repeats) compared to (d) a trace from the HPE 5’ RP-PCR assay for the same normal 
control sample. All traces are from GeneMarker (Soft Genetics) and x axis corresponds 
to size (bp) and y axis to relative fluorescent units. The inner box shows the zoomed in 
trace where the first peak corresponds with 30 repeats on the x axis.  
3.2.4.2 3’RP-PCR 
For the 3’RP-PCR, as for the flanking PCR, it was important to consider the genomic 
variability of the region adjacent to the repeat expansion, and the impact that this may have on 
PCR amplification. Indeed, it proved challenging to optimise the 3’ RP-PCR assay, although 
in this case the genomic variability did not seem to be the problem. Initially, as for the 5’ RP-
PCR assay, I tried the PCR mix and conditions described by Orpana et al., with the previously 
optimised RP-PCR primer concentrations (R2, Repeat F and Tail R), and then investigated the 
various aspects of the cycling conditions as for the flanking PCR (Figure 3.9a). As for the 
5’RP-PCR assay, constant temperature extension gave a slightly higher fluorescence signal at 
30 repeats than heat pulse extension so we used the latter (data not shown). It appeared that 
there was more amplification with slow (12%) ramping and a two-step denaturation improved 




Figure 3.16 Comparison of 3’RP-PCR with varying ramp rate and denaturation 
temperature 
Capillary electrophoresis traces of 3’RP-PCR products from a C9orf72 expansion carrier 
with (a) Two-step denaturation and 12% ramp rate (b) single-step denaturation and 12% 
ramp rate and (c) two-step denaturation and 100% ramp rate. The inner box shows an 
image of the baseline in the affected range. All traces are from GeneMarker (Soft 
Genetics) and x axis corresponds to size (bp) and y axis to relative fluorescent units. The 
inner box shows the zoomed in trace where the first peak corresponds with 30 repeats on 
the x axis.   
 
The resulting PCR was higher yielding as shown by the higher fluorescence on the capillary 
electrophoresis traces comparing the new assay to the original one for expansion carriers 
(Figure 3.17a-b), but it was notable that in the presence of an expansion, there was a lack of 
amplification from the normal allele, giving a notable pattern whereby the size of the first peak 
varied, which would be expected in the presence of insertions and deletions within the PCR 
amplicon (Figure 3.17c-d). However, this PCR also gave weak false positive results for two 
negative controls (Representative example; Figure 3.17e), both of which had two normal 
alleles on flanking PCR and no expansion detected by 5’ RP-PCR (data not shown). To try 
and increase the reaction specificity, I tried altering the annealing temperature. I ran a gradient 
(62-67°C) and found that increasing the annealing temperature appeared to reduce the false 
positive effect (Ta=62°C, Figure 3.16e; Ta=65°C, Figure 3.17f), but that it also reduced the 
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yield of the expected product from the normal and expanded alleles and so this did not offer 
an ideal solution. 
 
Figure 3.17 Optimisation of the re-designed 3’ RP-PCR assay 
(a) Capillary electrophoresis trace from the original 3’ RP-PCR assay of an expansion 
carrier compared to (b) a trace from the re-designed 3’ RP-PCR assay showing improved 
amplification. (c)  A sample with an apparent deletion within the PCR amplicon indicated 
by the shifted start position (from 93 bp to 81 bp) of the saw-tooth pattern (d) Result from 
a sample with an apparent insertion within the PCR amplicon indicated by the shifted start 
position (from 93 bp to 103 bp) of the saw-tooth pattern. (e) A negative control sample 
with weak saw-tooth pattern indicating a false positive result (Ta=62°C) (f) A negative 
control sample with weaker saw-tooth pattern (Ta=65°C). The x axis corresponds to size 
in base pairs (bp) and y axis to relative fluorescent units. The inner box shows the zoomed 
in trace where the first peak corresponds with 30 repeats on the x axis.   
To try and establish whether the primer choices were the cause of the false positive effect, I 
carried out PCR with several different flanking primers (R6, R7, R8, R9). None of these 
overcame the problem, as either they gave no product or they showed the same effect (data 
not shown), and therefore it seemed more likely that the repeat-binding primer needed to be 
re-designed. I removed one repeat unit from the primer and also altered the phase so that it had 
a different start point along the repeat tract. This primer, in combination with R6, eliminated 
the effect in most normal samples, with false positives being limited to samples with large 
normal alleles, with those over 15 repeats being affected (Figure 3.18). I tried reducing cycle 
number, reducing polymerase concentration and altering primer concentrations but these did 
not overcome the effect without having a significant impact on the yield of the expected 
product. I also designed a primer which was ‘clamped’ to the 5’ end of the repeat by the 
addition of 2 bases complementary to this region, to try and encourage specific binding from 
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the end of the repeat and reduce replication slippage but this did not eliminate the effect either 
(data not shown). 
 
Figure 3.18 3’RP-PCR artefact which is only present in the presence of normal 
alleles greater than 15 repeats, which is not observed for 5’RP-PCR.   
 (a) Heterozygous normal sample (2;5 repeats) (b) Heterozygous normal sample (2;15 
repeats) amplified with 3’RP-PCR showing weak stuttering into the affected range, with 
5’RP-PCR showing no presence of product >30 repeats. (c) Heterozygous normal sample 
(8;26 repeats) amplified with 3’RP-PCR showing stuttering into the affected range, with 
5’RP-PCR showing 10-fold weaker stuttering into the expanded range. (d) Heterozygous 
expansion carrier showing stronger signal in the affected (>30 repeat) size range in both 
assays compared to the samples with large normal alleles. All capillary electrophoresis 
traces are for 3’RP-PCR (left) and 5’RP-PCR (right), and are from GeneMarker (Soft 
Genetics). The x axis corresponds to size in base pairs (bp) and y axis to relative 
fluorescent units. The inner box shows the zoomed in trace where the first peak 
corresponds with 30 repeats on the x axis.   
Using the new primer combinations (R8 and Repeat F3), the traces for expansion carriers 
showed higher yield than for the original assay and larger products with this assay, as was also 
the case for the 5’RP-PCR. This assay was validated with 15 previously identified expansion 
carriers and 17 normal controls, which all gave concordant results.  
Although it appears from the pattern of altered start sites that this assay is detecting expansions 
even in the presence of insertions and deletions within the region, to confirm this I exploited 
the lack of amplification of normal alleles that was apparent during optimisation using primer 
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R6, to sequence the 3’ region of expanded repeat alleles following RP-PCR. The full results 
of this analysis are shown in Table 3. This showed that the optimised 3’RP-PCR was still 
amplifying product even in the presence of genomic variability at the 3’ end of the repeat 
expansion. 









Table 3.1 Variability detected at 3’ end of the repeat expansion in C9orf72 
positive ALS patients 
To determine the sensitivity of the assay for mosaicism, I carried out admixture experiments 
for both RP-PCR assays (Fig 3.19). These showed that even when expanded material was 
diluted 1% in normal control DNA, the presence of the expansion was still just detectable with 
30 repeats corresponding to 85-150 rfu (Figure 3.19d). 
 
Figure 3.19 Sensitivity of RP-PCR for mosaicism  
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Figure 3.19 Sensitivity of RP-PCR for mosaicism  
Capillary electrophoresis traces from 3’RP-PCR products (left) and 5’RP-PCR products 
(right) from GeneMarker (Soft Genetics). The x axis corresponds to size in base pairs (bp) 
and y axis to relative fluorescent units (box shows zoomed in trace where the first peak 
corresponds with 30 repeats on the x axis). The traces show amplification of heterozygous 
expanded DNA (2 and expansion) at varying degrees of dilution (a) 100% (b) 50% (c) 
10% (d) 1% and (e) 0% in heterozygous normal control DNA with 2 and 5 repeats.  
 
3.2.5 Screening for C9orf72 HRE in the Scottish ALS population 
I screened for the presence of a C9orf72 HRE in 529 DNA samples from the Scottish 
Regenerative Neurology Tissue Bank (1989-2015), which were linked to the Scottish MND 
Register (2010-2015). These samples were obtained from patients who fulfilled either the 
diagnostic criteria for MND as defined by the Modified World Federation of Neurology (1989-
1994) or ‘El Escorial’ (1995 onwards) (Brooks, 1994; Chancellor, 1992). All samples were 
first tested by conventional flanking PCR, and the 187 which were apparently homozygous 
for a normal allele were reflex tested for the presence of an expansion using both 3’RP-PCR 
and 5’RP-PCR. Of the 528 samples for which results were obtained, 50 (9.5%) were found to 
have an HRE greater than 100 repeats. There was one equivocal result due to discordance 
between the two RP-PCR assays. One sample failed due to low DNA concentration and 
quality. 
The equivocal result was in a sample which was apparently homozygous for 15 repeats, but 
which was negative for an expansion by 5’RP-PCR and positive by 3’RP-PCR. Due to 
insufficient DNA, it was not possible to test whether there was a primer binding site 
polymorphism inhibiting the 5’RP-PCR assay, or whether this was simply affected by the PCR 
artefact observed in the 3’RP-PCR assay, on samples with such large normal repeat alleles. 
There was also no information on the ethnic origin of the patient or whether there was a history 
of consanguinity, which may have made homozygosity more likely.  
The frequency of the repeat sizes that were detected are shown in Figure 3.. The commonest 
allele size is 2 repeats (48.8% of alleles), with 5 (13.4% of alleles) and 8 repeats (11.7%) also 




Figure 3.20 Distribution of repeat lengths of the C9orf72 (GGGGCC)n tract in 
Scottish ALS patients.  
Histogram of GGGGCC repeat numbers in Scottish patients from the MND Registry 
(1989-2015), with expansions represented as 100+ repeats.  
Of these patients, there was clinical phenotypic data available for 47/50 C9orf72 HRE carriers. 
There was a wide range of ages of onset, from 26-84 years. The average disease duration was 
38 months (range 8-247 months). 18 patients (38%) were recorded as having a positive family 
history. 19 (40%) had bulbar onset disease and 24 (51%) were male (Leighton, personal 
communication). 
 
3.2.6 Clinical diagnostic testing for C9orf72 HRE in the Scottish MND and 
FTLD population 
These PCR assays were validated within the South East Scotland Genetics Service for 
diagnostic use, and used to test 163 patients for a C9orf72 HRE between 2013-2016. These 
patients had a variety of clinical phenotypes including dementia, motor neuron disease and 
Huntington disease-like symptoms. For all of these patients, all three PCR assays were 
performed. Out of the 163 patients tested, 23 were found to have a C9orf72 HRE, giving a 
pick-up rate of 14.6%. A number of presymptomatic tests have also been performed, providing 
family members with information of their risk of developing C9orf72-related symptoms in the 
future. I will discuss two case studies that were of interest. 
115 
 
Case 1  
A 41-year-old patient was referred with a diagnosis of dementia, having had severe memory 
problems for one year. He had word-finding difficulties, and attention and concentration 
problems. His mother had also suffered from dementia from a young age and died of the 
disorder in her forties.  
C9orf72 testing revealed the presence of two alleles of 8 and 26 repeats. Because of the 
uncertainty surrounding the pathogenic range of C9orf72 HRE, and because this was the 
largest normal sized allele which we had detected, and the family history was strong, I was 
prompted to investigate reports in the literature of similar size expansions. There was a report 
in the literature of a patient with FTD and ALS in whom a 26 repeat allele was present, 
however it did not segregate with disease in the family (Simón-Sánchez et al., 2012).  
As it was decided that this allele was unlikely to be causative, this patient’s sample was then 
tested for variants in a number of other genes which are associated with ALS, FTD or early 
onset AD (APP, CHMP2B, FUS, GRN, MAPT, PSEN1, PSEN2, SOD1, SQSTM1, TARDBP, 
UBQLN, VAPB and VCP) using next generation sequencing. This revealed a known 
pathogenic variant in PSEN1 (c.436C>A; p.Met146Leu in NM_000021.3), which has been 
implicated in early-onset AD (Bruni et al., 2010; Sherrington et al., 1995; Sorbi et al., 1995). 
Due to the differences in disease aetiology of FTD and AD, it is likely that the PSEN1 mutation 
is the cause of this patient’s symptoms. However, we cannot rule out that the 26 repeats in 
C9orf72 are contributing to his phenotype, particularly as others have suggested that repeats 
of this size may predispose to neurological disease (Gómez-Tortosa et al., 2013). If family 
studies had been possible, this would have been interesting and potentially informative as to 
the influence of the C9orf72 short expansion. If post-mortem pathology was to be carried out 
on this individual, it would be interesting to establish whether there were TDP-43 inclusions 
present, or any other signs of C9orf72 involvement, in addition to the amyloid-beta plaques as 
predicted from a PSEN1 mutation (Russo et al., 2000).  
Case 2 
A 59-year-old patient was referred for testing as he had a five-year history of progressive 
cognitive impairment, with short term memory loss and expressive speech disturbance. There 
was a strong family history of early onset dementia.  
The C9orf72 flanking PCR revealed an apparent 7 repeat homozygote, and this was confirmed 
by both RP-PCR assays. Because this was a relatively rare allele size, I sequenced the flanking 
PCR products, which revealed that there was apparently a normal 7 repeat allele, plus an allele 
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with 5 repeats and a 12 base pair insertion, which made it appear as a 7 repeat allele. This was 
a reassuring result confirming the presence of two normal alleles.  
3.3 Discussion 
3.3.1 PCR assays for detecting C9orf72 expansions 
I have described the design and optimisation of PCR-based methods for testing for the 
presence of the C9orf72 HRE, within a clinical diagnostic setting. The extreme GC richness 
of the expansion makes PCR a challenge, and I have had to optimise numerous aspects of the 
reaction conditions to bring about incremental improvements in both the flanking and RP-PCR 
assays. 
One factor which has been key to the success of the assays has been the Taq polymerase which 
has been used. I have tried the Roche Fast Start polymerase, Qiagen HotStart polymerase 
(Figure 3.3a, Figure 3.12), and DyNAzyme EXT polymerase (Figure 3.9), and found that the 
latter gives a higher yield and permits larger fragments to be amplified in all of the assays. 
Since each polymerase has different manufacturer’s recommendations for optimal cycling 
conditions, I have not performed a direct comparison of each Taq polymerase under the same 
conditions.  
Another factor which I investigated with the original assays, which used Qiagen HotStart Taq 
polymerase, was the effect of co-solvents, such as DMSO, betaine and deaza-dGTP on the 
reaction success (Figure 3.4; Figure 3.12). It was clear that a combination of betaine and 
DMSO, and the addition of deaza-dGTP were beneficial for the amplification of larger 
fragments, and in particular allowed the RP-PCR to amplify longer fragments more effectively 
(Figure 3.12). Because the DyNAzyme EXT polymerase allowed amplification of even larger 
fragments with betaine alone, I decided not to investigate other co-solvents (Figure 3.15). The 
addition of deaza-dGTP interferes with detection of PCR products with intercalating dyes after 
agarose gel electrophoresis so was not desirable as the optimised assay amplified fragments 
which were larger than could be detected using the capillary electrophoresis instruments 
available. 
PCR cycling conditions were optimised for the assays in various ways. For the original RP-
PCR assays, it appeared to be beneficial for the generation of larger products if the early cycles 
had a high annealing temperature, which was then dropped in later cycles to promote 
amplification with Tail R (Figure 3.12g). For the re-designed assays, I investigated further 
how the cycling conditions affected the success of this PCR. It appeared that the heat pulse 
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extension step of the PCR, which was expected from the literature to be beneficial (Orpana et 
al., 2012), did not have a significant impact on the generation of RP-PCR products, and 
actually constant temperature extension gave a higher yield of product (Figure 3.14). The 
inclusion of slow ramping and two-step denaturation were also optimal for RP-PCR (Figure 
3.16). For flanking PCR, there was a slight increase in the yield of larger product with HPE, 
compared to constant temperature extension, but as the capillary electrophoresis traces show 
signs of saturation, it would have been better to re-run these at a lower concentration to allow 
a fairer comparison. It is likely that the two-step denaturation, which includes a 10 second step 
at 98°C, is beneficial for such a highly GC-rich amplicon as complete denaturation is required 
for efficient PCR. This is consistent with the observation that the effect is more pronounced 
for RP-PCR of expansions, which generate larger products which are more susceptible to 
secondary structure formation, than flanking PCR of normal sized alleles. It was, however 
clear that slow ramping was beneficial to the yield of larger products for the flanking assay 
(Figure 3.9). Slow ramping from annealing to extension is thought to give primers slightly 
longer to bind, and allow some polymerase activity to begin to help clamp the products to the 
template (Orpana et al., 2012). 
The re-designed and optimised flanking PCR allows detection of alleles which are larger than 
have previously been reported using similar methods. The largest alleles which were detected 
in blood were approximately 70-100 repeats in size, and revealed a high level of somatic 
mosaicism in two such samples (Figure 3.10d-f). There was a slight discrepancy between the 
sizing by PCR or Southern blot, however the higher resolution of capillary electrophoresis 
compared to agarose gel electrophoresis would enable PCR to provide more accurate sizing 
than Southern blotting. Whilst validating the optimised flanking PCR on blood derived DNA, 
I observed that some HRE positive samples revealed a background smear when the PCR 
products were separated by agarose gel electrophoresis. It was particularly striking that 
increasing the extension time enhanced the smear signal (Figure 3.9e). I suspected that this 
may reflect the amplification of the expanded allele, but the signal was weak due to somatic 
mosaicism. Although the pattern was not robust enough to be useful in a diagnostic setting, it 
suggested that the PCR was efficient and prompted me to investigate the upper size limit of 
detection. 
Using cell line DNA allowed detection of larger expanded material than had been detected in 
blood. The largest band detected corresponded to approximately 900 repeats.  Although cell 
line DNA is not a source routinely used in a diagnostic setting, the sharp bands observed for 
cell line DNA containing C9orf72 expansions suggest that the PCR is reliable in this range, 
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and the mosaicism seen in blood-derived DNA from the short expansion carriers is likely to 
be a real effect and not a PCR artefact caused by replication slippage. The ability to detect 
such expansions in cell line DNA was useful for my later studies using hiPSC derived models. 
Somatic mosaicism has been widely reported in C9orf72 expansions (Beck et al., 2013; Dols-
Icardo et al., 2014), with size varying between tissues within the same individual. For 
diagnostic purposes, DNA is normally isolated from whole blood or saliva samples, and 
therefore derives from lymphocytes. Lymphocytes have been shown to contain different sized 
expansions compared to neural tissue from the same patient, with the shortest expansions 
observed in cerebellum (van Blitterswijk et al., 2013b). Since neural tissue is usually only 
available to test post mortem, it is unclear whether there may be a change in size in C9orf72 
expansions over time, and that this may be involved in the triggering of the disease in middle-
age. Such an age-dependent effect has been observed for myotonic dystrophy type I 
(Radvansky and Kadasi, 2010). When interpreting results from Southern blotting, the large 
size range of expanded material makes detection more challenging, and makes it particularly 
difficult to correlate repeat size to clinical variables such as age at onset, disease severity and 
progression because the size range within each patient is mosaic. Some have observed a 
positive correlation between the median repeat number, and the range of the repeat sizes, 
which suggests that the repeat becomes increasingly unstable with increasing size. This can be 
observed even for normal alleles, as there appears to be more stutter peaks present in larger 
alleles (26 and 20) compared to shorter alleles (7 and 13) (Figure 3.10a-c).  
I have calibrated the flanking PCR assay using a variety of methods. As the original flanking 
PCR produced very short products in normal controls, direct Sanger sequencing of the 
products was not possible. To confirm the specificity of the products, I performed a nested 
PCR with the repeat containing primer used in in RP-PCR, which revealed a saw-tooth pattern 
with ~6 bp periodicity, as would be expected from the region (Figure 3.5). This suggested that 
the PCR was specific and also helped to confirm the relative sizing of alleles. A second 
flanking PCR had to be performed to allow sequencing and confirm the repeat number in a 
normal control sample. Upon redesigning the assay, direct sequencing of the PCR products 
allowed confirmation that the reaction was specific and allowed calibration between fragment 
size and repeat number. Furthermore, a number of previously tested DNA samples were re-
tested and had their repeat numbers confirmed with the new assay. Unless sequenced though, 
the repeat number from flanking PCR is an estimate based on the presence of normal sequence 
surrounding the GGGGCC locus. Genomic variability adjacent to the repeat may affect the 
apparent repeat number based on size, as was observed in case study 2, who was apparently 
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homozygous for 7 repeats, but actually had one 7 repeat allele and one 5 repeat with a 12bp 
insertion. 
The RP-PCR assays that I have developed appear to be higher yielding and produce a ladder 
of fragments corresponding with over 100 repeats, which is longer than has previously been 
published (DeJesus-Hernandez et al., 2011; Renton et al., 2011). Importantly, our 3’ RP-PCR 
assay has been shown to be robust even in the presence of a number of genomic variations 
next to the HRE. During the optimisation of the 3’RP PCR, conditions were observed which 
resulted in a failure of the shorter normal allele to amplify. These difficulties were exploited 
to allow sequencing of the expanded allele to be carried out, without the complicating factor 
of heterozygosity in data analysis. We detected a relatively higher degree of variation than has 
been reported in studies based on Southern UK populations, and detected six HRE cases with 
a 10 base pair deletion which has also been proposed to be common in a Northern England 
cohort (Rollinson et al., 2015). 
The admixture experiments which were carried out, where expansions can still be detected 
even when diluted to 1% in a normal background, suggest that these assays are not severely 
affected by preferential amplification, and the conditions seem to be optimal for PCR of longer 
fragments, and particularly of the expanded allele over the normal one.  
However, I have observed that in the 3’RP-PCR, normal alleles of greater than 15 repeats can 
lead to a PCR artefact with low level expanded material being observed. This presumed 
primer-product interaction, leading to replication slippage can only be reduced by measures 
which also drastically reduce the production of expanded material in HRE positive cases. 
Thus, this may be a limitation for product length for C9orf72 RP-PCR, as the 5’RP does not 
generate as large products and does not suffer from this artefact. The prevalence of false 
positive results in the recent blinded quality assurance style study (Akimoto et al., 2014) 
suggests that laboratories should be aware of such test limitations. Clearly elimination of false 
positive results would be desirable, however reduction of cycle number, reduction in 
polymerase quantity, alteration of primer concentrations and altering the repeat binding primer 
phase, all failed to solve this artefact. Another group have recently reported that they can 
overcome the problem by using a flanking primer slightly further from the repeat expansion 




3.3.2 C9orf72 repeat expansions in the Scottish ALS 
population 
I used the PCR methods described to screen a cohort of 528 Scottish ALS patients (1989-2014) 
for the HRE. Overall, this revealed that 9.5% of patients had a C9orf72 HRE, which is in line 
with what has been observed in other UK ALS cohorts (8.1%) (Beck et al., 2013). It appears 
that the number of C9orf72 HRE carriers in the MND registry with a positive family history 
is relatively low, but this may reflect that these are historical samples, and it is unlikely that 
given the knowledge at the time, that patients were questioned with regards to a more extensive 
family history to include dementia, for example, as the links between ALS and FTLD were 
not known.  
For clinical diagnostic testing, it is important to be aware of the common repeat sizes within 
the population as this can guide testing. Suspicion arises when a patient is apparently 
homozygous for a rare repeat size, particularly if these are in the 15-30 range which could 
hamper PCR amplification (Rollinson et al., 2015). In our experience, sequencing of the 
flanking PCR products in apparently homozygous cases can also reveal normal alleles with 
genomic variability, which has also been reported by others (Akimoto et al., 2014). For the 
sample from the MND Registry which was apparently a 15 repeat homozygote, it was 
unfortunate that there was insufficient DNA for further testing. Sequencing of the flanking 
PCR products, or trying alternative primers at the 5’ end may have allowed a result to be 
obtained more confidently, before Southern blotting would have been required to elucidate a 
result.  
3.3.3 Future directions 
The advances in PCR based detection of C9orf72 expansions allow accurate sizing of alleles 
although it is still unclear how large the expansions that can be detected in blood are. It was 
observed that some C9orf72 expansion positive blood samples did appear to give a large smear 
after flanking PCR, when ran on an agarose gel but this was not consistent across samples, and 
relatively difficult to distinguish from background. One way to determine whether these 
smears are from amplification of mosaic expanded material would be to carry out a Southern 
blot of PCR products. However, current PCR methods may be unable to assess the exact size 
of the largest repeat expansions which are reported to be up to 4 400 repeats, and so these 
would not be detected (Beck et al., 2013). Traditional Southern blotting is therefore required 
for studies to determine whether there is a genotype-phenotype correlation involving repeat 
size (Hubers et al., 2014). It may also be of interest and value to perform large scale studies to 
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determine the stability of repeat size in individuals, over time, in different tissues (van 
Blitterswijk et al., 2013b). 
Sanger sequencing is of limited use in determining repeat number, as it only works on alleles 
up to 20 repeats in size. Current next generation sequencing technologies also perform poorly 
on long repetitive DNA tract, precluding their use (Lyons et al., 2015). The latest sequencing 
technologies, such as single molecule real time sequencing may be capable of estimating 
C9orf72 repeat size in future (Loomis et al., 2013), but these are not readily available 
technologies and may not be capable of sequencing 100% GC rich fragments from large 
expansions.  
Several studies have also suggested that methylation status of the repeat can also influence the 
clinical phenotype, and this has not been assessed here. There has been some suggestion that 
higher levels of methylation are correlated with a shorter disease duration (Xi et al., 2014; Xi 
et al., 2015b; Xi et al., 2013), however it is not clear whether this association can be detected 
reliably in blood, and further work would be required before this could be used as a prognostic 
marker for disease progression, for example.  
3.4 Conclusion 
I strongly recommend carrying out all three PCR assays, which I have designed and optimised, 
in a clinical diagnostic setting. Results between the assays should be concordant before 
reporting, with the exception of rare cases which are affected by the 3’RP PCR artefact (where 
a large normal allele is detected on flanking PCR). There may be rare cases (1/528 in this 
study), where reflex testing with Southern blotting may be necessary, to distinguish between 
cases which are homozygous normal, and where an expansion is only apparent in one 
direction. In the particular case which gave an equivocal result in this study, it should be noted 
that further PCR based testing may have enabled a clear result to be obtained, but efforts were 
hampered by insufficient DNA.  
Both RP-PCR assays should be used together to minimise the risk of any rare genomic 
variability, including single nucleotide polymorphisms under primer binding sites, from 
affecting the test accuracy. This is in line with recommendations for other repeat expansion 
disorders, such as Myotonic Dystrophy type 1, where rare cases have been reported which 
have interspersed repeats at one end (Kamsteeg et al., 2012). Although this hasn’t been 
specifically documented in any C9orf72 expansion positive cases to date, there was a 
suggestion that this may explain a sample which gave a discrete banding pattern, rather than a 
typical smear, following Southern blotting with a repeat containing probe (Beck et al., 2013).  
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In conclusion, the PCR assays which I have developed are robust and allow detection of larger 
repeat expansions than previous published methods. The ability to accurately detect and size 
short repeat expansions (60-120 repeats) from blood samples may help to define the lower 
pathogenic range of C9orf72 HREs. Southern blotting for C9orf72 HRE in a diagnostic setting 
provides information on the size of large expansions, although as discussed previously the 
expansions are usually heterogeneous and mosaic in nature making it challenging to correlate 

















Chapter 4. Derivation of oligodendrocytes from 
patient derived induced pluripotent stem cells 
with C9orf72 hexanucleotide expansions 
4.1 Introduction 
The capacity to produce differentiated cells from patient derived hiPSCs allows the study of 
cell autonomous factors in disease. For neurodegenerative disorders, such as ALS, hiPSC 
technology is particularly useful as the cells of interest cannot be easily studied in vivo during 
disease progression, and pathological studies tend to be focussed around end-stage disease. 
The technology also allows the contribution of non-neuronal cells to the degenerative process 
to be investigated. Loss of gray matter spinal oligodendrocytes has been observed in a SOD1 
mouse model, and selective ablation of the mutation in oligodendrocytes was found to delay 
the onset of disease and enhance survival (Kang et al., 2013). Therefore, studying 
oligodendrocytes in the context of ALS is of interest. To generate oligodendrocytes from 
hiPSCs, knowledge of their in vivo development has been used to guide in vitro differentiation 
protocols based on the recapitulation of this process. Generating hiPSCs from patients with 
disease-causing mutations, and directing their differentiation to a cell type of interest is a 
widely recognised approach. The power of this has been demonstrated for C9orf72 HREs in 
the context of motor neurons (Donnelly et al., 2013; Sareen et al., 2013). A major limitation 
of this technique is the differing genetic backgrounds of carriers and controls ((Bock et al., 
2011; Rouhani et al., 2014). To overcome this problem, CRISPR/Cas-9 technology can be 
used to generate isogenic controls through the specific removal of the (GGGGCC)n expansion 
from hiPSCs. 
4.1.1 Generation of human oligodendrocytes from hiPSCs 
The first differentiation protocols to generate OPCs and oligodendrocytes from pluripotent 
cells were developed for rodents, and these were subsequently adapted for human systems (Li 
et al., 2009). The earliest published protocols for human cells take several months to produce 
oligodendrocytes from ES cells, compared to weeks for mouse cells (Hu et al., 2009a; Izrael 
et al., 2007; Kang et al., 2007; Nistor et al., 2005; Stacpoole et al., 2013). The application of 
such differentiation protocols to hiPSCs gave a low yield of cells (less than 0.01% O4 positive) 
and few cells went on to express mature markers such as MBP (Ogawa et al., 2011; Pouya et 
al., 2011). Most of the oligodendrocyte differentiation protocols which had been published 
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prior to the beginning of this study were only optimised for ES cells and their success when 
starting from hiPSC was not clear (Alsanie et al., 2013). 
4.1.2 Signalling for oligodendrocyte conversion 
Most differentiation protocols which have been developed for spinal oligodendrocytes rely on 
recapitulation of the events that occur during embryonic development. Within the blastocyst, 
the inner cell mass forms the three germ layers (ectoderm, mesoderm and endoderm) during 
gastrulation. The dorsal portion of ectoderm is specified to neuroectoderm by inhibition of 
activin and BMP signalling and activation of Wnt and FGF signalling. The neural tube then 
forms and the early specification of spinal cord derived oligodendrocytes occurs in the ventral 
ventricular zone of the neural tube, and is related to patterning of the rostral-caudal and dorsal-
ventral axes by morphogenic gradients of Shh and BMP (Emery and Lu, 2015; Richardson et 
al., 2000). Patterning along the rostral-caudal axis of the neural tube occurs via an RA gradient 
which helps form a boundary between spinal cord and hindbrain (Davis-Dusenbery et al., 
2014).  
Following caudalization, anterior-posterior patterning occurs through a gradient of Shh, which 
is secreted from the floor plate and notochord leading to ventral patterning. Opposing BMP 
and Wnt signalling from the roof plate results in the formation of the dorsal neural tube, and 
is inhibitory to formation of the oligodendrocyte lineage (He and Lu, 2013). The Shh gradient 
leads to the formation of six distinct progenitor domains along the dorsal-ventral axis, which 
are defined by their expression of specific transcription factors (Briscoe et al., 2000). The 
oligodendrocyte lineage mainly arises from the ventral pMN domain, after motor neurons have 
been produced from neural precursors which express the transcription factor Olig2 (Jacob and 
Briscoe, 2003; Richardson et al., 2000). Olig2 initially promotes the formation of motor 
neurons through binding to neurogenin-1 and neurogenin-2 (Zhou et al., 2001). It is then 
dephosphorylated at Ser147 which results in a switch to promote oligodendrocyte fate via 
preferential binding to different partner transcription factors (Li et al., 2011). Cells which co-
express Olig2 and Nkx2.2 develop into OPCs, and Olig2 is a consistent marker for the ventral 
oligodendrocyte lineage (Li et al., 2011; Ribes and Briscoe, 2009).  
Once OPCs have formed they begin to migrate throughout the CNS, with Olig2 expression 
continuing, along with Sox10 and Nkx2.2 (Liu et al., 2007; Zhou et al., 2001). These 
transcription factors promote PDGFR-α expression (Finzsch et al., 2008), which enhances 
survival and proliferation of OPCs via the binding of its ligand PDGF (Barres et al., 1993; 
Calver et al., 1998). PDGFR-α expression is characteristic of OPCs (Pringle et al., 1992) and 
125 
 
these cells have either bipolar morphology, or a few short branches (Jakovcevski and Zecevic, 
2005b) 
The differentiation of OPCs to oligodendrocytes requires that OPCs exit the cell cycle in a 
highly regulated manner such that myelination occurs at the correct time and whilst ensuring 
there is a remaining pool of OPCs (Emery and Lu, 2015). The Notch, BMP and Wnt signalling 
pathways inhibit OPC production and differentiation during development, and there are 
prodifferentiation factors which act to antagonize these inhibitory effects allowing 
differentiation to occur (Emery and Lu, 2015). The differentiation of OPCs to 
oligodendrocytes is characterised by the sequential expression of different immunomarkers, 
including the O4 sulfatide which is a late OPC-early oligodendrocyte marker (Jakovcevski and 
Zecevic, 2005b; Schachner et al., 1981) and then MBP which is expressed by pre-myelinating 
oligodendrocytes (Jakovcevski et al., 2009). As they differentiate, oligodendrocytes undergo 
morphology changes and extend elaborate process to contact axons, most of which are 
subsequently retracted after axons are ensheathed (Emery and Lu, 2015). Myelination begins 
in the final trimester and continues over several decades (Back et al., 2001; Jakovcevski et al., 
2007).  
4.1.3 Protocol for oligodendrocyte generation  
Our lab has developed a protocol for generating differentiated oligodendrocytes from hiPSCs 
(Livesey et al., 2016). This protocol first involves neuralizing hiPSCs by dual-SMAD 
inhibition (Chambers et al., 2009). This method (Phase I) causes differentiation by blocking 
two signaling pathways utilized by SMADs: BMP and transforming growth factor β (TGF-β). 
SB431542 is an inhibitor of the Lefty/Activin/TGFβ pathways, and reduces Nanog expression 
in pluripotent cells, leading to a loss of pluripotency (Chambers et al., 2009). The original 
protocol has been adapted, such that Noggin has been replaced with LDN193189, a 
dorsomorphin derivative which blocks BMP signalling. Overall,  dual-SMAD inhibition 
results in rapid and high (>80%) conversion to neural cell fates by preventing the development 
of trophoectoderm, mesendoderm and endoderm (Chambers et al., 2009). 
The resulting neuroectoderm cells can then be patterned to become many types of neural cells. 
To generate spinal oligodendrocytes, we first produce ventral spinal cord progenitors. This is 
carried out by adding RA as a caudalising signal (Phase II), followed by the addition of the 
Shh agonist purmorphamine, as a ventralizing signal (Phase III) (Hu et al., 2009a; Li et al., 
2008). Fibroblast growth factor (FGF), which has an inhibitory effect on BMP signalling, is 
required for the self-renewal of human NPCs, and thus its removal during the next stage (Phase 
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III minus FGF) promotes the differentiation of NPCs (Gorris et al., 2015), which then undergo 
further specification to generate oligodendrocytes (Figure 4.1). 
 
Figure 4.1. Schematic of protocol used to generate oligodendrocytes from 
hiPSCs 
hiPSCs are lifted (day 0) to generate spheres which are neuralised by feeding for 7 days 
in Phase I medium. Neurospheres are then patterned in Phase II (7 days), where 
exposure to RA gives a caudal identity. At the end of Phase II, spheres are plated down 
for 2-3 days, before neural cells are selected. These are lifted to generate spheres which 
are then fed Phase III medium, containing RA and the Shh agonist Purmorphamine to 
promote a ventral cell identity. Further differentiation then occurs when the cells are 
exposed to Phase III-FGF medium for a further two weeks, generating spinal cord neural 
precursor cells (scNPCs). Spheres are then transferred into Oligo Pro medium, which 
promotes glial cell specification. After two weeks, spheres can be dissociated with Papain 
and plated down in Oligo Diff media. Withdrawal of PDGF-AA, FGF2 and SAG promote 
differentiation of oligodendrocytes, with the presence of insulin-transferrin and selenium 
(ITS), T3 and IGF-1 promoting survival and maturation. Spheres in Oligo Pro can be 
maintained for up to two months by chopping every few weeks. Experimental time points 
are indicated with the *, at week 1 and week 3 post plate down. MACS was carried out at 
week 3 to enrich for O4 positive cells for biochemical experiments. 
 
To generate OPCs from NPCs in vitro,  FGF and PDGF-AA are used in our protocol (Alsanie 
et al., 2013). PDGF-AA is thought to play a role in the timing of oligodendrocyte 
differentiation via the promotion of OPC differentiation (Hu et al., 2008). It is an essential 
mitogen for OPC proliferation (Calver et al., 1998).  Fibroblast growth factor 2 (FGF2) may 
promote the proliferation of OPCs by the upregulation of Olig2 and PDGFRα (Naruse et al., 
2006), and so these are added to Oligo Pro medium to accelerate OPC proliferation via the 
activation of multiple kinases (He and Lu, 2013). Insulin Growth Factor 1 (IGF-1) and 
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Triiodothyronine (T3) are also thought to support the development of OPCs (Hu et al., 2009a; 
Sundberg et al., 2011; Sundberg et al., 2010). IGF-1 has been shown to support the 
development and maturation of OPCs in rodents (Barres et al., 1993; Carson et al., 1993), and 
may act partially by inhibiting BMP signalling (Hsieh et al., 2004). The addition of Shh 
agonists has been reported by others to increase OPC numbers (Sundberg et al., 2011), and 
previous work in our lab had shown that a combination of purmorphamine and Smoothened 
agonist (SAG) increased the yield of oligodendrocytes.  
When OPCs are dissociated using Papain and plated down, the substrate upon which they are 
cultured is important to cell proliferation, survival and differentiation (Alsanie et al., 2013). In 
this protocol we used a combination of poly-L-ornithine, laminin, matrigel and fibronectin. 
All of these components have been shown to promote these processes when tested on rat 
derived OPCs (Hu et al., 2009b). After plate down, mitogens are removed from the medium 
as FGF and PDGF-AA inhibit the maturation of these cells into oligodendrocytes (Bansal and 
Pfeiffer, 1997). The addition of IGF-1 and insulin promotes the survival of oligodendrocytes 
in vitro (Barres et al., 1993). T3 is thought to be important for the survival and proliferation of 
OPCs and may also promote differentiation to oligodendrocytes (Sundberg et al., 2010). 
The in vitro differentiation process can be followed using immunocytochemistry for selected 
cell surface markers such as PDGFRα, O4 and MBP, which represent increasing stages of 
differentiation (Figure 1.7; for more details see Materials and Methods). Oligodendrocyte 
precursor cells express PDGFRα, immature oligodendrocytes are positive for O4, while MBP 
is expressed by mature oligodendrocytes (Barateiro and Fernandes, 2014). Where required the 
differentiating oligodendrocytes can be purified using magnetic activated cell sorting (MACS) 
with the O4 marker.  
4.1.4 Objectives 
The aim of this chapter was to produce oligodendrocytes from hiPSC lines derived from 
patients with C9orf72-related ALS and controls, including an isogenic control which has been 
generated using CRISPR/Cas9 mediated gene editing. The presence or absence of the repeat 
expansion was verified in patient derived cells and controls respectively. The generation of 
oligodendrocyte lineage cells from each of the cell lines was compared using quantitative 
immunocytochemistry for OPC and oligodendrocyte specific markers. The presence of 
astrocytes and neurons were also quantified in each of the cell lines.  
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4.2 Results  
4.2.1 Maintenance of the C9orf72 hexanucleotide expansion in vitro 
To confirm the genotype of both carrier and control lines, flanking PCR and RP-PCR were 
used (Fig 4.2 a-e). These assays were used regularly to ensure that the cell lines were of the 
expected genotype. Interestingly, one of the samples from Carrier 2 hiPSCs showed the 
presence of an approximately 88 ± 2 repeat allele (Fig 4.2b). This was lower in intensity than 
was detected in blood samples with repeats of this size, suggesting that it represented 
mosaicism within the sample. However, there was no evidence of this shorter repeat allele at 
later passages of the same line (which was confirmed to be the same cell line by fingerprint 
analysis, data not shown), it is likely that cells with the shorter repeat were lost in culture. I 
tested DNA from cells at different stages of conversion from hiPSCs to oligodendrocytes and 
found no evidence of shorter repeat alleles at any of the stages tested (Fig 4.2e). In light of the 
reported presence of genomic instability in the 3’ region of the repeat expansion, I sequenced 
this in both carrier lines, and showed that while Carrier 1 matched the reference sequence, 
Carrier 2 had the common 10 base pair deletion (Fig 4.2f). It is currently unclear whether this 
difference has any impact on pathology, as only one study has made suggested a link between 
the 10 bp deletion and reduced risk of psychosis (Snowden et al., 2016). 
 




Figure 4.2 Genotyping results from hiPSC lines 
(a) C9orf72 flanking PCR for control 2 hiPSC showing two normal alleles with 2 and 8 
repeats. (b) C9orf72 flanking PCR for carrier 2 hiPSC showing an allele with 88 ± 2 
repeats. (c) 5’ RP-PCR result for Control 2 hiPSC showing no ladder and confirming the 
negative flanking PCR result. (d) 5’ RP-PCR result for carrier 2 hiPSC showing a ladder 
extending into the affected size range (> 30 repeats) indicating the C9orf72 
hexanucleotide repeat expansion. (e) Agarose gel electrophoresis of flanking PCR 
products from cells at the following stages of conversion for carrier 2: Lane 1. iPSC. 2. 
Phases III-FGF 3. Oligodendrocyte precursor cells. 4. Differentiated oligodendrocytes. 5. 
No DNA control (Note that no positive controls are shown but these samples were tested 
alongside those in Figure 3.9f). (f) Sanger sequencing results of the region 3’ to the repeat 
expansion in both carrier lines compared to reference sequence (NG_031977.1), showing 
the common 10 base pair deletion which is present in Carrier 2. 
4.2.3 Creation of an isogenic control line  
CRISPR/Cas-9 technology was used to specifically remove the (GGGGCC)n expansion from 
Carrier 2 iPS cells, and create an isogenic control line, which is referred to as Carrier 2 
∆(GGGGCC)n. This work was performed by Dr Bhuvaneish Selvaraj, and I contributed to the 
PCR screening for the cell lines. Two CRISPR guide (g) RNAs were designed (gRNA-1 and 
gRNA-2) which targeted each side of the GGGGCC repeat in intron 1 of the C9orf72 gene. 
Without a repair template, the double strand breaks introduced by Cas9 will re-ligate via non-
homologous end joining, so that the (GGGGCC)n repeats are removed. The gRNAs were 
initially tested in HEK-293 cells which contain three GGGGCC repeat units in the C9orf72 
locus, by transfection of gRNAs and Cas9 plasmid. PCR based screening was performed, 
which showed the presence of a truncated product following transfection, compared to wild-
type cells (data not shown). This suggested that the system and gRNAs was functioning as 
expected. Therefore, hiPSC from Carrier 2, which contained one allele with two repeats, and 
an expanded allele with around 750 repeats, were then nucleofected with Cas9 and the gRNAs. 
Flanking PCR results show the presence of the normal allele only (Fig 4.3a) as the larger allele 
is too large to amplify. Screening 164 individual single-cell-derived clones using flanking PCR 
identified 22 clones in which there was a truncated PCR product compared to that from Carrier 
2 hiPSCs. Testing these with 5’RP-PCR revealed that the expansion was still present in these 
clones (data not shown), and thus it appeared that the normal allele containing two GGGGCC 
repeats had been targeted for correction. Fortunately, there was one clone which had two 
truncated PCR products following flanking PCR, which suggested that both alleles had been 
targeted (Fig 4.3b). This was confirmed by 5’RP-PCR, which shows the presence of an 
expansion in the unedited iPSC (Fig 4.4 c) and the subsequent loss after editing (Fig 4.3d). 
This result was confirmed by Southern blotting and Sanger sequencing (Selvaraj, submitted). 
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The hiPSC cells were shown to be karyotypically normal and retained the pluripotency 
markers OCT3/4, TRA-1-60 and NANOG. (Selvaraj, submitted).  
 
Figure 4.3 Genotyping results for creation of isogenic line 
Capillary electrophoresis traces for flanking PCR products from (a) Carrier 2 (b) 
Carrier 2 after gene editing to remove (GGGGCC)n expansion. Capillary 
electrophoresis traces for 5’RP-PCR products from (a) Carrier 2 showing presence of 
expansion (b) Carrier 2 after gene editing to remove the (GGGGCC)n expansion in 
C9orf72. 
 
4.2.4 Derivation of OPCs and oligodendrocytes from neural precursor 
cells 
It has been reported that different hiPSC lines may have variable differentiation capabilities 
(Boulting et al., 2011), and therefore I wanted to characterise each of the control and C9orf72 
expansion carrying lines to determine if they produced equivalent numbers of differentiated 
cells.  
Quantitative immunocytochemistry was carried out 7 days after plate down of OPC spheres 
and mitogen withdrawal (Oligo Diff). Representative images and graphical representations of 
quantification are shown in Figure 4.4. This analysis revealed that the cultures contained a 
majority of Olig2 positive cells (Control 1, 74.5 ± SE 4.3%; Control 2, 61.9 ± SE 3.8%; Carrier 
1, 66.4 ± SE 8.9%; Carrier 2, 56.7 ± SE 3.6%; Carrier 2 ∆(GGGGCC)n, 52.1 ± SE 2.5%). 
There was no overall difference in Olig2 positive cells present in carrier and control cell lines 
(p=0.83, Mann-Whitney test). Oligodendrocyte precursor cells, identified by expression of 
PDGFR-α, were present at this time point (Control 1, 19.7 ± SE 2.5%; Control 2, 12.4 ± SE 
1.2%; Carrier 1, 11.7 ± SE 1.3%; Carrier 2, 13.4 ± SE 1.1%; Carrier 2 ∆(GGGGCC)n, 15.5 ± 
SE 0.7%). Overall, there is no difference between the percentage of cells which are PDGFRα 
positive between carrier and control cell lines (p=0.45, Mann-Whitney test). The cultures also 
contained O4 positive oligodendrocytes (Control 1, 2.4 ± SE 0.5%; Control 2, 3.0 ± SE 0.5%; 
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Carrier 1, 4.4 ± SE 0.6%; Carrier 2, 3.9 ± SE 0.7%; Carrier 2 ∆(GGGGCC)n, 2.0 ± SE 0.2%). 
Comparing carrier to control, there was no difference in the percentage of O4 positive cells 
generated by the cell lines (p=0.37, Mann-Whitney test). 
 
Figure 4.4 Immunocytochemical staining and quantification of 





Figure 4.4 Immunocytochemical staining and quantification of oligodendrocyte 
lineage markers 
(a) Immunocytochemical staining of the ventral transcription factor Olig2 (b) 
Immunocytochemical staining of the OPC marker PDGFR-α (c) Immunocytochemical 
staining of the oligodendrocyte markers O4 and MBP. Scale bar = 50µm. (d) Graph 
showing quantification of Olig2 (Control 1/Control 2/Carrier 1/Carrier 2/Carrier 
2/Carrier 2 ∆(GGGGCC)n: n=5/7/6/6/7), PDGFR-α (Control 1/Control 2/Carrier 
1/Carrier 2/Carrier 2 ∆(GGGGCC)n: n=6/13/10/16/15) and O4 (Control 1/Control 
2/Carrier 1/Carrier 2/Carrier 2 ∆(GGGGCC)n: n=5/8/10/9/8) positive cells after 7 days 
in Oligo Diff medium by immunocytochemistry.  
 
FACS analysis performed after three weeks of culture in Oligo Diff media showed a higher 
proportion of O4+ cells (Control 1, 76.4 ± SE 3.5%; Control 2, 54.6 ± SE 13.9%; Carrier 1, 
56.2 ± SE 9.4%; Carrier 2, 53.3 ± SE 7.9%; Carrier 2 ∆(GGGGCC)n, 34.9 ± SE 3.7%) as 
shown in Figure 4.5. Comparison of carrier with control cells revealed no difference overall 
between the cell lines (p=0.72, Mann-Whitney test). However, direct comparison between 
carrier 2 and the isogenic control line suggests there may be a trend towards a higher number 
of O4 positive cells in carrier 2 (p=0.066, Mann-Whitney test). For biochemical studies, this 
time point was selected and to further enrich for O4 positive cells, MAC sorting using O4 






Figure 4.5 Quantification of O4 positive cells at week 3 by FACS 
Graph displaying the percentage of O4 positive cells after three weeks in Oligo Diff 
medium by FACS analysis (Control 1/Control 2/Carrier 1/Carrier 2/Carrier 2 
∆(GGGGCC)n: n=3/4/6/3/5).  
 
To investigate the maturation of the oligodendrocyte lineage cells, I quantified the overlap of 
the PDGFR-α and O4, and O4 and MBP positive cells. There was a high level of co-expression 
between the O4 marker and MBP (Control 1, 92.5 ± SE 2.1%; Control 2, 87.9 ± SE 3.0%; 
Carrier 1, 84.0 ± SE 5.6%; Carrier 2, 73.6 ± SE 6.7%; Carrier 2 ∆(GGGGCC)n: 83.5 ± SE 
3.9%) as shown in Figure 4.6. Overall there was no difference between carrier and control 
lines in this respect (p=0.60, Mann-Whitney test). There was a lower overlap between O4 and 
PDGFR-α (Control 1, 7.4 ± SE 2.4%; Control 2, 8.0 ± SE 1.6%; Carrier 1, 9.1 ± SE 2.9%; 
Carrier 2, 9.2 ± SE 1.4%; Carrier 2 ∆(GGGGCC)n: 16.5 ± SE 3.9%) as shown in Figure 4.6. 





Figure 4.6 Overlap of O4 marker with PDGFRa and MBP 
Representative images of immunocytochemistry showing (a) lack of overlap of 
PDGFR-α positive and O4 positive cells (b) substantial overlap between O4 and MBP 
markers. Scale bar = 50µm (c) Mean percentage of O4 positive cells which express 
PDGFR-α (Control 1/Control 2/Carrier 1/Carrier 2/ Carrier 2 ∆(GGGGCC)n: 
n=3/5/4/5/5) and MBP (Control 1/Control 2/Carrier 1/Carrier 2/ Carrier 2 
∆(GGGGCC)n: n=6/8/8/8/5). Cellular specification was equivalent across the five cell 
lines. 
 
4.2.5 Presence of other cell types 
At week 1 post-plate down, quantitative immunostaining was also performed for the astrocyte 
marker glial fibrillary acidic protein (GFAP) and neuronal marker β-III-tubulin as shown in 
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Figure 4.7. GFAP positive cells were found to be present in the cultures (Control 2, 24.7± SE 
3.7%; Carrier 1, 25.2 ± SE 3%; Carrier 2, 20.0 ± SE 3.2%; Carrier 2 ∆(GGGGCC)n, 14.9 ± SE 
1.4%), with no overall difference between carrier and control cell lines (p=0.14, Mann-
Whitney test. There was also a low level of β-III-tubulin positive cells in the cultures (Control 
2, 5.4± SE 1.1%; Carrier 1, 6.3 ± SE 0.9%; Carrier 2, 9.3 ± SE 2.0%; Carrier 2 ∆(GGGGCC)n, 
8.8 ± SE 2.7%), which was equivalent between carrier and control lines (p=0.72, Mann-
Whitney test).                         
 
Figure 4.7 Immunocytochemical staining of GFAP and β-III tubulin positive cells 
and quantification 
 (a) Representative images of GFAP and β-III tubulin positive cells present. Scale bar 
= 50µm. (b) Graphs showing quantification of GFAP (Control 2/Carrier 1/Carrier 2/ 
Carrier 2 ∆(GGGGCC)n: n=7/8/8/8) and β-III tubulin (Control 2/Carrier 1/Carrier 2/ 
Carrier 2 ∆(GGGGCC)n: n=4/6/8/8) positive cells after 7 days in Oligo Diff medium. 
 
 4.2.6 Maturation of C9orf72 HRE oligodendrocytes from hiPSCs 
Electrophysiological recordings were made from PDGFR-α positive and O4 positive cells 
from both carrier and control cells to compare their maturation. This work was carried out by 
Dr Matt Livesey and Dr Owain James. In O4 positive cells at week 3, the percentage 
depression of rectification indices were measured (Control 1, 11.97 ± SE 3.8; Control 2, 12.4 
± SE 2.5; Carrier 1, 9 ± SE 3.6; Carrier 2, 16.3 ± SE 3.7) and found to be equivalent between 
control and carrier (p>0.27, unpaired t-test). At week 3 post plate-down, O4 positive cells 
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showed a strong functional downregulation of delayed-outwardly rectifying potassium 
channel and A-type potassium channel conductance, which was equivalent between control 
and carrier lines  (Livesey et al., 2016). There was also no difference in whole cell capacitance 
and input resistance between control and carrier cells (Livesey et al., 2016). AMPA receptor 
unitary conductances reduce upon maturation from OPC to oligodendrocyte, and again there 
was no difference in the reduction between carrier and control cell lines (Livesey et al., 2016). 
4.3 Discussion 
In this chapter, I have shown that the C9orf72 HRE was present in the carrier hiPSC lines, and 
was maintained in culture. There were no differences observed in the differentiation and 
maturation of oligodendrocytes containing C9orf72 HREs, compared to controls from studies 
on cellular specification. 
4.3.1 Validation of hiPSC lines 
All four cell lines used in this study generated hiPSCs which expressed pluripotency markers 
NANOG, SOX2, TRA-1-60 and OCT3/4 (see Materials and methods). They were shown to 
be capable of generating all three germ layers, demonstrating that the cells were indeed 
pluripotent, regardless of whether they were reprogrammed using retrovirus or Sendai virus. 
Ideally, the cell lines would be matched in terms of sex and the age at which fibroblasts were 
obtained. In this respect, control 1 and carrier 1 are well matched, as are control 2 and carrier 
2, although the latter differ in their reprogramming method.  
Karyotyping was performed and showed the presence of normal karyotypes, with the 
exception of one of the control lines (Control 1), which developed an abnormality in culture 
(47, XYY). For this reason, some of the later characterisation was not completed on this line 
as it was subsequently excluded from the study. Similarly, Control 2 developed trisomy 12 in 
culture and some data was therefore excluded from later analysis, reducing the number of 
conversions which it was possible to analyse. The development of karyotypic abnormalities 
have been well described in iPSC cultures, with one study showing 12.5% of hiPSC cultures 
showing some abnormality (Taapken et al., 2011). Karyotypic abnormalities include changes 
in chromosomal number and structure and copy number variations such as 
insertions/duplications, deletions and loss of heterozygosity due to acquired uniparental 
disomy (Martins-Taylor and Xu, 2012).  
Rates of aneuploidy increase with increasing passages, although they can occur at both early 
and late passages, so it is important that they are checked regularly (Taapken et al., 2011). The 
hiPSCs were also regularly tested for mycoplasma, and treated when required. This was 
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important as the presence of mycoplasma can have a substantial effect on gene expression and 
cellular behaviour, as well as influencing the differentiation capacity of pluripotent cells 
(Markoullis et al., 2009; Miller et al., 2003). 
4.3.2 Presence of the C9orf72 HRE 
The presence of a C9orf72 hexanucleotide repeat expansion in each of the two carrier cell lines 
was demonstrated using repeat-primed PCR. The control lines gave a negative result using this 
assay. Flanking PCR revealed that the size of the expansion changed during iPSC culture, with 
carrier 2 showing a repeat length of around 88 repeats, although there also appeared to be 
mosaicism for larger repeat expansions, which were exclusively present during other passages. 
This observation highlights the importance of checking the repeat size regularly and 
demonstrates the utility of the HPE assays, as this would not have been detected on the original 
PCR assays. Such instability is not unexpected and reveals the importance of having a reliable 
sizing assay and for strict quality control measures during culture. Studies on repeat stability 
in other repeat expansion disorders including myotonic dystrophy type 1 and Fragile X 
syndrome have shown high levels of instability in hES cells, with a tendency towards 
increasing size with passaging, however differentiation appears to be associated with a 
stabilization of repeat size (De Temmerman et al., 2008; Eiges et al., 2007; Seriola et al., 2011). 
It has been shown that skin-derived fibroblasts with C9orf72 expansions have a lower number 
of repeats than in blood from the same patients, which may reflect a selective advantage for 
cells in culture with shorter expansions (van Blitterswijk et al., 2013b). Cell lines were checked 
at the iPSC stage or during differentiation for each derivation of cells used in this study, and 
consistently showed the presence of at least 100 repeats at the C9orf72 HRE locus. The 
technique used did not allow assessment of the actual size of expansion present. 
4.3.3 Creation of isogenic control 
The creation of the isogenic control for Carrier 2 was a significant advance in reducing the 
background variation between control and carrier lines. This allows for increased confidence 
that any differences between control and carrier lines are due to the presence of the C9orf72 
HRE, and not simply due to background genetic differences between the lines. The generation 
of the isogenic line was an inefficient process, and this may have been related to design of the 
guide RNAs, which did not take into account the presence of a 10 bp deletion adjacent to the 
HRE, as this was only detected following the creation of the isogenic control. Ideally, of 
course, it would be desirable to have isogenic controls available for each of the carrier cell 
lines that are used, and this work is ongoing in the laboratory. The other cell lines have the 
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expected sequence adjacent to the HRE and therefore the efficiency of deletion of the HRE 
may be higher than for the line used in this study.  
It is worth noting, that even with the use of an isogenic control, there may still be differences 
which emerge through epigenetic changes which are specific to one or other of the cell lines, 
which may be related to passage number. The stringent checks on karyotypes and mycoplasma 
presence are still required to minimise the risk of differences emerging due to some other 
factor than the C9orf72 HRE. 
4.3.4 Differentiation of hiPSC to oligodendrocytes 
The protocol for generating OPCs and oligodendrocytes has been shown to be reproducible 
and consistent across the five hiPSC lines tested. There were no significant differences 
between the control and C9orf72 hexanucleotide expansion cell lines in their generation of 
oligodendrocyte lineage cells, as shown by the quantification of Olig2, PDGFR-α, O4 and 
MBP positive cells. There appeared to be more variation in the percentage of Olig2 positive 
cells and this may reflect more variable staining and subjective counting of positive cells with 
this nuclear marker. However, there is no trend apparent between control and carrier lines.  
When performing quantitative immunocytochemistry, I cultured the cells on glass coverslips, 
and this protocol appeared to produce a relatively low yield of O4 positive cells, however there 
appeared to be a greater percentage of O4 positive cells when the cells were cultured on plastic 
(Livesey et al., 2016). There were differences apparent in the cell adhesion to these different 
surfaces, with each requiring different fibronectin concentrations which may further contribute 
to the differences observed in the number of O4 positive cells. For much of the later analysis 
that I have performed (RNA-FISH, Sholl analysis and TDP-43/p62 staining), microscopy 
constraints required that the cells were cultured on glass, hence why I chose to quantify the 
cells under the same conditions.  
There was no apparent difference between the proportions of O4 cells which also display 
PDGFR-α or MBP between the lines. This gives a crude measure of the cell maturation pattern. 
The expected expression pattern would be that PDGFR-α positive cells differentiate to O4 
positive cells, before finally expressing MBP. The overlap between O4 and MBP is 
approximately 90%, and given the absence of cells solely expressing MBP, suggests that these 
cells are not yet terminally differentiated in the cultures as the levels of O4 sulfatide decrease 
during differentiation (Schachner et al., 1981). The similar levels of overlap seen for each of 
the cell lines suggests that there is not a gross differentiation abnormality present in the 
C9orf72 expansion carrying oligodendrocytes, although further work with regards to cell 
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proliferation and survival would be needed to investigate this more fully. The proliferation 
rates of control and carrier OPCs were investigated by Dr. Navneet Vasistha, using ethynyl 
deoxy-uridine (EdU) and Ki67, and these assays showed no consistent differences (Livesey et 
al., 2016). 
As well as showing consistent generation of oligodendrocyte lineage cells, the percentage of 
GFAP and βIII-tubulin positive cells were also similar between control and carrier cell lines. 
Other oligodendrocyte generating protocols have reported higher levels of GFAP positive cells 
from hiPSC lines, up to 40-50% of total cells, and suggest that these can arise from OPCs 
(Wang et al., 2013). Earlier studies on ES derived oligodendrocytes showed less than 5% 
neurons and astrocytes were present (Kang et al., 2007). 
For assays which were based on population studies rather than looking at individual cells, this 
cellular composition was particularly important, which was why MACS was used to enrich 
for O4 positive cells prior to these assays. For biochemical studies, the cells were cultured on 
plastic as this appeared to generate a much greater yield of O4 positive cells as described 
previously. MACS was then performed, which generated cell pellets with up to 90% O4 
positive cells for other cell lines (Magnani, personal communication).  
4.3.5 Maturation of C9orf72 HRE oligodendrocytes from hiPSCs 
During differentiation and maturation of OPCs to oligodendrocytes, the excitable membrane 
properties of the cells have been shown to change significantly in rodent systems. The 
maturation of oligodendrocytes from OPCs using the protocol described, has suggested that 
the electrophysiological changes which occur during this transition are conserved between 
rodents and humans (Livesey et al., 2016). Using an array of electrophysiological, 
immunocytochemical and biochemical approaches, these properties have been investigated in 
our hiPSC derived OPCs and oligodendrocytes. We found that as human oligodendrocytes 
develop and express more mature markers, there is a progressive decline in voltage-gated 
sodium and potassium channel activity, and a loss of tetrodotoxin-sensitive spiking activity 
(Livesey et al., 2016). At the same time, there is an increase in inwardly rectifying potassium 
channel activity and a change in the AMPA receptor composition (Livesey et al., 2016). These 
changes are observed equivalently in both control and C9orf72 HRE carrier oligodendrocytes 
(Livesey et al., 2016). In this study, we have only investigated the process of oligodendrocyte 
development and therefore cannot exclude changes that occur in the context of myelination, 




In this chapter, I have described the protocol which has been used to generate oligodendrocytes 
from hiPSCS. I have used this protocol to derive oligodendrocytes which carry the C9orf72 
HRE as well as controls. I have shown that the C9orf72 HRE has been maintained during cell 
culture, and described how an isogenic control was generated. Studies on cellular specification 
has shown that the cell lines with and without the C9orf72 HRE behaved in a similar manner 




















Chapter 5. Investigating pathological features of 
oligodendrocytes from patient derived induced 
pluripotent stem cells with C9orf72 
hexanucleotide expansions 
5.1 Introduction 
The involvement of oligodendrocytes in the pathogenesis of ALS has been investigated mainly 
through studies on SOD1 mutant rodents (Kang et al., 2013; Lee et al., 2012; Philips et al., 
2013). In SOD1G93A mice, oligodendrocyte progenitor cells in the spinal cord proliferate 
rapidly but fail to differentiate and mature effectively, which leads to progressive 
demyelination, before the onset of disease symptoms (Kang et al., 2013; Lee et al., 2012). In 
ALS patients, reactive changes in oligodendrocytes in the motor cortex have been reported, 
along with demyelination in the spinal cord and motor cortex in both sporadic and familial 
cases (Kang et al., 2013; Lee et al., 2012). Elegant studies whereby the SOD1G93A mutation 
has been selectively ablated from the oligodendrocyte lineage in mice resulted in delayed onset 
of disease and increased survival (Kang et al., 2013). Such experiments have highlighted the 
importance of non-cell autonomous mechanisms in ALS pathogenesis, but in a complex in 
vivo model it is very difficult to tease apart the individual cellular roles contributing to motor 
neuron degeneration. In vitro cellular models give a unique opportunity to study cells without 
the complexity of the in vivo environment. The effect of the commonest ALS causing genetic 
mutation, C9orf72 HRE, on oligodendrocytes is an area which has not been thoroughly 
investigated. The presence of RNA foci has been reported in oligodendrocytes from the frontal 
cortex of C9orf72 related frontotemporal dementia cases at post-mortem (Mizielinska et al., 
2013). One recent publication has used a similar methodology to that described in this thesis 
to investigate the influence of various ALS associated mutations in oligodendrocytes, on wild-
type motor neurons (Ferraiuolo et al., 2016).    
5.1.1 Pathological features of C9orf72 HRE 
There are three main proposed mechanisms by which the C9orf72 HRE results in pathology 
(see section 1.3.4). These are loss of function by reduced gene expression, or gain of function 
by either RNA toxicity or formation of dipeptide repeat protein production by RAN translation 
(Ling et al., 2013). Although these mechanisms have been investigated by others in the context 
of motor neurons, it is of interest to determine whether there is evidence for any of the 
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associated pathological signs in other cell types which could contribute to disease 
pathogenesis.  
5.1.2 Oligodendrocyte pathology in ALS 
Oligodendrocytes from patients with ALS have been found to contain p62 and TDP-43 
intracytoplasmic inclusions (Mackenzie et al., 2011; Neumann et al., 2006; Seilhean et al., 
2009). Post-mortem spinal cord and motor cortex samples from ALS patients show reduced 
myelin compared to unaffected controls (Kang et al., 2013). The rat SOD1G93A ALS model 
displays altered myelin composition, which is reported to occur even in pre-symptomatic 
stages of the disease, although it is not clear whether this is a secondary effect to axonal 
dysfunction (Niebroj-Dobosz et al., 2007). In the SOD1G93A mouse ALS model, 
oligodendrocytes have an altered morphology, even before symptoms appear (Philips et al., 
2013). In this model, oligodendrocytes have an increased turnover, with more cells dying and 
an apparent compensatory increase in oligodendrocyte precursor cell proliferation and 
differentiation (Kang et al., 2013; Philips et al., 2013). The resulting cells are dysfunctional in 
terms of myelination and trophic support, as indicated by reduced myelin basic protein (MBP) 
and monocarboxylate transporter (MCT1) expression respectively (Kang et al., 2013; Philips 
et al., 2013). The loss of MCT1 from oligodendrocytes is thought to contribute to 
neurodegeneration (Lee et al., 2012).  
5.1.3 Objectives 
The aims of this chapter were to investigate the pathological features in hiPSC derived 
oligodendrocytes related to the C9orf72 expansion, including C9orf72 mRNA levels, presence 
of RNA foci and DPR. Furthermore, I wanted to investigate whether there were any 
morphology differences apparent in C9orf72 HRE hiPSC derived oligodendrocytes. I also 
wanted to determine whether the C9orf72 HRE influence the mRNA levels of MBP and 
MCT1, whether there was evidence of TDP-43 mislocalisation or p62 accumulation and 
whether there was a susceptibility of these cells to endoplasmic reticulum (ER) stress.  
5.2 Results 
5.2.1 C9orf72 mRNA expression levels in O4+ cells 
To check whether there was evidence for a loss of function of C9orf72 in oligodendrocytes, I 
carried out qRT-PCR experiments to investigate mRNA levels in control versus carrier cells. 
I investigated the expression of the three mRNA isoforms of C9orf72 (Fig 5.1a) on cells which 
had been cultured for 3 weeks in Oligo Differentiation medium, and then MACS sorted for 
O4. The most abundant transcript was found to be variant 2, followed by variant 3 and then 
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variant 1 (data not shown). The relative fold change (all data normalised to the geometric mean 
of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and β-actin, and calculated relative 
to one sample from control 2 using the ∆∆Ct method) was calculated for variant 1 (Control 1, 
3.9 ± SE 1.4; Control 2, 5.4 ± SE 1.5; Carrier 1, 4.6 ± SE 1.0; Carrier 2, 4.6 ± SE 1.2, Carrier 
2 ∆(GGGGCC)n: 2.2 ± SE 0.3, N=5, Fig 5.1b), variant 2 (Control 1, 3.2 ± SE 0.8; Control 2, 
2.1 ± SE 0.6; Carrier 1, 1.1 ± SE 0.1; Carrier 2, 1.8 ± SE 0.7, Carrier 2 ∆(GGGGCC)n: 1.6 ± 
SE 0.4, N=5, Fig 5.1b) and variant 3 (Control 1, 2.5 ± SE 0.9; Control 2, 4.2 ± SE 1.6; Carrier 
1, 4.1 ± SE 0.8; Carrier 2, 8.3 ± SE 2.3, Carrier 2 ∆(GGGGCC)n: 3.7 ± SE 0.5,  N=5, Fig 5.1b). 
No consistent reduction was observed in C9orf72 mutant oligodendrocytes compared to 
controls. The effects were variant specific with no difference for variant 1 (p=0.28, Mann-
Whitney test), while for variant 2, there was a trend for lower expression in carriers than 
controls (p=0.06, Mann-Whitney test). For variant 3, the trend was reversed with higher 
expression in carriers than controls (p=0.07, Mann-Whitney test). The observed variability 
may be due to the low expression levels of all C9orf72 transcripts in oligodendrocytes, which 
make it challenging to interpret as the assays are at the limit of sensitivity of qPCR. 
Comparison of expression levels to cortical neurons (n=1) suggested that levels in O4+ cells 
were lower (relative fold expression with respect to hiPSC derived control cortical neurons: 
V1, 41.7%; V2, 11%; V3, 3.9%) which is consistent with reports in the literature of low 













             
 
Figure 5.1 Transcript levels of C9orf72 in oligodendrocytes 
a. Schematic of the three transcript variants generated from the C9orf72 gene (top): 
variant 1 (V1: NM_145005.5), variant 2 (V2: NM_01835.4) and variant 3 (V3: 
NM_001256054.1). The UTRs are represented by the pink boxes, coding exons by 
white boxes and the location of the hexanucleotide repeat expansion is represented 
by the red circle. Adapted (Rohrer et al., 2015). b. qRT-PCR analysis of the three 
C9orf72 transcripts on mRNA extracted from cell pellets (N=5 for each cell line) 
obtained after three weeks of differentiation and MACS sorting for O4. Data were 
analysed by normalising to GAPDH and β-actin and comparing to a control using the 
∆∆Ct method.  
 
5.2.2 Presence of RNA foci 
To check whether RNA foci were present in C9orf72 HRE hiPSC derived oligodendrocytes, I 
optimised a previously published RNA fluorescence in situ hybridization (FISH) protocol by 
increasing the hybridisation temperature and used this to show the presence of sense RNA foci 
in oligodendrocyte lineage cells derived from hiPSCs (Almeida et al., 2013). I initially 
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optimized the RNA-FISH protocol on two hiPSC lines carrying C9orf72 repeat expansions 
and one control. As shown in Figure 5.2, the presence of nuclear, and occasional cytoplasmic, 
(GGGGCC)n foci were observed in the expansion containing lines, but not in controls. 
Treatment with RNase A prior to probe hybridisation prevented detection of any foci, 
suggesting that the foci contain RNA. Hybridisation with a control probe targeting an unrelated 
CCTG repeat (probe (CAGG)6 showed no RNA foci containing such a repeat, supporting the 
specificity of the (CCCCGG)4 probe. 
 
Figure 5.2 RNA-FISH validation with controls and carriers 
RNA FISH with a (CCCCGG)4 probe on control cells reveals that no GGGGCC foci 
(red) are observed, whereas these are present in both hiPSC derived cell lines from 
a patient carrying the C9orf72 hexanucleotide repeat expansion. These foci are 
mainly nuclear, and occasionally cytoplasmic. Treatment with RNase A prior to 
performing RNA-FISH results in loss of GGGGCC foci (red) which suggests that the 
observed signal is from an RNA containing structure. RNA FISH with a (CAGG)6 probe 
(red) does not result in detection of foci, as would be expected. All counterstained with 
Hoescht. Scale bar 10µm. 
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Following the optimisation of the RNA-FISH technique for sense RNA foci, I then combined 
it with immunocytochemistry to determine if foci were present in different cell types derived 
from C9orf72 hexanucleotide repeat expansion hiPSCs. Sense RNA foci were detected in 
PDGFR-α (Figure 5.3a) positive cells, O4 positive cells (Figure 5.4a), and cells labelled with 
MBP and GFAP (Figure 5.5).  
It was clear that not all cells contained sense RNA foci, and therefore I quantified the number 
of cells which contained foci. Using RNA-FISH, I observed that hiPSC-derived PDGFR-α 
positive cells contain nuclear sense RNA foci one week post plate-down (Control 2, 1.8 ± SE 
1.5%; Carrier 1, 20.5 ± SE 9.4%; Carrier 2, 27.1 ± SE 5.8%, N=3, Fig 5.3b). There were 
significantly more foci in carriers compared to controls (p=0.02, Student’s unpaired t-test). 
Although it was expected that there would not be any RNA foci present in controls, there was 
very occasional cells in which a single foci were detected, which is likely to represent very 

















Figure 5.3 hiPSC derived PDGFR-α positive oligodendrocyte precursor cells 
with C9orf72 HRE exhibit nuclear GGGGCCexp RNA foci while controls do not.  
(a) RNA-FISH with (CCCCGG)4 probe in control and carrier cell lines, with staining of 
O4 positive cells in upper panel. Dashed box indicates area which is shown in lower 
panel. Scale bar upper panel 30µm; lower panel 10 µm. All counterstained with 
Hoescht. (b) Graph of quantification of PDGFRα positive cells which have nuclear 







Quantification of RNA foci in hiPSC derived O4 positive cells was performed at weeks 1 and 
3 post plate-down. (Control 2 week 1, 0.5 ± SE 0.5%, N=6; Control 2 week 3, 1.2 ± SE 0.7%, 
N=4; Carrier 1 week 1, 38.6 ± SE 3.8%, N=6; Carrier 1 week 3, 42.2 ± SE 5.2%, N=6; Carrier 
2 week 1, 49 ± SE 7.1%, N=6; Carrier 2 week 3, 61.0 ± SE 3.8%, Carrier 2 ∆(GGGGCC)n 
week 1: 0 ± SE 0%, Carrier 2 ∆(GGGGCC)n week 3: 0 ± SE 0%, Fig 5.4b). There was a 
significantly higher number of cells with RNA foci in carriers than controls (week 1: 
p=0.0034; week 3: p=0.0008, Mann-Whitney test). To investigate whether there was a change 
in the number of foci containing cells over time, I compared matched batches of cells which 
were quantified at weeks 1 and 3 (Figure 5.4c). There was not a significant difference between 
RNA foci at weeks 1 and 3 (Carrier 1 (N=3), p=0.0669; Carrier 2 (N=3), p=0.2117, Student’s 
paired t-test), although there is a trend for Carrier 1 to show an increase in foci over time. In 
the O4 positive cells which contained nuclear foci, the average number of foci per cell was 3.7 
for Carrier 1 and 5.6 for Carrier 2, with the mode being 1 RNA foci for both cell lines. It was 
not possible to compare OPCs and oligodendrocytes directly because the combined 
immunostaining had to be done differently for each of the markers. In particular, PDGFRα 
staining was poor unless the ethanol incubation step was omitted, however, this 
permeabilization step increased the number of RNA foci detected by 57 ± SD 13% when no 
staining was performed (N=2) and therefore the number of PDGRFα positive cells which 
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Figure 5.4 hiPSC derived O4-positive oligodendrocytes with C9orf72 HRE 




Figure 5.4 hiPSC derived O4-positive oligodendrocytes with C9orf72 HRE 
exhibit nuclear GGGGCCexp RNA foci.  
 (a) RNA-FISH with (CCCCGG)4 probe (red) in control and carrier cell lines, with 
staining of O4 positive cells (green) in upper panel. Dashed box indicates area which 
is shown magnified in lower panel. Scale bar upper panel 30µm; lower panel 10 µm. 
All counterstained with Hoescht. (b) Graph of quantification of PDGFRα positive cells 
which have nuclear sense RNA foci at week 1 post plate-down (N=3). (c) Graph of 
quantification of O4+ cells which have nuclear sense RNA foci at both week 1 and 




Figure 5.5 hiPSC derived GFAP-positive astrocytes and MBP-positive 
oligodendrocytes with C9orf72 HRE exhibit nuclear GGGGCCexp RNA foci.  
(a) RNA-FISH with (CCCCGG)4 probe (red) in control and carrier cell lines, with 
staining of GFAP positive cells (green) in left hand panel. (b) RNA-FISH with 
(CCCCGG)4 probe (red) in control and carrier cell lines, with staining of MBP positive 
cells (green) in left hand panel.   Scale bar panel 20µm. All counterstained with 
Hoescht.  
 
I went on to perform Sholl analysis on O4 positive cells, to investigate whether there was a 
morphology difference between cells which contain RNA foci or not. There does not appear 
to be any consistent differences between the number of branches observed in cells which 
contain foci compared to those which do not. This suggests that the RNA foci are not 




Figure 5.6 Sholl analysis on O4 positive cells with and without RNA foci 
(a) Sholl analysis performed on O4 positive cells at 1 week post-plate down, stratified 
for presence of absence of sense RNA foci. Carrier 1 (Foci, n=95 cells; no foci, n=149 
cells), Carrier 2 (Foci, n=106 cells; no foci, n=108 cells). (b) Sholl analysis performed 
on O4 positive cells at 3 weeks post-plate down, stratified for presence of absence of 
sense RNA foci. Carrier 1 (Foci, n=112 cells; no foci, n=143 cells), Carrier 2 (Foci, 
n=66 cells; no foci, n=54 cells).  
 
5.2.3 Presence of DPR 
To investigate the presence of DPR in hiPSC derived C9orf72 expansion carrying 
oligodendrocytes reliable antibodies against these were required. To test whether the 
commercially available C9 RAN antibodies could detect DPR, I ectopically expressed each of 
the DPR in human embryonic kidney (HEK) cells by transfecting with a plasmid that encoded 
a specific DPR (GA, GP, GR, PA or PR), along with a V5 tag, and then tested the antibodies 
by immunocytochemistry. By comparing the expression pattern of the V5 tag, which acted as 
a positive control for the transfection, to that of the DPR antibody, the specificity of the 
C9RAN antibodies could be tested. Overlapping staining by antibodies against V5 and DPR 
were the desired result from a reliable antibody. Another PhD student within the laboratory 
tested the antibodies in parallel using Western blotting.  
 
The first commercial C9RAN antibody (Novus) revealed non-specific binding, predominantly 
in nuclei. There is also background present in the non-transfected negative control. However, 




Figure 5.7 Novus C9RAN antibody testing on transfected HEK cells 
HEK cells transfected with each of the DPR plasmids, followed by 
immunocytochemistry using the V5 tag and Novus C9RAN antibody. Counterstained 
with Hoescht. Scale bar 50µm. 
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The second antibody (Millipore) also gave non-specific background staining, but appeared to 
pick up poly-GA dipeptides in cells expressing these, and showed weak staining for poly-PR 
and poly-GP (Figure 5.8). 
 
Figure 5.8 Millipore C9RAN antibody testing on transfected HEK cells 
HEK cells transfected with each of the DPR plasmids, followed by 
immunocytochemistry using the V5 tag and Millipore C9RAN antibody. 
Counterstained with Hoescht. Scale bar 50µm. 
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Because both of these commercially available antibodies suggested that there were issues with 
background, non-specific staining, and to enable the detection of individual DPRs rather than 
several, Biogen Idec generated antibodies which were shared with us to try. Again, I used HEK 
cells transfected with each of the DPR plasmids to test these (Figure 5.9). Anti-GA antibody 
staining overlapped with GFP staining. Anti-GP appeared to stain appropriately but was not 
completely specific as there was some background staining. Anti-GR staining completely 
failed. Anti-PA antibody appeared to be both sensitive and specific, while anti-PR gave non-





Figure 5.9 Biogen C9RAN antibody testing on transfected HEK cells 
HEK cells transfected with each of the DPR plasmids, followed by 
immunocytochemistry using the V5 tag and specific Biogen antibody for that DPR. 







As the anti-PA antibody appeared in the previous experiments to bind specifically, I went on 
to test this further in post-mortem brain material. Material was kindly supplied from three 
C9orf72 HRE cases from Colin Smith’s laboratory (University of Edinburgh), who prepared 
the tissue and provided slices for staining. Control material was obtained from the Netherlands 
brain bank. This was stained using anti-PA, which did not provide conclusive evidence that 
inclusions were C9orf72 HRE specific, as there was some evidence of inclusion-like staining 
in controls as well as shown in Figure 5.10. 
 
 
Figure 5.10 Immunohistochemistry using Biogen anti-PA antibody 
Immunohistochemistry using Biogen anti-PA antibody on post-mortem material from 
three C9orf72 HRE carriers (upper panels: SD010/14, SD012/14 and SD016/14) and 
three control patients (2004 049, 2005 068, 2007 032). Scale bar 100µm. 
Counterstained with haematoxylin. 
Because of the difficulties in detecting DPR with the available antibodies, extracted protein 
from control and C9orf72 hiPSC derived oligodendrocytes was sent to Chris Shaw’s 
laboratory where Younbok Lee (King’s College, London) performed Western blots with anti-
GA, anti-GP and anti-PA antibodies (Figure 5.11). The anti-GA antibody showed a high 
degree of non-specific binding, and a protein of the correct size was detected in both control 
and C9orf72 HRE carriers. This suggests that the antibody is not specific to the DPR. The 
Western blot with anti-GP and anti-PA antibodies showed no GP or PA DPRs in any of the 





Figure 5.11 Western blots with anti-GA, anti-GP and anti-PA antibodies 
Western blots with DPR specific antibodies carried out by Younbok Lee (Kings 
College London) with anti-GA, anti GP and anti-PA antibodies, with GAPDH as a 
loading control. Samples 1, 2: Control 2; Samples 3, 4: Carrier 2; Samples 5, 6: Carrier 
1.  
5.2.4 TDP-43 and p62 pathology 
I investigated the mRNA expression levels of TDP-43 using in control and carrier O4 positive 
cells (Control 1, 0.64 ± SE 0.4; Control 2, 0.76 ± 0.3; Carrier 1, 0.53 ± SE 0.1; Carrier 2, 0.97 
± 0.3, Carrier 2 ∆(GGGGCC)n: 0.67 ± SE 0.2, N=5, Figure 5.12a).  These results reveal that 
there is no difference between the TDP-43 mRNA levels between carrier and control O4 
positive cells (p=0.749, Mann-Whitney test). Using immunocytochemistry at week 3 post 
plate-down, no TDP-43 mislocalisation was detected in any of the hiPSC derived O4 positive 
cells (N=3, >156 cells images per line, representative image Figure 5.12b).  
Inclusions containing p62 were detected in a small number of cells at week 3 post plate-down 
(Control 2, 0.6 ± SE 0.6%; Carrier 1, 2.4 ± SE 2.4%; Carrier 2, 1.1 ± SE 0.7%, N=3, >189 
cells per line, representative image Figure 5.12b). The presence of areas of punctate staining 
(such as in the lower right panel of Figure 5.12b) were taken as positive. As long as there were 
such areas on the slides, the staining was assumed to have been successful, as such staining 
was not observed in a secondary only control. 
Preliminary investigations by Western blotting were performed but as these were only 
performed on two independent cultures in one experiment, conclusions cannot be drawn from 
this data. The suggested trend is for the control to have higher levels of TDP-43 and p62, 






Figure 5.12 TDP-43 mRNA expression levels, TDP-43 and p62 






Figure 5.12 TDP-43 mRNA expression levels, TDP-43 and p62 
immunocytochemistry and Western blots 
(a) qRT-PCR results for TDP-43 mRNA expression from cell pellets (N=5 for each cell 
line) obtained after three weeks differentiation and MACS sorting for O4. Data were 
analysed by normalising to GAPDH and β-actin and comparing to a control using the 
∆∆Ct method.  (b) Representative images following immunocytochemistry for control 
and carrier cell lines showing nuclear TDP-43 localisation in O4 positive cells and a 
lack of p62 inclusions in O4 positive cells. Scale bar 30 µm. All counterstained with 
Hoescht. (c) Western blot image of TDP-43, p62 and GAPDH. (d) Preliminary 
quantification data for TDP-43 and p62 Western blots, normalised to GAPDH (N=2 
for each cell line).  
5.2.5 MBP and MCT1 mRNA expression levels 
Based on reports that MBP and MCT1 levels are reduced in ALS oligodendrocytes, I 
performed qRT-PCR on week 3 MACS sorted O4 positive cell pellets, to investigate mRNA 
expression levels. qRT-PCR was used to determine the relative expression levels of MBP in 
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C9orf72 HRE carrier O4 positive cells compared to controls (Control 1, 1.09 ± 0.24; Control 
2, 1.11 ± 0.33; Carrier 1, 0.53 ± 0.13; Carrier 2, 1.06 ± 0.30, Carrier 2 ∆(GGGGCC)n:  0.56 ± 
SE 0.3, N=5, Figure 5.13). There was no difference in MBP mRNA levels between carrier and 
control O4 positive controls, and inter-cell line variability is apparent (p=0.95, Mann-Whitney 
test). The MCT1 mRNA levels were compared between control and carrier O4 positive cells 
(Control 1, 1.31 ± 0.18; Control 2, 1.44 ± 0.25; Carrier 1, 1.01 ± 0.13; Carrier 2, 1.30 ± 0.39, 
Carrier 2 ∆(GGGGCC)n:  1.36 ± SE 0.4, N=5, Figure 5.13). This analysis revealed that there 
was no difference in MCT1 mRNA levels between carrier and control O4 positive cells, which 
were quite consistent across the cell lines (p=0.85, Mann-Whitney test). 
 
Figure 5.13 mRNA expression levels of MBP and MCT1 
Graphical representation of results from qRT-PCR analysis of MBP and MCT1 on 
mRNA extracted from cell pellets (N=5 for each cell line) obtained after three weeks 
differentiation and MACS sorting for O4. Data were analysed by normalising to 
GAPDH and β-actin and comparing to a control using the ∆∆Ct method. 
5.2.6 Baseline cell death and susceptibility to tunicamycin 
To investigate cell death in the cultures, FACS analysis was performed on cells which had 
been differentiated for three weeks. The baseline levels of O4 positive cells which stained for 
cleaved caspase-3, which is an apoptotic marker, were measured. The results showed that there 
were fairly consistent levels of caspase-3 activation in O4 positive cells from each of the cell 
lines (Control 1, 26.9 ± 4.4; Control 2, 27.1 ± 1.1; Carrier 1, 22.4 ± 3.9; Carrier 2, 30.9 ± 6.0, 
Carrier 2 ∆(GGGGCC)n: 29.8 ± SE 3.4, N=4/3/3/6/5, Figure 5.14a). Overall, there was no 
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difference observed between carrier and control cells in terms of their baseline levels of 
caspase-3 activation (p=0.66, Mann-Whitney test). 
Because oligodendrocytes are cells which produce a vast amount of protein, and given that ER 
stress has been implicated in ALS (Walker and Atkin, 2011), I decided to investigate the effect 
of tunicamycin on hiPSC derived oligodendrocytes. The number of caspase-3 activated O4 
positive cells which were present after exposure to tunicamycin for 24 hours were measured, 
and normalised to baseline, to give an indication of the percentage change in cell death. The 
results were quite variable between the cell lines, and also within, particularly in the case of 
carrier 2 (Control 1, 23.9 ± 13.9; Control 2, -0.5 ± 3.1; Carrier 1, 6.5 ± 2.3; Carrier 2, 40.5 ± 
17.7, Carrier 2 ∆(GGGGCC)n:  23.0 ± 11.1, N=4/3/3/6/5, Figure 5.14b). Overall, there was no 
difference between carrier and control lines in terms of their activation of caspase-3 in 
response to tunicamycin induced ER stress (p=0.93, Mann-Whitney test). 
 
Figure 5.14 GGGGCCexp carrying oligodendrocytes show no baseline survival 
phenotype (population) by FACS and response to ER stress 
(a) Graph of caspase-3 positive O4 positive cells in basal conditions, three weeks 
post-plate down, measured using FACS. (b) Graph of caspase-3 positive, O4 positive 
cells after 48 hours of tunicamycin treatment to induce ER stress, measured using 
FACS. 
5.3 Discussion 
5.3.1 Loss of function of C9orf72 
The low mRNA expression levels that were detected are consistent with observations that 
C9orf72 is not highly expressed in glia, which have come from a mouse model generated with 
a LacZ insertion targeted to the C9orf72 orthologue suggested that the gene was highly 
expressed in neuronal specific nuclear marker (NeuN) positive cells in the cortex and spinal 
cord, but not in activated microglia or GFAP positive cells (Suzuki et al., 2013). These low 
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levels make it difficult to quantify levels accurately as qRT-PCR is not sensitive enough when 
threshold cycle (Ct) values are greater than 30, as was the case for C9orf72 variants 1 and 3. 
For variant 2, which is the most highly expressed isoform, there were no consistent differences 
between controls and carriers. Comparison of control 1 and carrier 1 for this variant suggests 
that there is downregulation, but this is not the case for carrier 2 and the carrier 2 isogenic 
control so may be an effect related to genetic background. For variant 3, there appears to be 
an increase in expression in carrier 2 compared to controls. This has been observed in another 
study which suggested that there was a shift in transcription from variant 2 to variants 1 and 3 
(Sareen et al., 2013). The observed variability is likely to be partly due to low expression 
levels, but may also reflect intrinsic differences in the particular cell lines. Repeating these 
experiments using a more sensitive technique, such as droplet digital PCR or RNA-seq may 
help to elucidate whether there is indeed altered expression. Hypermethylation of the C9orf72 
promoter has been associated with reduced mRNA expression (Liu et al., 2014), and I have 
not investigated whether the C9orf72 HRE carrier lines tested differ in their methylation status. 
Another possibility is that the 10 base pair deletion at the 3’ end of the HRE detected in carrier 
2, or some cis-acting locus, has a differential impact on transcription.  
Although O4 positive cells were selected by MACS prior to these experiments, the enrichment 
may not reach 100%, and therefore other contaminating cell types may be present. However, 
previous data has shown that the proportions of different cell types are consistent between the 
cell lines tested using this protocol.  In the context of C9orf72, because it is expressed at a 
higher level in neurons than glia (Suzuki et al., 2013), contamination of the cell pellet by 
neurons could be a source of potential variability, although the low levels of neurons prior to 
MACS reduces this possibility. 
It would be of interest to determine whether there is reduced expression at the protein level, as 
even if there is no detectable difference in mRNA levels, the presence of the expansion in the 
transcript may affect its translation, particularly with regards to undergoing RAN translation. 
However, a lack of reliable commercial antibodies for C9orf72 at the time of this study, made 
this unfeasible (DeJesus-Hernandez et al., 2011). 
5.3.2 RNA foci detected in OPCs and oligodendrocytes  
The results obtained during optimisation of the RNA FISH protocol showed the presence of 
(GGGGCC)n sense RNA foci specifically in HRE carriers and not in controls. Treatment of 
cells with RNase A ablated the signal, suggesting that the foci detected are indeed RNA, rather 
than DNA. Using a control probe of equal length (CAGG)6 resulted in no signal, which 
supports the specificity of the (CCCCGG)4 probe for the C9orf72 HRE.  
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Combining the RNA-FISH protocol with immunostaining allowed identification of the cell 
types which contained RNA foci. RNA foci were detected in OPCs, oligodendrocytes (labelled 
with either O4 or MBP) and also astrocytes (labelled with GFAP). It proved challenging to 
combine RNA-FISH with staining for the OPC marker PDGFRα, as the inclusion of ethanol 
to permeabilise membranes prior to RNA-FISH appeared to prevent immunostaining of the 
marker. The addition of this permeabilization step nearly doubled the number of cells in which 
RNA foci were detected, and therefore it is not possible to comment on the number of foci 
detected between different cell types. To try and elucidate whether there was a change in the 
number of cells containing foci over time, I compared this at one and three weeks post-plate 
down. This did not show a significant difference although it is not possible, using this 
technique, to identify whether the number of foci may increase over time in individual cells.  
There has been one report following a post mortem study of the presence of sense RNA foci 
in approximately 10% of oligodendrocytes in the frontal cortex, whereas 37% of neurons 
displayed RNA foci using the same technique, which focused on C9orf72-related FTD 
(Mizielinska et al., 2013). In this study, I have detected RNA foci in approximately 40-50% 
of oligodendrocytes in vitro (indicated by O4 marker). This difference might be due to a higher 
sensitivity of the technique in our cell culture system compared to post-mortem tissue, where 
RNA may be degraded and the RNA-FISH technique is necessarily harsher, requiring 
extended heating times at 80°C. It may also reflect a difference in the oligodendrocyte marker 
used, with CAII used in the post-mortem study (Mizielinska et al., 2013). Another possible 
explanation could be the influence of disease stage on foci number. It may be that the hiPSC 
derived cells are representative of cells earlier in disease progression than end stage cells 
studied in post-mortem tissue.  Foci containing cells may have undergone cell death during 
disease progression, as studies in cells transfected with 38 or 74 GGGGCC repeats, which 
showed RNA foci, had increased caspase-3 activation (Lee et al., 2013). Other studies on 
hiPSC derived cells have thus far excluded oligodendrocytes. In studies of hiPSC derived 
neurons, approximately 20-50% of cells were found to contain sense RNA foci (Almeida et 
al., 2013; Donnelly et al., 2013; Sareen et al., 2013). Methodological differences could account 
for the variation in RNA foci detection as there are many factors which differ between studies. 
These include fixing and permeabilisation methods, the type of probe used (RNA, DNA, 
locked nucleic acid), type of probe label, hybridisation conditions including temperature and 
time, and imaging methods. The protocol I used was most similar to the that used in the study 
reporting the highest proportion of cells with RNA foci, with sense RNA detected in up to 
68% of hiPSCs (Almeida et al., 2013). 
164 
 
Because of the observation of altered oligodendrocyte morphology in the SOD1 mouse model 
(Kang et al., 2013), and because of the hypothesis that the presence of RNA foci in 
oligodendrocytes may result in sequestration of key RNA binding proteins, I undertook Sholl 
analysis to compare the morphology of O4 positive cells which contained foci versus those 
with no foci. There were no consistent differences in the number of branches that were detected 
in cells with or without RNA foci, suggesting that the presence of RNA foci do not alter 
cellular pathways which influence cellular branching. Further investigation could be carried 
out using imaging platforms such as the Image Express which may allow detection of subtle 
morphology differences between the oligodendrocytes from different cell lines. 
5.3.3 RAN translation 
My investigations into whether hiPSC derived oligodendrocytes from C9orf72 HRE carriers 
express DPRs proved challenging due to a lack of reliable antibodies against these species. 
Both commercial antibodies which I tried did not give reliable staining patterns when they 
were used on HEK cells which had been transfected with plasmids to overexpress specific 
DPRs. It is likely that due to the nature of DPR, they are difficult to raise antibodies to, and 
there may be interactions with other proteins which contain similar regions resulting in non-
specificity. Unfortunately, the antibodies that were obtained from Biogen Idec did not give 
specific staining either. Although the results for anti-PA were promising on transfected HEK 
cells, the staining patterns were similar in C9orf72 carrier and control post-mortem brain. 
Protein samples were sent to King’s College London for analysis with antibodies which were 
thought to be more reliable, and these results suggested that there were no GP or PA DPR 
present in the oligodendrocytes.  
Several studies on hiPSC derived neurons from C9orf72 patients have shown the presence of 
RNA foci, but the presence of DPR inclusions has not been reported, with only low level 
expression detectable (Almeida et al., 2013; Donnelly et al., 2013; Sareen et al., 2013). It may 
be that the formation of DPR inclusions is a slow process and there is insufficient time in these 
in vitro cell cultures for these to accumulate to an appreciable level (Edbauer and Haass, 2015).  
Therefore, using hiPSC derived oligodendrocytes may not be the best system for assessing 
whether DPR are present, and studies in post-mortem tissue are required specifically to 
investigate the presence of DPR inclusions in oligodendrocytes. This type of approach has 
proved challenging due to difficulties in immunostaining oligodendrocytes in formalin fixed 
tissue, meaning that early studies which suggested that these cells were affected by TDP-43 
relied on cell morphology. More recently, the use of the p25α oligodendrocyte specific 
antibody has allowed double-labelling to be carried out with pTDP-43 (Fatima et al., 2015). 
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Similar studies using p25α alongside DPR antibodies are required to determine if these are 
present in vivo. IHC studies on post-mortem have the disadvantage, however, of only assessing 
end-stage disease in the vast majority of cases, and it is possible that the cells expressing DPR 
may have already died, particularly if these are produced in the mid-stage of disease as has 
been suggested (Edbauer and Haass, 2015). 
It has been suggested that the occurrence of RNA foci and DPRs are mutually exclusive 
(Donnelly et al., 2013), however others have found an equal proportion of poly-GA in neurons 
which either contained RNA foci or did not, arguing against this model (Cooper-Knock et al., 
2014). Further studies showed that cerebellar Purkinje neurons and motor neurons, which have 
with higher levels of antisense foci, also have higher levels of antisense DPR. A correlation 
between higher levels of sense foci in cerebellar granular cells, and sense DPR products have 
also been observed (Cooper-Knock et al., 2015).  
5.3.4 TDP-43 mislocalisation and p62 accumulation 
I have performed qRT-PCR for TDP-43 on hiPSC derived oligodendrocytes selected by 
MACS for O4 and found that the mRNA expression levels are approximately the same for 
controls and C9orf72 HRE carriers. This result was expected given that TDP-43 is 
autoregulated and maintains a constant level of mRNA in cells (Ayala et al., 2011).  Western 
blot analysis also suggested that there was no increase in TDP-43 or p62 protein levels. There 
was insufficient insoluble protein to allow assessment of TDP-43 levels in this fraction, which 
is unfortunate and should be investigated in future work. Immunocytochemistry provide no 
evidence that C9orf72 carrying hiPSC derived oligodendrocytes display TDP-43 
mislocalisation or a significant increase in p62 inclusions compared to controls. Where 
available, hiPSC derived oligodendrocytes which contain pathogenic variants in TARDBP 
were used as a positive control for this technique. Although these cells were not always 
available to stain alongside the C9orf72 cells, the nuclear staining of TDP-43 indicates that 
the antibody staining has been successful. For p62, areas of punctate staining were taken as an 
indication that the staining had been successful, as a secondary only control was clear of 
staining. Preliminary results from quantitative Western blots suggest that there is no difference 
in levels of TDP-43 or p62 in the soluble protein fractions from C9orf72 HRE carriers and 
controls. However, this needs to be repeated to confirm in further plate downs, and importantly 
the insoluble fraction should also be investigated. The protein levels were too low in the 
insoluble fractions that I extracted and therefore more starting material needs to be used to 
generate this for future studies.  
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5.3.5 MBP and MCT1 mRNA expression levels 
I investigated the mRNA expression levels of MBP and MCT1 using qRT-PCR, and found 
that there was no difference for either of these transcripts in hiPSC derived oligodendrocytes 
containing the C9orf72 HRE compared to controls. No difference in MCT1 mRNA levels in 
C9orf72 HRE containing hiPSC derived oligodendrocytes was observed in another study, 
although the gene was downregulated in hiPSC derived oligodendrocytes with SOD1 
mutations (Ferraiuolo et al., 2016). 
Only one of the two studies reporting downregulation of MCT1 found this to be at the mRNA 
level (Lee et al., 2012). The other study suggested that the reduction in MCT1 occurred only 
at the protein level (Philips et al., 2013). Further work to investigate MCT1 levels at the protein 
level is therefore warranted, but none of the antibodies that were tried within our lab appeared 
to be reliable for Western blotting. Ideally, a functional assay for lactate transport to neurons 
would be beneficial to help elucidate whether the C9orf72 HRE causes any defects in this 
process. The recent publication on C9orf72 HRE carrier oligodendrocytes investigated lactate 
levels in conditioned media using a colorimetric assay, and found no lactate deficit in these 
cells (Ferraiuolo et al., 2016), although confirming these findings on hiPSC derived cells from 
more carrier lines would still be beneficial. 
5.3.6 Cell death and susceptibility to ER stress 
To investigate the baseline levels of apoptosis, I assessed the levels of caspase-3 activation in 
O4 positive cells by FACS, and found that they were similar between control and C9orf72 
HRE lines. This suggests that the C9orf72 HRE does not result in a survival difference in 
hiPSC derived oligodendrocytes. Ideally, this should be confirmed by longitudinal live cell 
imaging which permits individual cells to be followed over time (Bilican et al., 2012). It 
proved challenging to set up such a system for oligodendrocytes as expression of the mCherry 
protein was not well tolerated but this remains an area worthy of future work.  
When examining the response of hiPSC derived oligodendrocytes to ER stress, the effect of 
the C9orf72 HRE was not entirely clear. Carrier 2 showed a variable response, which I had 
hoped to clarify by repeating these experiments several more times, but this was not possible 
as the hiPSC cells developed karyotypic abnormalities in culture and so were unsuitable. These 
experiments need to be repeated, ideally on additional cell lines to clarify whether there is a 
response. It would also be useful to perform a dose response to tunicamycin on the carrier cell 
lines and also investigate levels of ER stress markers such as BIP, CHOP and spliced XBP1 




The aim of this chapter was to investigate C9orf72 related pathology in hiPSC derived 
oligodendrocytes. There was no difference found in mRNA levels in C9orf72 carrier versus 
control hiPSC derived oligodendrocyte, although it was noted that the expression levels were 
lower than in neuronal cultures. Sense RNA foci were detected in C9orf72 HRE carrier hiPSC 
derived oligodendrocytes, as well as astrocytes and OPCs. These were not associated with any 
altered morphology as detected by Sholl analysis. It proved challenging to establish whether 
there were DPR present in the cells, due to a lack of reliable antibodies and so this was 
inconclusive. There was no evidence of alteration in TDP-43 and p62 accumulation in the 
C9orf72 HRE hiPSC derived oligodendrocytes, athough further Western blotting would be 
required to confirm this as there were technical issues which prevented a fuller investigation. 
There was no evidence of reduced gene expression of MBP or MCT associated with the 
C9orf72 HRE. Finally, the baseline levels of cell death were similar between carrier and 
control hiPSC derived oligodendrocytes, and there was no clear difference observed in the 
















Chapter 6: General Discussion 
The main aim of this study was to determine the effect of the C9orf72 HRE on hiPSC derived 
oligodendrocytes, and to my knowledge this was the first study to examine this. A recent 
publication overlaps with some of my work (Ferraiuolo et al., 2016). An important aspect of 
this work was developing PCR based assays to detect the presence of the pathogenic 
expansion, which was required as a key quality control measure of the cell culture based work 
and in screening during the creation of an isogenic control line. The assays which I developed 
and optimised were used not only in this context, but also in screening an archival cohort of 
Scottish MND patients, and have also been implemented within a diagnostic setting for 
patients with MND and FTD. 
The effect of the C9orf72 HRE in oligodendrocytes was investigated by applying a protocol 
for oligodendrocyte differentiation to hiPSCs. My aim was to determine whether there was 
any difference in the production of glial and neuronal cell types using this protocol, between 
control and C9orf72 HRE containing cell lines. After establishing that these cell lines 
responded in an equivalent manner to the differentiation protocol, I went on to investigate 
whether the C9orf72 HRE hiPSC derived oligodendrocytes showed any pathological features 
associated with this variant. The proposed mechanisms by which the C9orf72 HRE results in 
disease include loss of function through haploinsufficiency, or gain of function by either RNA 
foci or dipeptide repeat proteins. Although I found that C9orf72 was expressed at low levels 
in hiPSC derived oligodendrocytes, there was no significant change in mRNA expression 
levels in carrier versus controls. I detected the presence of sense RNA foci in a proportion of 
hiPSC derived oligodendrocytes with the C9orf72 HRE, and showed that the presence of these 
was not associated with a change in branching pattern as assessed by Sholl analysis. I had 
difficulty detecting DPR, so cannot conclusively say whether these were present or not in the 
hiPSC derived oligodendrocytes. Furthermore, I went on to investigate whether any 
downstream changes which are associated with the C9orf72 HRE, including mislocalisation 
of pTDP-43 or accumulation of p62, were present. These preliminary results suggested that 
there was no change in the levels or localisation of these proteins between carrier and control 
hiPSC derived oligodendrocytes. Finally, the study concluded with an examination of cell 
death in basal conditions and in the presence of tunicamycin induced ER stress, which 
suggested that there was no difference in the basal cell death rates or response to ER stress in 




6.1 Genetic testing for C9orf72 
Our understanding of the genetic basis for ALS and FTD has improved dramatically over the 
last few years, particularly with the discovery of the C9orf72 HRE which is implicated in not 
only familial, but also apparently sporadic cases (DeJesus-Hernandez et al., 2011; Renton et 
al., 2011).  
The C9orf72 HRE, by its GC-rich and highly repetitive sequence, provides technical 
challenges for detection which have been highlighted in a large international study (Akimoto 
et al., 2014). Sequencing by Sanger methodology, or second generation sequencing 
technologies does not permit detection and therefore RP-PCR and/or Southern blotting is 
required. Although widely regarded as the ‘gold standard method’, Southern blotting for 
C9orf72 HREs which are heterogeneous in size due to somatic mosaicism is challenging: it 
requires large amounts of DNA and is slow and labour intensive (Beck et al., 2013; Nordin et 
al., 2015). The exact size of the repeat may be estimated from Southern blotting, but the 
clinical utility of this is debatable and certainly unclear at this stage (Beck et al., 2013; van 
Blitterswijk et al., 2013b). As PCR based methods can use 100-1000 times less DNA than 
Southern blotting, and are rapid and high-throughput, it is desirable to develop these to 
robustly detect the presence or absence of the HRE.  
There has been an increased demand from patients and clinicians for genetic testing for ALS 
and FTD. Although the results do not currently inform clinical treatment, owing to a lack of 
effective ALS treatments, they can help to speed up diagnosis, prevent other unnecessary 
investigations from being carried out and inform other family members of a potential increased 
risk of ALS and FTD. In addition, to accurately carry out investigations using hiPSC derived 
cells, it is important to genotype the cell lines periodically and ideally this should be carried 
out using as few cells, and therefore as little DNA, as possible to allow there to be sufficient 
material for other experiments. There were therefore a number of reasons why developing 
PCR-based methods to detect the C9orf72 HRE was important in this study.  
I developed three PCR based assays: a flanking PCR for sizing the repeat, and RP-PCR of 
both 3’ and 5’ directions from the repeat. The first set of conditions which were developed 
were later improved upon by the use of a different Taq polymerase and extensive optimisation 
of cycling conditions, using heat-pulse PCR are a starting point (Orpana et al., 2012).  
The flanking PCR in particular can be applied to DNA derived from cell cultures to check 
repeat sizes. A particular strength of the assay developed here was the detection of expansions 
of up to 900 repeats in cell line DNA. This makes the assay able to identify accurately whether 
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there has been shrinkage of the expansion in culture. This assay may prove useful to help 
determine the lower range of disease causing repeat sizes, and I showed that samples of even 
100 repeats in blood can be highly mosaic in nature, which has also been observed by others 
(Gijselinck et al., 2016; Nordin et al., 2015). The ability to visualise alleles in this range 
following fluorescent PCR and capillary electrophoresis should make this assay more sensitive 
for such HREs than Southern blotting. However, Southern blotting may still be required to 
establish whether there is a mosaicism for a larger repeat in such cases, as was detected in one 
sample in this study (Fratta et al., 2015).  
The observation of somatic mosaicism for C9orf72 HRE lengths highlights a possible 
challenge for genetic testing as a disparity could arise between the size of an expansion in 
lymphocytes, which are typically where DNA is obtained for testing, and the length in 
neuronal tissue (Nordin et al., 2015). A study on 38 paired blood and CNS tissues from 
sporadic ALS patients showed concordant results for the presence of an expansion between 
these tissues, and suggested that misdiagnosis is unlikely when results are based on 
lymphocyte derived DNA (Pamphlett et al., 2013). There does remain a possibility that 
differences in the exact size of the HRE could occur between these tissues, and this may be 
confounding efforts to link expansion size to phenotype. Another factor which remains to be 
intensively investigated for C9orf72 is whether the size of the HRE changes over a patient’s 
lifetime, as has been observed in myotonic dystrophy type 1 (Higham et al., 2012). 
It would be interesting to investigate whether there are any differences in the expansion size 
between neuronal and glial cells. Since neuronal cells are terminally differentiated and glial 
cells undergo more cell division throughout life, it is possible that glial cells have more 
potential for repeat size changes throughout life. A similar hypothesis has been postulated with 
regards to the smaller repeat size detected in the cerebellum compared to frontal cortex tissue 
and blood, which may be due to the abundance of non-dividing terminally differentiated cells 
in this region (van Blitterswijk et al., 2013b).  If neuronal and glial cells were to be separated 
following post-mortem, the relative size of the expansion could be compared, and it may be of 
interest to determine if there was a correlation with any clinical phenotypes. Somatic 
mosaicism for repeat sizes is also thought to arise during DNA repair processes, including 
mismatch repair (Gomes-Pereira et al., 2004), base excision repair (Kovtun et al., 2004) and 
nucleotide excision repair (Hubert et al., 2011). The particular pathways used depends on both 
the transcriptional activity of the locus and the expression level of particular repair proteins in 




The original RP-PCR assays which were published only allowed determination of whether 
alleles were up to around 30 repeats in length (DeJesus-Hernandez et al., 2011; Renton et al., 
2011). The first RP-PCR assays which I developed were similarly limited. The further work 
that I carried out to optimise the RP-PCR assays permitted amplification of up to 100 repeats 
in blood samples, which was an improvement on previously published methods. Given that 
the lower size range for pathogenic alleles has still not been well established, it is important to 
be able to extend the size range of detection. From a clinical diagnostic viewpoint, establishing 
that an expanded allele is greater than 100 repeats in size is important in view of a report of an 
unaffected individual who had 70 repeats on an allele which then expanded in his offspring 
who were affected (Xi et al., 2015a). Although conclusions cannot be drawn from one case, 
this highlights the importance of identifying such cases to aid understanding of how alleles of 
different sizes behave upon meiotic transmission. Short repeat expansions (45-78 repeats) have 
been found to co-segregate with disease in another two families studied (Gijselinck et al., 
2016). It is well established in other repeat expansion disorders such as Fragile X syndrome 
and Huntington’s disease that premutations, which are alleles not implicated in disease but are 
at risk of expansion into the affected size range, exist (Fu et al., 1991; Goldberg et al., 1993). 
There also tends to be a predominant sex through which expansions occur in these disorders 
(Rousseau et al., 1991). The emerging evidence with C9orf72 suggests that indeed such 
phenomena occur, and this is an area which requires further research and is highly important 
to genetic counselling. In time, and with increased genetic testing for the disorder, more family 
studies should emerge which will contribute to our knowledge of how C9orf72 HREs behave 
through meiosis. In the recent study which detailed the familial association of disease to alleles 
of as few as 50 repeats, there was some evidence of anticipation in a few of the families studied  
(Gijselinck et al., 2016). 
One key issue which had to be overcome with the RP-PCR assays was ensuring they were 
robust in the presence of genomic variability at the 3’ end of the repeat (Rollinson et al., 2015). 
By carefully selecting primers outwith the known variable region, I overcame these issues and 
developed a method which allowed Sanger sequencing to be performed across the repeat. This 
allowed identification of a range of indels which were present next to the repeat. It has been 
suggested that the presence of indels can affect the clinical phenotype, and further studies are 
required to investigate this (Snowden et al., 2016). There is some evidence that the presence 
of either 5 or 23 bp deletions are associated with decreased transcription levels (Gijselinck et 
al., 2016). Whether variation next to the repeat expansion affects its stability upon meiotic 
transmission is unknown but of interest. It is also possible that indels at the 3’ end of the HRE 
could affect the production of DPRs, for example leading to a predominance of a specific type, 
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which could lead to differing cellular toxicity profiles and consequent phenotype. Investigating 
a correlation between these sequence variants and clinical phenotypes could offer insight into 
why C9orf72 HRE lead to such a vastly variable phenotype. 
For genetic testing purposes, it is important that the RP-PCR methods are highly sensitive at 
picking up the expanded allele. Using a series of dilutions of C9orf72 positive carrier DNA in 
a normal DNA background, I showed that we could detect an expansion even at when only 
present at 1%. This shows that the mutation could be detected in a mosaic state, but is also 
something to be aware of in terms of the risk of contamination giving false positive results. 
This would be particularly important in the context of prenatal testing, which although unlikely 
to be requested in a late-onset condition in which the penetrance is not well established, should 
be taken into consideration. Appropriate, sensitive controls should be included in the event of 
such testing and it would be pertinent to back up results with analysis of linked markers given 
the sensitivity of the RP-PCR assay to contamination.  
The observation that false positive results can occur using 3’ RP-PCR in samples with normal 
alleles in the >15 repeat allele range is significant, and shows the importance of using several 
PCR based assays to ensure that results are accurate. This was something which, despite 
extensive efforts, was minimised but unfortunately not eliminated. It may be due to the 
products of incomplete amplification forming megaprimers, and annealing out of register to 
generate PCR products of different sizes (Hommelsheim et al., 2014). This PCR artefact has 
been noted by others, who suggest that the flanking primer needs to be moved by several 
nucleotides to eliminate this effect (Biasiotto et al., 2016). 
When investigating the frequency of the C9orf72 HRE in an archival collection of DNA 
samples from Scottish MND cases, which were a mixture of sporadic and familial cases, I 
found that it was detected in ~10% of cases. This corroborates with other studies from 
Northern European populations (Byrne et al., 2012; Majounie et al., 2012).  
In the future, genetic testing is likely to be used within the context of clinical trials for ALS 
and FTD to determine whether mutations in particular genes cause a differential response to 
new drug therapies (Picher-Martel et al., 2016). In a research context, imaging studies of 
unaffected individuals, who have undergone presymptomatic testing and carry a C9orf72 HRE 
could provide insight into early disease processes. My future work on genetic testing in ALS 
will focus on further investigating the genetic epidemiology of ALS in Scotland, by 
introducing test for a larger set of genes by next generation sequencing. This will allow 
genotype-phenotype correlations to be made between different genetic forms of ALS and may 
help inform future patients of their prognosis, based on their genetic findings. 
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6.2 Disease modelling in ALS with hiPSC derived cells 
Human iPSC derived cells have most commonly been used to investigate motor neurons in the 
context of ALS, with some additional studies on astrocytes (Almeida et al., 2013; Donnelly et 
al., 2013; Sareen et al., 2013; Serio et al., 2013). This was the first study to my knowledge 
using this technology to investigate ALS pathology in oligodendrocytes. hiPSC derived 
oligodendrocytes have been used by others to investigate demyelinating disorders and multiple 
sclerosis, showing the validity of this technique (Douvaras et al., 2014; Numasawa-Kuroiwa 
et al., 2014). A recent publication investigating hiPSC and iNPC derived oligodendrocytes 
from sporadic and genetic ALS (SOD1 D90A, FIG4 C27T, TARDBP G298S, and C9orf72 
HRE) has replicated many of the findings, particularly with regards to lactate metabolism, 
from the SOD1G93A mouse model and demonstrates the power of this methodology (Ferraiuolo 
et al., 2016). Interestingly their observations suggest that the disease mechanism in C9orf72 
HRE cases is distinct from SOD1 mutant and sporadic cases (Ferraiuolo et al., 2016). 
For disease modelling in ALS, a clear advantage of this approach is the physiological 
expression levels of C9orf72, as one of the significant disadvantages of animal models would 
be that the expression levels of a transgene may be significantly different from the true disease 
context (McGoldrick et al., 2013). Due to the GC-rich, complex secondary structures and large 
size of C9orf72 HRE, these are also difficult to handle experimentally and therefore hiPSC 
derived models allow the pathogenesis relating to the mutation to occur in its native state, 
without requiring cloning or other challenging manipulations. Although it is possible to obtain 
neural precursor cells at post-mortem for use in disease studies and drug screening, this is also 
technically demanding and the tissue is in short supply (Haidet-Phillips et al., 2011). These 
cells also represent end-stage disease and therefore are unlikely to be informative of early 
disease processes, which the hiPSC approach can potentially overcome (Meyer et al., 2014).  
6.2.1 Reprogramming methods 
The first step in disease modelling using hiPSCs is reprogramming of somatic cells to a 
pluripotent state, and this can be performed from a variety of starting cell types and 
methodologies. Both control cell lines and carrier 1 were reprogrammed from fibroblasts using 
a retroviral method, which involves the integration of the factors into the genome (Brock et 
al., 2012). This may result in random mutagenesis, which is a major reason why there has been 
significant developments in the field to develop integration free methods (Yu et al., 2009). 
Another issue that can arise with integrated methods is residual expression of reprogramming 
factors (Kang et al., 2015). Reprogramming with Sendai virus is a preferable method, as it is 
non-integrating, and was the method used for carrier 2 (Fusaki et al., 2009; Zhou and Freed, 
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2009). Ideally, all cell lines used would have been reprogrammed using the same method to 
make the lines as consistent as possible and, now that episomal-based methods have emerged, 
this would be the method of choice (Yu et al., 2009). Although carrier 2 was reprogrammed 
using a different method compared to the controls, an isogenic control was created for this 
line.   
6.2.2 Gender of cell line donors 
Another factor to consider when comparing cell lines is the gender of the donor. It has been 
shown that there is greater variation in transcriptional and DNA methylation between female 
cell lines than male ones which is thought to be due to sporadic reactivation of the inactive X 
chromosome (Mekhoubad et al., 2012; Tomoda et al., 2012). Because there are a large number 
of X-linked genes which function in the nervous system, a perturbation in dosage 
compensation could impact studies such as this one (Tomoda et al., 2012). For example, one 
known X-linked oligodendrocyte gene is proteolipid protein 1 (PLP1), mutations in which are 
associated with the leukodystrophy Pelizaeus-Merzbacher disease (Sistermans et al., 1998). In 
this study, control 1 and carrier 1 are male, whereas control 2 and carrier 2 are female, and 
hence pairwise comparisons are best between each of these.  
6.2.3 Isogenic controls 
Because of the previously mentioned factors, as well as variation intrinsic to cell lines, the use 
of isogenic controls which can be generated by gene editing technologies offer an advantage 
over generic controls. The generation of isogenic controls for more C9orf72 carrier hiPSC 
lines was ongoing while this project was being carried out, however given the time taken to 
carry this out, these were not available to me in a feasible time scale for my project. This 
should offer a more robust platform with which to perform future studies since the background 
genomic variability between control and carrier lines has been essentially removed. There will 
still be epigenetic differences between the lines but they still offer the best controls that we 
can currently create, and deriving cells from these concurrently offers the most robust platform 
with which to detect phenotypic differences relating to a particular genetic change.   
During the creation of isogenic lines, there is a risk of off-target effects from the gene editing 
process. Typically, these have been identified by exome sequencing and array comparative 
genome hybridisation (Soldner et al., 2011). In our study, we assessed highly homologous 
targets which were predicted to be the likeliest regions to be targeted, by Sanger sequencing 
(Selvaraj et al, submitted). As the creation of isogenic lines involves clonal selection, it is 
possible that due to random mutagenesis, coincidental genetic variants could appear, which 
may affect the phenotypic outcome (Ding et al., 2013). Because of this, it is recommended that 
175 
 
multiple clones should be produced so that there are several isogenic controls available 
(Sandoe and Eggan, 2013). For the C9orf72 gene targeting, the efficiency of HRE excision 
was very low for carrier 2 and therefore this was not possible for this line: only 1 clone out of 
164 was successfully targeted. It is probable that the 10 base pair deletion, which was not 
detected until after the gene editing process, was the reason behind the low efficiency. There 
are two more C9orf72 hiPSC lines for which isogenic controls have now been created in the 
lab, which will allow future studies to be performed in a more robust manner. These lines had 
no indels at the 3’ end and the efficiency of excision of the C9orf72 HRE was subsequently 
higher, and several isogenic control lines were created for each (Selvaraj et al, submitted). 
Another consideration in relation to the generation of isogenic controls is the effect of the 
transformation process on the hiPSC, as such it may be preferable to transfect cells without 
using gRNA as a control for this, so that the process itself can be ruled out as the cause of any 
observed differences.  
6.2.4 Genomic stability of hiPSCs 
Conventional karyotyping using G-banding has been the most commonly used method for 
checking the genomic integrity of hiPSCs (Lund et al., 2012a) and is the method that has been 
used in this study. This allows accurate detection of abnormalities in heterogeneous 
populations, although the analysis is usually only performed on a small number of cells rather 
than the entire population, and the technique is expensive, labour intensive and slow which 
limits the regularity with which it can be carried out (Lund et al., 2012a). Using array 
comparative genome hybridisation allows a higher resolution analysis to be carried out, and 
can be cheaper and quicker than conventional karyotyping. Expertise, as well as specialised 
analysis software is still required, particularly for interpretation when small scale copy number 
changes are detected, which are of unknown significance (Lund et al., 2012a). For 
interpretation of such changes, it is important that DNA from the patient is available to confirm 
whether these have arisen in vitro. There are also differences in the types of abnormalities 
which can be detected, as karyotyping is required to detect balanced translocations, while 
single nucleotide polymorphism (SNP) arrays may allow detection of loss of heterozygosity, 
which would not be detectable by other methods but may have phenotypic consequences. It 
may be that as array technology becomes cheaper, that this is a more suitable approach than 
karyotyping, given that the results may be obtained more quickly. This is important when 
differentiated cells may have already been used experimentally before karyotyping results are 
obtained, and therefore subsequent abnormal karyotype results mean that data needs to be 
excluded, which has clear cost implications. The drawbacks of detecting smaller copy number 
variations can be reduced by comparing fibroblast DNA and excluding common variants 
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between this and hiPSC DNA, and also filtering for only common variants which are known 
to affect differentiation and malignant potentials of the cells.  
During this study, chromosomal abnormalities were detected on two occasions. Control 1 
hiPSCs were found to have developed an XYY karyotype, and this line was therefore 
subsequently removed from the study. It is difficult to assess the impact of this chromosomal 
at the cellular level, but this karyotype occurs in 1 in 1000 live male births, and is associated 
with tall stature and impaired language and motor skills (Geerts et al., 2003; Linden et al., 
2002; Ratcliffe et al., 1992). In a small study on eight XYY males, there was a trend for 
increased grey and white matter volumes (Bryant et al., 2012), which suggests that this 
karyotypic abnormality may impact cell growth and division. However, there is likely to be an 
ascertainment bias in such studies as healthy XYY individuals may never be diagnosed and so 
the phenotype may be milder than these studies suggest (Bryant et al., 2012). Carrier 2 hiPSCs 
developed trisomy 12, which is one of the most common cytogenetic abnormalities which 
arises in vitro (Taapken et al., 2011). This abnormality is also observed in both solid tumours 
and haematological malignancies, and it may be that such an abnormality occurs during in 
vitro culture as it is a permissive aneuploidy which is not selected against (Taapken et al., 
2011). Because karyotypic abnormalities in cell lines are likely to result in changes in gene 
expression, and aneuploidy leads to deficiencies in cellular processes (Mayshar et al., 2010; 
Upender et al., 2004), experimental results from cells with these changes are unreliable and as 
such cannot be used in disease modelling.  
6.2.5 Verification of pluripotency of cell lines 
Pluripotency measurement has been carried out by qualitative immunostaining, which showed 
that each of the cell lines were able to generate all three germ layers are required (Devlin et 
al., 2015). Recently, quantitative approaches have been developed and these would be better 
suited to highlight any differences between the hiPSCs studied (Bock et al., 2011; Müller et 
al., 2011). 
6.3 Derivation of hiPSC derived oligodendrocytes 
There are several recent published protocols for generating oligodendrocytes from hiPSCs, 
The first report of the generation of O4 positive cells from hiPSCs showed very low efficiency 
(<0.01%), despite attempts using two protocols previously optimised on hESCs (Ogawa et al., 
2011). Several groups have focused their efforts towards cell transplantation, and therefore 
assessed the production of OPCs with less focus on in vitro differentiation and maturation of 
oligodendrocytes (Wang et al., 2013). In this case, the protocol contained six stages as ours 
did, but took longer (190 days) to generate terminally differentiated cells (Wang et al., 2013). 
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This protocol generated a yield of 4-12% O4 positive cells but in their case was at a later time 
point than when a similar yield was present using our protocol (Wang et al., 2013).  
More recently, protocols with higher yield and shorter differentiation times have been 
published (Douvaras and Fossati, 2015). The major differences between our protocol and this 
one is that they combine RA with the dual SMAD inhibitors (SBN431542 and LDN193189) 
and use adherent cultures for a larger proportion of time, which would be predicted to expose 
cells to a more consistent concentration of morphogens (Douvaras and Fossati, 2015). Our 
protocol is largely based on neurospheres, and therefore the cells are exposed to a different 
morphogen concentration depending on their location within the sphere, and this likely 
contributes to the generation of undesired cell types, and is also why maintenance of spheres 
by regular chopping is important.  
Another protocol that has been developed demonstrates the utility of deriving cells in hypoxic 
conditions, showing a two fold increase in Olig2 expression at 3% oxygen compared to 20% 
(Stacpoole et al., 2013). Low oxygen levels are more physiologically relevant to in vivo 
conditions, and have been suggested to enhance oligodendrocyte survival, as this lineage has 
been shown to be particularly sensitive to oxidative stress (Casaccia-Bonnefil, 2000; Stacpoole 
et al., 2013).  
Using a similar approach to ours, another group have used patient derived hiPSCs with PLP1 
mutations to investigate their effect on oligodendrocytes (Numasawa-Kuroiwa et al., 2014). 
Their derivation protocol was similar to ours in their use of RA and Shh agonists in the initial 
stages, while their OPC proliferation stage utilised epidermal growth factor (EGF) and 
neurotrophin-3 (NT-3) and lacked SAG compared to ours, and they used leukaemia inhibitory 
factor (LIF) and ciliary neurotrophic factor (CNTF) rather than IGF-1 in the differentiation 
phase (Numasawa-Kuroiwa et al., 2014). It is difficult to compare the efficiency of this 
protocol to others as they used a unique scoring method for number of O4 positive cells.  
All of the protocols are similar in that they take several months to form mature 
oligodendrocytes, and it would therefore be useful to have a stable and expandable 
intermediate precursor cell population which can be used so that the entire differentiation 
process does not need to be performed each time. This has been achieved in one protocol, 
where radial glia-like cells are used in this manner (Gorris et al., 2015). In our protocol, OPCs 
can be maintained as spheres for up to two months, but the efficiency of oligodendrocyte 
differentiation may vary over this time period.  
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Interestingly, development of more direct methods of cell generation from fibroblasts have 
emerged which bypass the hiPSC stage, allowing neurons and oligodendrocyte precursor cells 
to be generated from human fibroblasts by direct reprogramming using a combination of 
transcription factors (Ferraiuolo et al., 2016; Meyer et al., 2014). Such approaches are 
potentially time saving, and a reduced time in culture means there is less time for potential 
genetic defects to occur and reduced infection risk, as well as being more economical.   
In the protocol which I have used in this study, the cell purity is a limitation. As the yield of 
oligodendrocytes was less than 100% after three weeks of oligodendrocyte differentiation, to 
carry out biochemical studies, it was necessary to enrich for cells of interest with MAC sorting. 
However, it is technically challenging to perform a quality check each time, as material is 
limiting and therefore I cannot exclude contamination with different cell types including 
astrocytes and neurons. I also therefore cannot exclude that the results obtained have been 
influenced by the non-cell autonomous effects of other cell types. Switching to a protocol 
which is higher yielding and has few contaminating cell types would be a significant advance 
and allow for more cell population based assays to be performed. One simple alteration which 
could improve yield would be to try a higher IGF-1 concentration in the differentiation 
medium (50ng/ml), as this was found to give a higher yield of MBP positive cells in a recent 
study (Ferraiuolo et al., 2016).  
Other ways in which the protocol could be altered include optimisation of RA and Shh 
concentrations early on to mimic the embryonic spinal cord. (Douvaras et al., 2014). In this 
protocol, adherent cultures were used for a longer duration of time, which results in cells being 
exposed to a more consistent concentration of morphogens than if they are within a 
neurosphere. In the latter, cells will have different exposure levels depending on their position 
within the sphere. Douvaras et al. also used a significantly lower RA concentration than others 
(Nistor et al., 2005) and no FGF. Although FGF has been shown to promote Olig2 expression 
in chicken, and has been used in several hES and hiPSC (Nistor et al., 2005), protocols have 
now emerged which show that this factor is not required for oligodendrocyte production 
(Douvaras et al., 2014).  
Additional survival factors could be added to try and maintain oligodendrocytes in culture for 
longer. Neurotrophins including NT-3, CNTF, LIF and interleukin 6 are thought to work 
together to promote survival additively in rat cells in vitro (Barres et al., 1993). NT-3 is thought 
to be a potent mitogen for OPCs, as well as being a survival factor and further work to 
investigate whether this factor could increase yield in this protocol could be useful. This could 
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improve the yield of these cells, allowing more population based assays to be used without 
cell sorting.  
Others have recently investigated oligodendrocyte differentiation from hiPSC and iNPCs in 
the context of ALS-associated mutations, and also found that there was no difference in marker 
expression between ALS samples and controls (Ferraiuolo et al., 2016). Because this group 
used samples from multiple sources and their protocol was different to ours, this backs up our 
findings and suggests that differentiation defects are not present in C9orf72 HRE 
oligodendrocytes, which is also consistent with the disease being late-onset and not arising 
early in development. However, it is not possible to exclude that defects in differentiation and 
maturation of newly formed oligodendrocytes could contribute to the development of ALS at 
a later stage. Indeed, cell aging is an important consideration in disease modelling using 
hiPSCs, particularly given that increased age is the main risk factor for neurodegenerative 
diseases such as ALS. It is important to consider how reprogramming and directed 
differentiation affects cellular aging, and it may be that direct conversion of fibroblasts to 
oligodendrocytes might allow this to be retained as has been suggested for neurons (Mertens 
et al., 2015). 
There is a gap in knowledge of the regional identities of oligodendrocytes, and this has not 
been addressed in current hiPSC derivation protocols. With regards to the C9orf72 HRE, it is 
of interest to investigate cortical oligodendrocytes, given that this mutation also causes FTD. 
There is even less known about oligodendrocytes in FTD than in ALS, and therefore many of 
the investigations on spinal oligodendrocytes should be repeated on cortical oligodendrocytes. 
This work is ongoing by another member of the laboratory (Barton, personal communication). 
6.4 Pathology of C9orf72 HRE hiPSC derived oligodendrocytes 
Any of the proposed pathological mechanisms relating to C9orf72 HREs that have been 
suggested could be affecting cell types other than neurons. Therefore, I investigated whether 
any of these features were apparent in hiPSC derived oligodendrocytes. 
6.4.1 Loss of function 
At the beginning of this study, very little was known with regards to the role of C9orf72 HRE 
in oligodendrocytes, and it was not clear whether these cells were affected by the presence of 
the mutation, or to what extent they might contribute to the development of disease. Using 
hiPSC derived oligodendrocytes was a novel approach to addressing some of these questions, 
mostly with regards to cell autonomous effects of the C9orf72 HRE on oligodendrocytes.  
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It has subsequently emerged, from a mouse model with LacZ expressed from the C9orf72 
promoter, and human gene expression studies that C9orf72 is mostly expressed in neurons and 
macrophages, with low expression levels in glia (Rizzu et al., 2016; Suzuki et al., 2013). This 
was backed up by the results which I obtained from mRNA expression analysis using qPCR 
which showed low expression levels in hiPSC derived oligodendrocytes compared to hiPSC 
derived cortical neurons, and similar to the levels detected in the laboratory for astrocytes 
(Zhao, personal communication). There was not a significant difference in the expression 
levels between carrier and control hiPSC derived oligodendrocytes, although there was some 
variability between the lines. This is probably due to the low expression levels and subsequent 
limitations in the sensitivity of the technique. Within the literature, similar experiments on 
hiPSC derived neurons have shown variable results, with some showing a reduction in C9orf72 
mRNA expression of specific transcripts (Almeida et al., 2013) and others showing that other 
transcripts are upregulated (Sareen et al., 2013). Some reasons for inconsistencies between 
studies examining mRNA levels include variability in sample sizes, nomenclature differences, 
methodology, tissue types investigated and RNA quality (van Blitterswijk et al., 2015). As yet 
it is still unclear to what extent a loss of function of C9orf72 contributes to pathogenesis.  
Due to a lack of reliable antibodies to C9orf72, I have not investigated the expression of the 
protein in hiPSC derived oligodendrocytes. It would have been interesting to check for co-
expression with oligodendrocyte markers using immunohistochemistry, as well as look at 
expression levels of purified cell lysates by Western blot. Further work to investigate the 
epigenetic status of the C9orf72 HRE and surrounding genomic region could potentially be 
interesting, particularly if there were any differences detected between the cell lines as this is 
a potential source of variation.  
6.4.2 Gain of function (RNA) 
Using RNA FISH, I detected sense RNA foci in hiPSC derived oligodendrocytes, which 
corroborates findings from post-mortem studies showing RNA foci in oligodendrocytes in the 
frontal cortex of FTD patients (Mizielinska et al., 2013). I detected RNA foci in a higher 
percentage of oligodendrocytes (40-50%) than this study (10%), however this likely reflects 
the differences between an in vitro system and analysis on post-mortem tissue. RNA-FISH for 
the latter requires harsh sample treatment including heating to 80°C, which is likely to result 
in RNA degradation. The stage of disease studied using post-mortem tissue is also unlikely to 
be replicated in hiPSC derived cells, so this is likely to influence the number of foci containing 
cells. Studies have shown that in cells which have been transfected with 38 or 74 GGGGCC 
repeats, those which display RNA foci are associated with increased caspase-3 activation (Lee 
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et al., 2013). In other studies of hiPSC derived neurons, sense RNA foci were detected in 20-
50% of cells (Almeida et al., 2013; Donnelly et al., 2013; Sareen et al., 2013). Variation in the 
detection of RNA foci may reflect procedural differences in the RNA-FISH technique, 
including fixation and permeabilisation methods, type of probe used (RNA, DNA, locked 
nucleic acid), type of probe label, hybridisation conditions including temperature and time, 
and imaging methods. The protocol I used was based on that used in the study reporting the 
highest proportion of cells with RNA foci, with sense RNA detected in up to 68% of hiPSCs 
(Almeida et al., 2013).  
The presence of RNA foci has been reported in most cell types that have been investigated, 
including fibroblasts, peripheral blood leukocytes, immortalized lymphoblasts, astrocytes, 
microglia and various neuronal types including motor neurons, cortical neurons, lumbar 
interneurons, cerebellar Purkinje cells and hippocampal neurons (Donnelly et al., 2013; 
Lagier-Tourenne et al., 2013; Mizielinska et al., 2013; Zu et al., 2013). Since there is no overt 
clinical phenotype affecting cell types such as fibroblasts and leukocytes, this suggests that the 
presence of RNA foci alone is not cytotoxic. If RNA foci are sequestering proteins, it may be 
that the various cell types have different RNA binding proteins which are perturbed, and how 
crucial these are to cellular function determines whether there is a cellular phenotype or not. 
Various RNA binding proteins, including ADARB2, hnRNPA1, hnRNPA3, Pur-α and 
nucleolin have been proposed to be involved but no real consensus on which are important 
(Donnelly et al., 2013; Haeusler et al., 2014; Mori et al., 2013b; Sareen et al., 2013; Xu et al., 
2013). Among the most elegant experiments carried out to establish binding partners of 
C9orf72 sense RNA foci in the central nervous system involved pull down assays with 
subsequent mass spectrometry to identify candidate binding proteins (Cooper-Knock et al., 
2014). This study identified multiple targets and co-expression studies revealed colocalization 
of RNA foci with hnRNP A1, hnRNP H1/F, ALYREF and SRSF2 in motor neurons (Cooper-
Knock et al., 2014). It would be interesting to investigate whether there are differences in 
which proteins are sequestered by RNA foci in oligodendrocytes compared to neurons or 
astrocytes. This could be done on hiPSC derived cells, or following cell purification on post-
mortem samples. So far, most studies have focused on neurons and have failed to reach a 
consensus on the factors involved, and therefore there does not appear to be a ‘master’ factor, 
unlike in myotonic dystrophy where sequestration of muscleblind proteins by RNA foci are 
significantly implicated in disease pathogenesis (Miller et al., 2000).  
The morphology of oligodendrocytes in the SOD1G93A mouse model, and in ALS post mortem 
tissue is thought to be abnormal (Kang et al., 2013). Because of this, I investigated whether 
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the branching pattern of oligodendrocytes was affected by the presence of RNA foci using 
Sholl analysis. There was not a clear and consistent effect on the number of branches as 
determined by Sholl analysis, which suggests that the presence of RNA foci is not disrupting 
any of the cellular pathways involved in creating the branching network in oligodendrocytes. 
Clearly, however this analysis does not exclude an influence of RNA foci on many other 
cellular processes.  
Further work is required to determine whether hiPSC derived oligodendrocytes contain 
antisense RNA foci. Despite numerous attempts, I did not manage to get a protocol for this to 
work, possibly due to the formation of secondary structures in the (GGGGCC)4 probe. Repeats 
of GGGGCC are thought to form highly stable G-quadruplexes in vitro and it may be that 
despite attempts to denature the probe with extended heating times, that this may be 
contributing to the lack of signal obtained (Fratta et al., 2012; Reddy et al., 2013). Published 
methods for RNA-FISH to detect antisense foci have tended to be optimised for post-mortem 
tissue or peripheral blood cells and have included longer hybridisation at temperatures greater 
than 60°C, which may be too harsh for the cells used in this study (Cooper-Knock et al., 2015; 
Mizielinska et al., 2013; Zu et al., 2013). Locked nucleic acid probes have also been used by 
several groups as these are thought to reduce secondary structure formation and improve probe 
specificity and sensitivity for RNA-FISH (Lagier-Tourenne et al., 2013). 
6.4.3 Gain of function (protein) 
The difficulties that I had with specificity and sensitivity of the available antibodies to DPR 
highlight the challenges of working with these proteins as reliable antibodies are still scarce. I 
cannot confirm or exclude from my work whether DPR were present in the hiPSC derived 
carrier oligodendrocytes or not. The Western blots that were carried out suggest that PA and 
GP dipeptides were not present, however the experiments were only carried out once using 
two cell pellets from each of control 2, carrier 1 and carrier 2, and so ideally they would be 
repeated to confirm the results.  
I had intended to investigate the presence of DPR in oligodendrocytes from post-mortem tissue 
from C9orf72 HRE positive patients, however again this work was hampered by the lack of 
reliable antibodies. Had this worked, it would have been very interesting to see if the results 
were similar in hiPSC derived oligodendrocytes compared to those present at end stage 
disease.  
There have not been any other studies to investigate the presence of DPR in oligodendrocytes 
carrying C9orf72 HRE in the literature that I am aware of. There has been one report of 
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transmission of DPR from conditioned media obtained from GFP-DPR expressing cortical 
neurons to mature oligodendrocytes in vitro (Westergard et al., 2016). This study suggests that 
DPR can be transmitted between CNS cell types and that this may provide an explanation for 
the progressive spread of the disease (Westergard et al., 2016). 
6.4.4 TDP-43 and p62 accumulation 
I found no evidence of TDP-43 mislocalisation related to the C9orf72 HRE in hiPSC derived 
O4 positive cells using immunocytochemistry, and there was no increase in TDP-43 in the 
soluble fraction following protein extraction and Western blotting. Unfortunately, insufficient 
protein was obtained from the insoluble fraction to allow assessment of TDP-43 levels, which 
needs to be repeated on fresh material. This contrasts with evidence from post-mortem material 
which suggests that TDP-43 becomes mislocalised in oligodendrocytes in ALS cases 
(Brettschneider et al., 2014; Rohan et al., 2014). However, the literature focuses on sporadic 
cases and this has not specifically been assessed in oligodendrocytes which have a C9orf72 
HRE. It may be that TDP-43 mislocalisation has not been detected in this study due to the 
kinetics of the accumulation with regards to the development of the disease. Although the 
accumulation of TDP-43 in oligodendrocytes it is thought to reflect an early disease process, 
it may be that the cultured cells have not been exposed to the appropriate cellular conditions 
which trigger this in vivo (Brettschneider et al., 2014; Rohan et al., 2014).  
It is possible that in vivo, the TDP-43 mislocalisation observed in oligodendrocytes could be 
due to the presence of damaged motor neurons. This could still occur prior to symptom onset, 
for example, excitotoxicity in motor neurons in the early disease stages could have a 
detrimental effect on surrounding oligodendrocytes, which ultimately leads them to 
mislocalise TDP-43. Alternatively, TDP-43 could also spread between cell types as has been 
suggested for DPR (Fatima et al., 2015; Feiler et al., 2015).   
There was no evidence of increased p62 using either immunocytochemistry or Western 
blotting in C9orf72 HRE containing hiPSC derived oligodendrocytes. However, further work 
is required to verify these results as there was limited protein available for analysis.  
6.4.5 Cell death and ER stress susceptibility 
In this study, I have used FACS to determine the levels of caspase-3 activation, which is a cell 
death marker, within O4 positive cells. I did not find any difference in levels of caspase-3 
activation between carrier and control O4 positive cells under basal conditions. This finding 
has been supported by another group who transduced human oligodendrocytes with red 
fluorescent protein under the MBP promoter and showed that when cultured with motor 
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neurons, there was no difference between control and ALS derived oligodendrocyte number 
(Ferraiuolo et al., 2016). A caveat here is that the ALS patients are a pooled group and it is not 
stated how many of these were C9orf72 HRE carriers, and the study could have benefited from 
time lapse survival analysis rather than a cell count at the end of co-culture.  
The application of tunicamycin to cells to induce ER stress, followed by FACS analysis to 
determine levels of caspase-3 activation revealed no significant susceptibility of C9orf72 HRE 
carriers to ER stress. There was variability between the cell lines however, and ideally this 
experiment would be repeated using more isogenic controls as this would help reveal whether 
the difference is specifically due to the presence or absence of the C9orf72 HRE. If a difference 
was revealed after further analysis, it would be pertinent to perform a dose response curve to 
determine that the effect is specifically due to the application of tunicamycin. Furthermore, 
checking whether any response was reversed by agents which inhibit the ER stress response, 
such as salubrinal or tauroursodeoxycholic acid, would back up such results. This type of 
experimental approach could also be used to investigate whether there is a susceptibility to 
many other types of cellular stress, such as oxidative stress which have been implicated in 
ALS.  
6.4.6 Other potential pathogenic mechanisms in oligodendrocytes 
I investigated expression levels of MBP and MCT1 as they have previously been reported to 
be reduced in SOD1 mutant oligodendrocytes (Kang et al., 2013; Philips et al., 2013). I did 
not observe a significant difference in mRNA levels for either of these markers in C9orf72 
HRE oligodendrocytes. Given that one report of reduced MCT1 appeared to be a post-
transcriptional effect (Philips et al., 2013), an obvious next step would be to measure 
expression at the protein level.  
Another area worthy of investigation is lactate metabolism, to investigate whether there is any 
difference in how well the oligodendrocytes may be able to support motor neurons. Recently, 
lactate release has been measured in conditioned media from control and ALS 
oligodendrocytes by another group, who found that there was no difference at the beginning 
of differentiation, but after three weeks in culture there is a decrease in lactate production by 
human ALS oligodendrocytes compared to controls (Ferraiuolo et al., 2016). However, 
looking specifically at C9orf72 HRE oligodendrocytes, there did not appear to be a reduction 
in lactate release, intracellular lactate concentration or MCT1 mRNA expression levels, 
suggesting that this effect is specific to SOD1 and TARDBP mutant oligodendrocytes 
(Ferraiuolo et al., 2016).  
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6.5 Further research 
The key question regarding the role of oligodendrocytes in the pathogenesis of C9orf72 HRE 
related ALS is whether there is an impact on neuronal health and function. To extend this 
study, the functionality of hiPSC derived oligodendrocytes needs to be investigated. Ideally, 
this requires a reliable in vitro protocol for co-culturing human oligodendrocytes and neurons, 
so that cell non-autonomous effects can be examined.    
A recent publication describes an in vitro human co-culture system between wild type Hb9-
GFP+ motor neurons and either hiPSC or induced neural progenitor cell derived 
oligodendrocytes with various ALS-associated genetic variants. In the presence of 
oligodendrocytes carrying either a C9orf72 HRE, or pathogenic variants in SOD1, TARDBP 
or FIG4, motor neurons displayed reduced survival (Ferraiuolo et al., 2016). The application 
of conditioned media from human ALS oligodendrocytes to motor neurons resulted in a 15-
40% increase in motor neuron death compared to control oligodendrocytes, suggesting that 
part of this effect is mediated via soluble factors (Ferraiuolo et al., 2016). It would be of great 
interest to determine what biochemical differences there are between conditioned media from 
control and C9orf72 HRE oligodendrocytes. In order to investigate this, a higher yielding 
protocol would be required, otherwise it is possible that there would be a significant influence 
from contaminating astrocytes. From preliminary experiments that I carried out on co-cultures 
with hiPSC derived neurons, the most effective contact between oligodendrocytes and neurons 
appeared to occur when OPC spheres were used, rather than MACS sorted O4 positive cells. 
This meant using cells from earlier in the protocol, and as such the oligodendrocyte yield was 
low and the cell population included astrocytes. Therefore, it would be impossible to tease 
apart whether any detected changes in neuronal function were due to oligodendrocytes or 
astrocytes.  
A further challenge following on from this study is to show that the hiPSC derived 
oligodendrocytes can function and form myelin sheaths. The widely regarded ‘gold-standard’ 
method for showing function is in vivo transplantation into the congenitally hypomyelinated 
shiverer mouse model (Douvaras et al., 2014; Wang et al., 2013). This work is currently 
ongoing by others in the laboratory and external collaborators. In addition, another student in 
the laboratory has had success using oligodendrocytes derived using the same method as this 
project, with slice cultures from the MBP-lacking shiverer mouse. These have given promising 
results suggesting that the oligodendrocytes are indeed functional in respect to myelination 
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